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Abstract 
 
A chemical mutagenesis approach has been used to generate novel models carrying point 
mutations in mouse Tardbp, the gene encoding TDP43. TDP43 is a highly conserved protein, 
which in humans has been shown to be critical in amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD-TDP). The aims of the work described in this thesis 
are to assess ten TDP43 point mutations at a behavioural, cellular and molecular level to 
determine whether they are functional and if they can be used as tools or models to 
understand TDP43 function and dysfunction in the mouse.  
A comprehensive behavioural assessment of four mouse mutant lines has been completed to 
assess for TDP43 mutant phenotypes. Behavioural assessment has encompassed general 
health assessment through to motor capabilities. Tests regularly applied include SHIRPA, grip 
strength, rotarod and open field. All mutations have also been assessed in vitro using a cystic 
fibrosis transmembrane regulator (CFTR) add-back assay. 
The data presented in this thesis characterises the nonsense mutation Q101X, and a missense 
mutation K160R, generated in mice. The K160R mutation lies within the first RNA recognition 
motif of TDP43. Compound mutants (TardbpQ101X/K160R) were also generated and assessed. 
Q101X causes homozygous lethality as occurs in knockout TDP43 mice. This supports the 
Q101X mutation as being an alternative null allele. Q101X, K160R and compound mutants 
(TardbpQ101X/K160R) show common neuronal associated phenotypes in the SHIRPA, including 
limb grasping and a softer body tone. The compound mutants (TardbpQ101X/K160R) also present 
novel alterations at six months as demonstrated using electron microscopy. Additionally, 
weight and preliminary anxiety phenotypes have been shown. Q101X heterozygotes were also 
crossed to transgenic SOD1G93A mice to generate double mutants. Mutations in SOD1 also 
cause ALS. Modifying effects were assessed through behavioural characterisation with no 
overt interaction identified.  
All missense mutations were assessed in vitro using a CFTR mini-gene assay. Out of ten 
identified point mutations, F210I, a mutation in the second RNA recognition motif of TDP43 
showed deficient splicing activity. This was further confirmed ex vivo in mouse embryonic 
fibroblasts (MEFs). The F210I mutation is an RNA-binding hypomorphic allele. It shows 
disrupted Tardbp transcript regulation, supporting potential perturbations in TDP43 auto-
regulation. There are also further alterations in RNA metabolism, two processes potentially 
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critical to ALS and FTLD-TDP. F210I demonstrates the importance of the second RNA 
recognition motif in RNA-binding function. 
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Glossary 
 
ALS – amyotrophic lateral sclerosis. A form of motor neuron disease resulting in both upper 
and lower motor neuron degeneration. 
Auto-regulation – the ability of a gene to control its own protein levels. In the case of TDP43, it 
binds its 3’UTR in a concentration dependent manner to regulate protein coding transcript 
levels. In turn this mechanism results in maintenance of steady TDP43 protein levels. 
Dominant missense mutation – a change of a single nucleotide in one allele, which alters the 
functional output of the protein produced from that allele. This mutation causes phenotypes 
despite being in the presence of a wild-type allele. 
ENU - N-ethyl-N-nitrosourea. A chemical mutagen which acts randomly throughout the 
genome causing mainly heritable point mutations. 
hnRNPs - heterogeneous nuclear ribonucleoproteins. Family of proteins with extensive RNA-
binding and regulation roles. They form RNA and protein complexes. TDP43 is a member of 
this family. 
Inclusions – aggregations of proteins and other potential components in the cytoplasm or 
nucleus which can be stained or labelled with antibodies. 
RNA metabolism – the processing of RNA through its formation (transcription), regulation, 
modification and degradation.  
Stress granules – cytosolic aggregations of RNA bound to protein formed in cells under 
stressful conditions. RNA in stress granules is silenced and stabilised during the stress period. 
TARDBP – Tar DNA Binding protein. Highly conserved gene encoding for the protein TDP43, 
located on chromosome one in humans and on chromosome four in the mouse. 
TDP43 - TAR DNA Binding protein 43 kDa. Protein in which mutations cause the disease 
amyotrophic lateral sclerosis.  
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List of abbreviations 
 
BC – backcross – term used to show the degree to which the mouse assessed has been 
backcrossed towards the C57BL/6J background. Figures showing the exact genetic makeup of 
the mice for each line are given with backcross mice being more than 50% C57BL/6J. 
IVF – in vitro fertilisation – mice carrying mutations in TDP43 were rederived using stored 
sperm by in vitro fertilisation. 
OU – outcross – term used for mice which do not have more than 50% of their genetic 
background belonging to a single inbred strain such as C57BL/6J. 
WT – wild-type – term used for littermate control mice that do not contain any mutations in 
TDP43 or SOD1. 
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1. Introduction 
 
The work described in this thesis characterises a series of mouse TDP43 point mutations 
generated by chemical mutagenesis. Mice carrying a number of identified mutations have 
been derived and assessed to determine the functionality and impact of these mutations. 
Multiple TDP43 models have been published whilst undertaking this work with varying degrees 
of success in modelling TDP43 proteinopathies. The ENU mutants presented here provide 
alternative tools to understand the function and potential dysfunction of TDP43. 
 
1.1. ENU approach 
 
1.1.1. Molecular mechanism 
 
N-ethyl-N-nitrosourea (ENU) is the preferred chemical mutagen because it creates stochastic 
heritable point mutations throughout the genome and is highly potent (Russell et al., 1979). It 
is used to generate mutations in multiple model organisms ranging from Drosophila 
melanogaster through to Mus musculus and is a complementary approach to knock out 
strategies or transgenic modification of model organisms. The stochastic manner through 
which it acts on individual bases throughout the genome mean it is hypothesis generating in 
producing random point mutations. 
ENU acts as an alkylating agent that transfers its ethyl group onto nitrogen and oxygen atoms 
of nucleotides. This forms a DNA adduct which during cell replication results in misreading / 
mutating the nucleotide at the specific base containing the adduct (Justice et al., 1999). The 
result is an individual base change (or in rare cases a small region deletion) that creates a point 
mutation. In mice, spermatogonial stem cells are highly mutagenized by ENU which initially 
depletes these cells. Remaining stem cells repopulate by mitosis and produce sperm by 
meiosis (Bielas & Heddle, 2000; O'Neill, 2000). The resultant sperm each carry multiple ENU 
mutations, with each sperm carrying a unique array of mutations to the other. Each offspring 
from the original mutagenized animal therefore carries a unique array of mutations. 
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Depending on the location of the point mutation, many potential outcomes are possible. 
Within coding regions, missense mutations may change the encoded amino acid resulting in a 
gain or loss of function effect on the protein. Nonsense mutations will produce truncated 
protein products. Mutations outside coding regions can also impact on promoter activity and 
splicing, resulting in multiple potential mechanisms in altering gene function. 
 
1.1.2. Identifying mutations at MRC Harwell / RIKEN 
 
To utilise ENU in the mouse, multiple centres around the world employ ENU mutagenesis 
screens. The major centre in the UK is MRC Harwell applying both forward and reverse genetic 
approaches to identify novel mutants generated through ENU mutagenesis. In the forward 
genetics approach, ENU mutagenized offspring (G1 mice) from a mutagenized male (G0 
mouse) can be phenotyped for dominant mutations. Alternatively, through a breeding 
programme using the G1 males (G0 male is that injected with ENU, G1 are the offspring), G3 
mice can be screened for recessive mutations, as reviewed elsewhere (Acevedo-Arozena et al., 
2008).  
The work described in this thesis has adopted a complementary reverse genetics approach. At 
MRC Harwell a programme to generate an archive of mutations continues to run. ENU 
mutagenized sperm from G1 offspring of ENU mutagenized males are harvested with matching 
DNA samples. Over 10,000 sperm samples have been collected from males each carrying 
unique arrays of ENU mutations and all carrying multiple ENU mutations at a rate of 
approximately one mutation per one and a half mega bases (Quwailid et al., 2004). The rate 
has been maximised through balancing the toxic effects of ENU versus that which efficiently 
produces the most mutations in viable mice. ENU injection produces a period of temporary 
sterility following treatment and is also carcinogenic. The aim is to treat males with a dose 
where there is a low sterility period (usually three months) with an extended period of time for 
the male to produce the first generation of offspring (G1 mice) which will each carry multiple 
unique ENU mutations. Any autosomal gene can be screened for mutations in the matching 
DNA samples by high resolution melting (HRM). In HRM, a polymerase chain reaction (PCR) 
product is heated beyond the temperature that separates the double stranded DNA. This 
temperature will slightly vary depending on the DNA sequence, being different between two 
strands with and without a mutation. This is detected using fluorescent dyes which bind the 
double stranded DNA and therefore will show different melt curves for DNA sequences being 
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separated at different temperatures.  Dominant mutations on the X chromosome in female G1 
mice can also be assessed, however only male sperm and tissue samples are stored in the 
archive. Once desired mutations are identified the matching sperm can be used to generate 
mice carrying these mutations through in vitro fertilisation (IVF).  
The archive at Harwell was screened prior to the beginning of my PhD for mutations in all 
coding Tardbp exons. A non-sense and two missense mutations were identified as shown in 
Figure 1.1. In order to expand the allelic series, one and a half years into my PhD, all coding 
exons in the RIKEN (Japan)  ENU archive were also screened identifying a further seven 
missense mutations. A summary of the mutations and the conservation of those residues are 
given in Figure 1.1. 
 
Figure 1.1: TDP43 mutations. Figure showing mouse TDP43 protein domains with point mutations identified from 
the Harwell and RIKEN ENU archives. Protein structure domains given: NLS, Nuclear Localisation Signal, NES, Nuclear 
Export Signal, RRM1, RNA Recognition Motif 1, RRM2, RNA Recognition Motif 2, Glycine rich region. The mutations 
identified from the MRC Harwell archive are shown in red with the mutations identified from the RIKEN ENU archive 
in black. Residue conservation across species is given for each mutation. 
 
1.1.3. Mutations studied as mouse lines 
 
Whilst working to produce this thesis the timing of mutation identification has partly 
determined which mutations have been studied and which mice rederived. When the Harwell 
archive mutations were identified there were no published animal models and very little was 
known functionally about TDP43, so all Harwell mutations were rederived as mice for 
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phenotypic assessment. Sperm carrying the Q101X and K160R mutations were successfully 
rederived by IVF with ensuing mouse generation. These mice were partially backcrossed to 
remove other ENU mutations. They were not backcrossed to become fully congenic to remove 
all other ENU mutations for this study due to time constraints, but littermate controls were 
used in phenotyping tests as the most suitable control. Whilst this study has taken place, the 
mutant lines have been backcrossed onto a congenic C57BL/6J background. Models used to 
estimate mutation effects also show that despite carrying multiple mutations (in the founder 
mice, this is estimated at 30-50 functional mutations), phenotypes are usually the result of an 
individual ENU point mutation (Keays et al., 2006). The T153A mutation from Harwell proved 
difficult to rederive by IVF (taking over one and a half years) and continues to be phenotyped. 
Due to this delay it is not presented in this thesis. 
The expanded array of mutations supplemented by those identified at RIKEN have all been 
characterised in vitro and to early stages in vivo based on results. Full behavioural 
characterisation of these lines was not possible in the timeframe of this PhD. However, data 
collected warrant extensive behavioural characterisation in the future. 
With nine missense and one nonsense mutation identified in Tardbp a large number of alleles 
are available to use in further understanding mouse TDP43 function. The mutations are 
present in all major characterised domains of TDP43 and may have partial to complete loss of 
function, gain of function or dominant negative effects. The aim of the work described in this 
thesis is to assess this functionality behaviourally and molecularly with these mice being 
complementary to knock out and transgenic gene overexpressing mice. They also provide a 
framework in which the mutations are expressed endogenously at the right time, in the right 
place and at the correct level providing a complementary approach to study this gene. This is 
particularly relevant for TDP43 as it has been shown that altering the levels of wild-type TDP43 
(both increasing and decreasing) in various cellular and animal models is toxic as reviewed 
elsewhere (Joyce et al., 2011). Complete absence of TDP43 is not permissive to survival in 
mammalian organisms and high overexpression is toxic. This is discussed in detail when 
assessing alternative models, showing that an ENU approach allows for assessment of the 
functional effects of mutations without being uncertain of alternative effects, such as 
overexpression. 
 
 
22 
 
 
1.2. Amyotrophic lateral sclerosis and frontotemporal lobar 
degeneration 
 
1.2.1. Pathology 
 
Jean-Martin Charcot initially described amyotrophic lateral sclerosis (ALS) in 1869. Usually 
striking in mid-life, ALS is a rapidly progressive motor neuron disease affecting both upper and 
lower motor neurons. Upper motor neurons project from the motor cortex down the spinal 
cord and lower motor neurons project to muscle. In humans, ALS usually strikes around mid-
life carrying a lifetime risk of approximately 1 in 1000. Once initial symptoms are detected and 
the disease diagnosed, there is a rapid progression to end stage in typically three years due to 
respiratory failure. During the disease course, motor neurons which control voluntary 
movement are lost leading to muscle weakness and atrophy resulting in paralysis and death. 
So far, only riluzole treatment appears to extend lifespan by a few months (Miller et al., 2007). 
More recently, increasing clinicopathological data supports ALS being part of a spectrum of 
disease with frontotemporal dementia in which inclusions are ubiquitin positive and tau 
negative (FTLD-TDP). This is one of the two major groups of frontotemporal dementia, FTD 
(the other contains tau positive inclusions) which form the second most common form of 
young onset dementia, which classically presents with frontal and temporal atrophy as well as 
hyper metabolism. Distinct subtypes of the spectrum of disease include language variant 
semantic dementia, a behavioural variant form and progressive non-fluent aphasia which can 
all overlap with motor neuron disease, as reviewed (Seelaar et al., 2011). Around 50% of ALS 
patients develop cognitive impairments (Lomen-Hoerth et al., 2003) and cosegregation has 
been shown within families (Talbot & Ansorge, 2006). As well as clinical overlap, these disease 
share underlying pathology surrounding the alteration of TDP43 protein which undergoes a 
number of changes including mislocalisation, hyperphosphorylation, polyubiquitination, 
cleavage and altered solubility. These changes are discussed in depth in section 1.4. 
In ALS and FTLD-TDP there are a number of hallmarks accompanying selective neuron 
degeneration. Within motor neurons, degeneration is accompanied by changes in axon 
structure. This can include disruption of neurofilaments which leads to protein accumulation 
and also alterations in critical components such as tubulin, dynein and dynactin in which 
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disruptions have been shown to result in motor disorders with altered axon transport 
(Hafezparast et al., 2003; Puls et al., 2003). Losses of synaptic vesicles have been shown to be 
an early event in pathogenesis as well (Hirano, 1996). The proteasome fails to function 
effectively due to misfolded ubiquitinated labelled proteins “clogging” up the system as well as 
evidence for endoplasmic reticulum stress (Petrucelli & Dawson, 2004). Critically, 
mitochondrial dysfunction within motor neurons, which can also promote motor neuron 
death, also occurs (Manfredi & Xu, 2005). Motor neurons are also hyper-activated resulting in 
elevated intracellular calcium which activates programmed cell death. The exact nature of the 
cause / effect changes within motor neurons continues to be established. 
Motor neuron cell death is also marked by the elevation of stress responses in surrounding 
cells. Activated astrocytes have been shown to be critical in the progression of the disease 
producing unidentified factors which are toxic to motor neurons (Nagai et al., 2007; Haidet-
Phillips et al., 2011). Microglia and oligodendrocytes may also be crucial in mediating disease. 
Within capillary endothelial cells there is also a loss of tight junctions resulting in 
microhaemorrhages in the spinal cord which also contribute to motor neuron degeneration. 
Patients also show increased levels of glutamate excitotoxicity (Shaw & Ince, 1997). 
Simultaneously, there is an inflammatory response (Graves et al., 2004). Overall, there are 
multiple perturbations associated with motor neuron degeneration. A summary schematic of 
changes and stresses which may cause or contribute to neuronal cell death is given in Figure 
1.2. 
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Figure 1.2: Mechanisms contributing to motor neuron dysfunction and death. Summary schematic taken from 
(Ilieva et al., 2009) showing the environment of motor neurons and the known changes which can contribute to 
motor neuron death. In the example schematic, mutations in SOD1 are causative however mutations in other genes 
which cause ALS result in similar motor neuron changes and ultimately death. 
 
1.2.2. Genetics 
 
The majority of cases of ALS and FTLD-TDP present sporadically. Most of these cases show 
underlying TDP43 pathology, excluding a minority of cases where mutations in some known 
(superoxide dismutase 1, SOD1 and fused in sarcoma, FUS) and unknown genes cause the 
disease. For familial cases of ALS and FTD, approximately 10% and 30% of cases respectively 
are thought to be inherited. SOD1 was one of the first genes to be identified as having 
mutations causative of ALS (Deng et al., 1993). More than 150 mutations have now been 
identified within SOD1 accounting for around 20% of familial cases. Later in 2006, mutations in 
TDP43 were also found to be causative of ALS with rare mutations also causing FTLD-TDP. 
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TDP43 mutations cause approximately 4% of familial ALS (fALS) cases (Gitcho et al., 2008; 
Sreedharan et al., 2008). Since then, many other genes have been found to cause ALS, atypical 
forms of ALS and FTLD-TDP. Within FTLD-TDP, mutations in progranulin (GRN), as discussed 
elsewhere (van Swieten & Heutink, 2008) and the recently identified chromosome 9 open 
reading frame 72 (C9ORF72) account for most cases with rarer causative mutations in valosin 
containing protein (VCP), TDP43 and other unknown factors also causing disease. Mutations in 
identified causal and risk factor ALS and atypical motor neuron disease genes are given in 
Table 1.1. In all non-SOD1 and FUS cases, TDP43 is pathologically altered as described in 
section 1.4.  
Alsin ALS2 (Hadano et al., 2001; Yang et al., 2001) 
Angiogenin (risk factor and 
potentially causative) 
ANG 
(Greenway et al., 2006; Wu et al., 2007; Gellera 
et al., 2008; Paubel et al., 2008) 
Ataxin 2 (risk factor) ATX2 
(Elden et al., 2010; Daoud et al., 2011; Van 
Damme et al., 2011) 
Chromosome 9 open 
reading frame 72 
C9ORF72 
(DeJesus-Hernandez et al., 2011; Renton et al., 
2011) 
Dynactin 1 (risk factor) DCTN1 
(Puls et al., 2003; Munch et al., 2004; Vilarino-
Guell et al., 2009) 
Elongator protein 3 (risk 
factor) 
ELP3 (Simpson et al., 2009) 
Fused in sarcoma FUS 
(Kwiatkowski et al., 2009; Vance et al., 2009; 
Corrado et al., 2010; Hewitt et al., 2010; Waibel 
et al., 2010; Yan et al., 2010) 
Neurofilament protein, 
heavy polypeptide 
(risk factor) 
NEFH (Figlewicz et al., 1994; Al-Chalabi et al., 1999) 
Optineurin OPTN 
(Maruyama et al., 2010; Del Bo et al., 2011; van 
Blitterswijk et al., 2012) 
Peripherin (risk factor) PRPH (Gros-Louis et al., 2004; Corrado et al., 2011) 
Senataxin SETX (Chen et al., 2004; Avemaria et al., 2011) 
Superoxide dismutase 1 SOD1 
(Deng et al., 1993; Rosen, 1993) more than 150 
missense mutations identified in SOD1  
Tar DNA binding protein 43 TDP43 
(Kabashi et al., 2008; Kuhnlein et al., 2008; 
Sreedharan et al., 2008) more than 30 missense 
mutations identified in TDP43 
Ubiquilin 2 UBQLN2 (Deng et al., 2011) 
Valosin containing protein VCP (Johnson et al., 2010) 
VAMP (vesicle-associated 
membrane protein)-
associated protein B and C 
VAPB 
(Nishimura et al., 2004; Landers et al., 2008; Chen 
et al., 2010) 
 
Table 1.1: Typical and atypical ALS causative genes. Table showing the genes in which mutations increase 
susceptibility or that cause typical and atypical forms of ALS. Genes highlighted in blue have characterised roles in 
RNA processing or in the case of C9ORF72, may disrupt RNA processing due to a hexanucleotide repeat expansion.  
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Mutations in genes with a variety of known functions may increase the risk or directly result in 
atypical-ALS, ALS and FTLD-TDP. Genes in which mutations may increase the risk of ALS include 
ANG, ATX2, DCTN1, ELP3, NEFH, and PRPH. ANG mutations have been identified in familial and 
sporadic ALS cases, although there is no conclusive proof that the variants segregate with 
disease as the families studied were not large enough.  Several mutations have also been 
shown to increase the risk of ALS particularly in Irish and Scottish populations (Greenway et al., 
2006). ANG is a member of the pancreatic ribonuclease A superfamily with RNase activity of 
ANG being important for its angiogenic activity. ATX2 has been shown as a strong modifier of 
TDP43 mediated toxicity in yeast and animal models with the two proteins binding in an RNA-
binding dependent manner (Elden et al., 2010). Several studies have shown that an 
intermediate number of CAG repeat expansions in ATX2 (around 29 repeats) is associated with 
increased risk of ALS. DCTN1 is a subunit of dynactin, a macromolecular complex binding both 
microtubules and cytoplasmic dynein and as such, impacts on multiple cell processes via 
axonal transport. Mutations in DCTN1 are rare, however can increase susceptibility to ALS 
(Munch et al., 2004) with mutations having been identified in sporadic and familial cases of 
ALS. ELP3 has a characterised role as the catalytic subunit of the histone acetyltransferase 
elongator complex with a multistage association study for ALS across three populations 
showing linkage to this locus (Simpson et al., 2009). Disrupted neurofilament processing is a 
prevalent feature of ALS, and NEFH motif deletions are rare but can be risk factors for ALS (Al-
Chalabi et al., 1999). Considering the rare nature of mutations in NEFH, disrupted 
neurofilaments and altered structure may modify disease.  Furthermore, a deletion identified 
in PRPH, a type III intermediate filament protein similar to neurofilaments also supports 
increased susceptibility to ALS, (Gros-Louis et al., 2004). Independent mutations have been 
identified in two sporadic cases (Gros-Louis et al., 2004) however further data is required to 
rule out these being rare polymorphisms. Overall, there are a variety of genes in which 
mutations appear to enhance the risk of ALS. However, it can be difficult to determine whether 
mutations cause disease outside of individual cases unless there is additional data such as 
familial segregation supporting this effect.  
As well as mutations increasing ALS susceptibility, mutations in ALS2, C9ORF72, FUS, OPTN, 
SETX, SOD1, TDP43, UBQLN2, VCP and VAMP cause various forms of ALS. When considering 
known gene function, ALS2 is a guanine nucleotide exchange factor for the small GTPase RAB5 
with established roles in endosomal trafficking, as shown in ALS2 deficient mice (Devon et al., 
2006). Mutations have been shown to cause juvenile onset ALS in multiple studies. In 
autosomal dominant frontotemporal dementia and / or ALS families, two studies have very 
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recently identified a heterozygous expanded intronic hexanucleotide repeat (GGGGCC) in 
C9ORF72. This gene has not yet been functionally characterised, however the identified repeat 
expansion is the most common causal variant of ALS and FTLD-TDP identified to date, causing 
almost 40% of familial ALS cases as well as sporadic cases. Like C9ORF72, mutations in FUS 
cause both ALS and FTLD (however with FUS positive, TDP43 negative inclusions). FUS protein 
is highly similar to TDP43 with multiple established roles in RNA metabolism, with the two 
proteins having been shown to function in the same pathways in D. melanogaster (Lanson et 
al., 2011; Wang et al., 2011).  Rare mutations in OPTN also cause ALS. OPTN interacts with a 
variety of proteins with anticipated roles in cellular morphogenesis, membrane trafficking, 
vesicle trafficking, and transcription activation (Faber et al., 1998; Hattula & Peranen, 2000; 
Moreland et al., 2000). Mutations in SETX have been found to be causative of juvenile ALS 
(Chen et al., 2004) as rare autosomal dominant mutations. SETX protein contains a helicase 
domain and has been shown to interact with transcription and RNA processing proteins 
(Suraweera et al., 2009). More recently, five mutations in X-linked UBQLN2 have been 
identified as causative of familial forms of ALS (Deng et al., 2011). UBQLN2 is a member of the 
ubiquitin-like protein family. Similarly, heterozygous mutations have been identified in ALS 
families using exome sequencing in VCP, a member of the AAA+ ATPase family of proteins. 
Mutations in VCP also cause FTLD-TDP and inclusion body myopathy with paget disease of 
bone (IBMPD), in both cases causing TDP43 pathology. Finally, rare mutations have also been 
identified in VAPB protein which has known roles in the unfolded protein response (Nishimura 
et al., 2004).  
Genes associated with ALS and FTLD-TDP have multiple known and unknown functions. 
Furthermore, many genes which contribute towards and cause ALS and FTLD-TDP remain to be 
identified. This is further being addressed through genome wide association studies which aim 
to provide a tool to identify critical loci or provide a reference point for investigation (Schymick 
et al., 2007). There are limitations in the ability to identify causative alleles using this approach 
which include phenotypically variable syndrome presentation, different disease causing alleles 
within a gene, optimal statistical analysis and the importance of rare variants. However, 
despite the variation in known and unknown genes associated with disease, there is 
convergence of multiple pathways in selective neuronal degeneration with TDP43 pathology. 
Broadly, current data supports many characterised functions appearing to show RNA 
metabolic roles or protein stability / degradation functions. For those genes with central roles 
within RNA metabolism multiple potential perturbations may occur. In C9ORF72, a 
hexanucleotide expansion drives disease and this is the most common identified causal variant 
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of familial and sporadic ALS (Majounie et al., 2012; Rademakers, 2012). Outside of C9ORF72, 
FUS and TDP43 have been shown to interact in the same pathways with TDP43 acting 
upstream of FUS in having multiple roles in RNA metabolism (Wang et al., 2011). This has 
extended the data for a subset of ALS and FTLD-TDP causative genes that RNA biology may be 
critical to pathology with mutations potentially altering these RNA roles in driving disease. 
Alternative genes in which mutations cause pathology such as VCP and UBQLN2 also have 
established roles in protein folding and degradation pathways. With clusters of genes in which 
causative mutations surround various known functions further understanding is required. 
There is emerging support for RNA metabolism being critical to TDP43 perturbations which is 
pathologically altered in nearly all ALS and FTLD-TDP cases irrespective of the causative gene in 
which the mutation resides. This may be anticipated considering the extensive interaction 
between TDP43 and the transcriptome. 
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1.3. TDP43 biology pre 2006 
 
1.3.1. Tardbp encoding transcripts 
 
The protein TDP43 is encoded for by the gene TARDBP. In humans, this gene lies on 
chromosome 1. However, in the mouse it is on chromosome 4. Its RNA expression profile is 
given in Figure 1.3 showing that its transcripts are ubiquitously expressed. 
 
Figure 1.3: Tardbp expression profile. Left panel shows human adult tissue expression and right panel shows 
mouse adult tissue expression, as taken from (biogps.org). Colours show tissue type. Values have been normalised 
showing that TDP43 encoding transcripts are widely expressed in both human and mouse tissue. 
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Multiple annotated transcripts are present for TDP43 in human and mouse tissue indicating 
that there is significant complexity in TARDBP / Tardbp RNA processing. This is shown in Figure 
1.4. 
 
 
Figure 1.4: Tardbp transcripts. Figure taken from www.ensembl.org showing Tardbp annotated human and mouse 
transcripts. In both cases Tardp-001 encodes for full length TDP43 however multiple alternate transcripts exist with 
significant variation for both species in the 3’ UTR. 
 
TDP43 protein was first identified for its role in repressing HIV1 transcription (Ou et al., 1995). 
TDP43 was found to bind the Tar DNA sequence and repress transcription through an 
unknown mechanism. Tar is an HIV1 element required for its transcription, with this role 
providing TDP43’s name: Tar DNA binding protein – 43 kDa. Being identified for this role prior 
to its protein structure being characterised, it was later found structurally to belong to the 
family of heterogeneous nuclear ribonucleoproteins (hnRNPs). These are RNA-binding proteins 
involved in multiple aspects of RNA metabolism. They affect processing through localisation, 
transport and translation of mRNAs but also impact on non-coding RNAs (Dreyfuss et al., 2002; 
Chaudhury et al., 2010). As a result, TDP43 is normally localised to euchromatic regions such as 
nuclear speckles and perichromatin fibrils which are regions where splicing and transcription 
occur. 
The characterised protein domains of TDP43 reflect these hnRNP functions as shown in Figure 
1.5 for mouse TDP43. 
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Figure 1.5: Structural domains of mouse TDP43. TDP43 is a 414 amino acid protein. It contains three caspase 
cleavage motifs (purple boxes), DXXD at positions 10, 86 and 119. It also contains a nuclear import (yellow box) and 
export signal (orange box) at positions 82-89 and 239-250 respectively. Two RNA recognition motifs that bind both 
single stranded DNA and RNA are shown (green boxes) with overlapping positions in the mouse, RRM1 at 104-200, 
RRM2 at 192-262. A glycine rich domain is present (red box) at position 274 - 413. Domains defined from 
www.uniprot.org. 
 
TDP43 is highly conserved across species. Amino acid conservation between human and mouse 
protein is 96%. Across multiple species, the poorly defined N-terminal region (all amino acids 
up to the first RNA recognition motif) is highly conserved as are the RNA recognition motifs. 
The N-terminal region was recently shown to mediate a protein-protein interaction with P65. 
However, its high conservation (100% between mouse and human) supports further critical 
roles for TDP43 function (Swarup et al., 2011b). 
RNA recognition motif 1 (RRM1) is necessary and sufficient for RNA-binding (Buratti et al., 
2001; Giordana et al., 2010). TDP43 has a high affinity for binding UG6 and TG repeats with 
increasing affinity as the number of repeats increases (Buratti & Baralle, 2001; Acharya et al., 
2006; Kuo et al., 2009). Deletion studies suggest that RRM2 is not critical for RNA-binding with 
very little known about its functions. It has been proposed to be involved in chromatin 
reorganisation (Ayala et al., 2008b) and has also been shown to interact with single-stranded 
DNA (Kuo et al., 2009). 
The C-terminal (glycine rich region) mediates major protein interactions with other hnRNPs 
and proteins (Wang et al., 2004; Buratti et al., 2005; D'Ambrogio et al., 2009). This region has 
also been shown through deletion experiments to be critical for completing RNA-binding 
functions requiring protein interactions. The C-terminal region is not as highly conserved as 
other domains and modelling supports it being relatively unstructured. It has been shown to 
be a prion-like domain (Udan & Baloh, 2011) which is speculated to play an important role in 
aggregation and pathology as discussed later. The unstructured C-terminal domain may 
provide functional flexibility to enable alterations and multiple protein interactions. TDP43 
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itself functions as a dimer and is predominantly localised to the nucleus. However, it has been 
shown to shuttle to and from the cytoplasm. 
Prior to 2006, TDP43’s identification in binding the TAR DNA sequence was followed by its 
characterisation as a splicing factor for the cystic fibrosis transmembrane regulator (CFTR) and 
apo-A-II genes (Buratti & Baralle, 2001; Buratti et al., 2001; Buratti et al., 2004; Ayala et al., 
2005; Buratti et al., 2005; Mercado et al., 2005). In 2006, it was discovered that TDP43 is a 
major component of ubiquitinated inclusions in ALS and FTLD-TDP (Arai et al., 2006; Neumann 
et al., 2006). Since then, over 600 papers have been published regarding what has emerged as 
the TDP43 proteinopathies (Kwong et al., 2008; Geser et al., 2009; Neumann, 2009). The 
TDP43 proteinopathies consist of ALS and FTLD-TDP where TDP43 pathological changes are 
seen in cases with and without TDP43 causative mutations. Secondarily, in other 
neurodegenerative diseases including some tauopathies, α-synucleinopathies and poly Q 
disorders, pathological alterations in TDP43 are also observed. A large diversity of approaches 
and techniques have been applied to model and modify TDP43 disease. Despite the significant 
progress that has been made, the primary roles of TDP43 in neurons susceptible to 
neurodegeneration are poorly characterised as is the extent to which human mutations are 
gain versus loss of function (both elements are thought to be important and this is discussed 
below when reviewing existing TDP43 models).  
 
1.3.2. TDP43 functions 
 
The diversity of roles for TDP43 in RNA metabolism continues to be established. A 
characterisation by RNA sequencing and exon arrays has established that TDP43 affects around 
30% of the murine transcriptome (Polymenidou et al., 2011). Discussed in more detail in 
Chapter 5, this study was one of the first to show the impact of TDP43 down regulation in 
adult mouse striatum on the transcriptome. With hundreds of mRNA transcript level and 
splicing changes upon TDP43 knock down, TDP43 plays a central role in multiple aspects of 
RNA metabolism, which is anticipated to be relevant to pathology. Disease models and TDP43 
alteration in human pathology are discussed in the next section. Results since 2006 driven by 
TDP43’s roles in neurodegeneration have shown that TDP43 has central roles in general RNA 
metabolism as shown in Figure 1.6. 
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Figure 1.6: TDP43 known roles. Image of a cell showing some of the known functions of TDP43 relating to RNA 
metabolism. Within the nucleus, TDP43 has published roles for interacting with hnRNP family members to affect 
splicing of target RNAs (Buratti et al., 2001; Mercado et al., 2005; Bose et al., 2008; Dreumont et al., 2010), editing 
RNA (Aizawa et al., 2010) and playing roles in pre-miRNA formation by interacting with DROSHA (Buratti et al., 
2010; Kocerha et al., 2011; Kawahara & Mieda-Sato, 2012). As characterised with HIV1 Tar, TDP43 can bind single 
stranded DNA and through unknown mechanisms promote transcription silencing. Inside and outside of the 
nucleus, TDP43 is involved in mRNA stability and RNA transport (Ayala et al., 2008a; Wang et al., 2008; Fiesel et al., 
2010; Godena et al., 2011). Under stress conditions, stress granules form which are thought to silence non-essential 
RNAs and store them during the stress. TDP43 associates with stress granules potentially silencing multiple RNAs 
(Colombrita et al., 2009; Moisse et al., 2009a; Liu-Yesucevitz et al., 2010; Dewey et al., 2011; Parker et al., 2012). 
 
Alongside TDP43’s established roles in RNA metabolism, it has emerged that TDP43 auto-
regulates its own protein levels (Ayala et al., 2011; Polymenidou et al., 2011). The mechanism 
continues to be characterised however there is in vivo data in this thesis and published knock 
out mouse models (Kraemer et al., 2010; Sephton et al., 2010; Wu et al., 2010) for TDP43 auto-
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regulation. TDP43 binding to its own 3’ UTR has been established as critical for auto-
regulation. Data from various models also shows that TDP43 levels are tightly regulated and 
that both significantly reduced and increased levels results in toxicity. Alongside TDP43’s role 
in RNA metabolism, levels of TDP43 protein are also speculated to be important in TDP43 
human pathology, although conclusive data of this remains to be presented. 
Finally, assessment of TDP43 function has shown that the first RRM is necessary and sufficient 
for RNA-binding with the C-terminal glycine rich region being critical for major protein-protein 
interactions. Little information regarding the roles of the highly conserved N-terminal region or 
the second RRM is available. As part of the work described in this thesis, mutations from all 
major domains are functionally assessed to determine their importance in potentially 
establishing the roles of these domains in TDP43 function. 
 
1.4. TDP43 pathology 
 
1.4.1. TDP43 mutations which cause ALS 
 
Mutations in TARDBP are causative of ALS. In rare cases they are also causative of FLTD-TDP 
and these two diseases are part of a clinicopathological spectrum (Geser et al., 2010). They are 
the core of the TDP43 proteinopathies in which TDP43 is pathologically mislocalised and 
modified irrespective of whether the causative mutation is within TDP43. 
Mutations in TDP43 shown to be causative of ALS are given in Figure 1.7. More than thirty 
mutations have been identified clustering in the C-terminal glycine rich region. All mutations 
are dominant causing both familial and sporadic ALS cases. The mutations are reviewed in 
more detail elsewhere (Da Cruz & Cleveland, 2011). 
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Figure 1.7: TDP43 mutations which cause ALS. Figure showing the functional domains of TDP43 and where human 
causative mutations have been identified. Nearly all mutations cluster in the C-terminal glycine rich region. All 
mutations are dominant missense mutations except Y374X which is a nonsense mutation. The mutation D169G was 
identified in a sporadic case and is located in the first RRM, however no other mutations have been identified in this 
region. 
It is unknown whether TDP43 mutations cause loss or gain of function with extensive data 
from cell culture and animal models (discussed below) showing both elements as being critical 
to TDP43 pathology. The result in human patients is TDP43 aggregates in neurons and glia in 
the central nervous system (Neumann et al., 2006). Pre-inclusions have been observed, 
thought to form at early disease stages (Mori et al., 2008; Sreedharan et al., 2008). This is 
followed by dense inclusions in motor neuron axoplasm, as well as filamentous skeins. In FTLD-
TDP, pathology is seen as inclusions in nuclei, axoplasm and neurites of forebrain neurons 
(Mackenzie et al., 2006; Sampathu et al., 2006; Mackenzie et al., 2011) reflective of the disease 
phenotypes in the patient. Most, but not all inclusions are ubiquitinated (Giordana et al., 
2010). These changes are primary hallmarks of pathology in these TDP43 proteinopathies. In 
ALS and FTLD-TDP, spinal cord inclusions are labelled with both N- and C-terminal antibodies, 
but only C-terminal antibodies recognise inclusions in brain (Igaz et al., 2008) showing cleaved 
fragments in disease.  
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1.4.2. TDP43 pathological changes 
 
TDP43 undergoes a series of molecular changes in TDP43 proteinopathies. The cause / effect 
of each of these continue to be investigated to find the critical alterations which are the 
drivers of pathology. The pathological changes are listed below. 
 
Hyperphosphorylation and polyubiquitination 
TDP43 protein is hyperphosphorylated (at multiple residues including S409 / 410) correlating 
with a shift towards insoluble protein. These residues are not detected as being 
hyperphosphorylated in a non-ALS context. This has been shown in patients and replicated in 
animal models (Wegorzewska et al., 2009; Shan et al., 2010; Stallings et al., 2010). 
Hyperphosphorylation appears as an early event and is hypothesized to affect protein 
degradation and toxicity, although it is not required for TDP43 cleavage, toxicity and 
aggregation in cell culture models (Dormann et al., 2009; Zhang et al., 2009). TDP43 is also 
poly-ubiquitinated (both hyperphosphorylated and polyubiquitinated forms are not readily 
detected in normal brain tissue). 
 
Solubility changes 
 
TDP43 is sequestered in predominantly cytoplasmic sarkosyl insoluble inclusions (intranuclear 
inclusions can also occur). There is a shift towards increased insolubility occurring in glia and 
neurons (Neumann et al., 2006; Sampathu et al., 2006). This correlates with nuclear clearance, 
hyperphosphorylation, polyubiquitination and mislocalisation. There is data for mislocalised 
TDP43 in forming pre-aggregate structures (Mori et al., 2008; Giordana et al., 2010) which are 
speculated to be the precursors of inclusions. This may link in to TDP43’s role in stress 
granules. As discussed above, TDP43 naturally localises to stress granules potentially silencing 
and protecting its RNA bound targets during stress. Stress coupled with the effects of TDP43 
mutations may alter this process in contributing towards aggregate formation although in 
models, TDP43 aggregation itself appears not necessary for toxicity, as discussed later. TDP43 
solubility change and mislocalisation is also hypothesised to affect TDP43 auto-regulation 
(Polymenidou et al., 2011). 
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Protein cleavage 
 
TDP43 is cleaved into smaller 35 and 20-25 kDa C-terminal fragments (these are not detected 
in wild-type brains and have been shown at different lengths, seen particularly in the cerebral 
cortex). These cleavage products are labelled in inclusions (Igaz et al., 2008). TDP43 contains 
caspase 3 motifs at locations which have been suggested as being able to produce the 35 and 
25 kDa fragments (Zhang et al., 2007). Overexpressing the C-terminal fragments results in 
hyperphosphorylated and poly-ubiquitinated C-terminal fragments (Caccamo et al., 2009; 
Nishimoto et al., 2010). Data in models without C-terminal fragments indicates that toxicity 
can also occur without their presence (Shan et al., 2010; Igaz et al., 2011). 
The pathological changes within TDP43 protein correlate highly with each other and continue 
to be investigated to determine the nature of which occur early / late and which are cause / 
effect. This ultimately results in ALS or other TDP43 proteinopathies. The sequence of changes 
that occur and which are protective versus those that are toxic has yet to be shown. Modelling 
approaches with animals and cells have begun to show the order of changes that occur, for 
example, hyperphosphorylation is thought to be an early event with polyubiquitination 
occurring later. Further data is required to assess the impacts of these changes on known 
functions of TDP43, with particular focus on how they impact on TDP43’s RNA metabolism 
functions including splicing and other transcript processing roles. 
 
1.4.3. TDP43 models 
 
In order to understand TDP43 biology and deconstruct the disease process, multiple cell and 
animal models have been generated. The consensus from loss and gain of function modelling 
approaches has shown that levels of TDP43 are critical to survival and neuronal health. A 
significant reduction or increase in protein levels results in toxic consequences with data 
supporting both reduced and enhanced TDP43 levels impacting on neuronal function and 
survival. Within humans, it is not known whether mutations result in a loss or gain of function, 
however animal modelling approaches support both mechanisms contributing to disease. 
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Loss of function models 
Knock out TDP43 lines have been generated in Caenorhabditis elegans (worm), D. 
Melanogaster (fruit fly), Danio rerio (zebra fish) and M. musculus (mouse). In worms, knockout 
of tdp-1, the Tardbp ortholog, does not result in overt defects (Liachko et al., 2010). However, 
worm tdp-1 contains a poorly conserved glycine rich region whose lack of conservation may 
contribute to the absence of overt phenotypes. In the fly, knocking out TBPH (the Tardbp 
homolog) is lethal or results in severe phenotypes. In fly TBPH knockouts, survival through 
hatching from the pupal developmental stage is significantly reduced with those flies able to 
hatch displaying shortened lifespan and strong motor phenotypes (Feiguin et al., 2009). These 
fly TBPH knockouts can be rescued by ectopic expression of the wild-type human TDP43 
transgene. Alternative fly knock out models also show semi-lethality and neuronal phenotypes 
including abnormal neuromuscular junctions and reduced dendritic branching (Feiguin et al., 
2009; Lu et al., 2009; Fiesel et al., 2010). Likewise knockdown of fish TARDBP results in motor 
neurons that are shorter and display abnormal branching (Kabashi et al., 2010).  
Within the mouse, three knock out models have been made (Kraemer et al., 2010; Sephton et 
al., 2010; Wu et al., 2010). In all three cases, homozygous embryonic lethality is observed 
between embryonic day E3.5-8.5 days post coitum (dpc) due to inner cell mass growth defects. 
An attempt to surpass this developmental lethality through the generation of a tamoxifen 
inducible knock out TDP43 has also been made (Chiang et al., 2010). Once the knock out was 
activated a rapid lethality resulted. A further loss of function approach from Professor 
Zuoshang Xu (UMass) was presented at the American Society for Neuroscience conference 
2011. These results have not been published at the time of writing this thesis. In this approach, 
a transgenic RNAi mouse has been generated modelling partial loss of TDP43 function. The 
transgenic RNAi knocks down Tardbp RNA levels to 50% and TDP43 protein levels to 80% of 
that of non transgenic controls. This results in a progressively “wobbly” gait which progresses 
to paralysis by 9 weeks. There is around 60% motor neuron loss with TDP43 negative, ubiquitin 
positive inclusions. In parallel to these mouse models at a cellular level, knockdown of TDP43 
in HeLa, U2OS and Neuro-2a cell lines results in cell death and in the Neuro-2a cells affects 
neurite growth (Iguchi et al., 2009).  
Complete loss of TDP43 across cell lines and various animal models is generally not conducive 
with survival. Where fly and fish survive, neuronal defects in branching and size are observed. 
This indicates that TDP43 plays critical roles in multiple neuronal processes that are 
significantly altered in the absence of TDP43. In the mouse, Professor Xu’s transgenic RNAi 
39 
 
approach does show selective neuronal degeneration that matches human selective 
degeneration in progressive motor neuron loss. But the model does not contain TDP43 in 
inclusions, TDP43 mislocalisation from the nucleus or C-terminal fragments as seen in human 
patients. This shows that through a loss of function mechanism, the output of motor neuron 
loss can occur in mice, but the pathological hallmarks are not identical to those in humans. 
Purely through loss of function, the mouse as a model may not be able to recapitulate certain 
elements of human pathology. The data from across species is that pathology and neuronal 
dysfunction are associated with loss of function and this will be critical to human pathology. It 
may also be associated with gain of function and possible dominant negative effects. This is 
outside of TDP43’s overtly important role in development in multiple species, where it is 
unknown whether these roles at this stage are relevant to neuronal pathology. 
 
Transgenic models 
A vast number of transgenic models across species have been generated. They have been 
reviewed previously (Joyce et al., 2011). In nearly all cases, overexpression of wild-type or 
mutant TDP43 is toxic with a dose dependent effect. Transgenic models with various TDP43 
alterations (sequence deletions or human pathogenic mutations) have also been generated, 
showing overall that multiple alterations in TDP43 can impact on the pathological outcome. 
 
Saccharomyces cerevisiae, Danio rerio, Caenorhabditis elegans and Drosophila melanogaster 
Overexpression of human TDP43 in yeast results in toxicity that is dependent partly on 
mitochondrial dysfunction and oxidative stress. Overexpression of both wild-type and mutant 
forms is toxic (Braun et al., 2011). In fish overexpressing wild-type human TDP43, the result is a 
motor axonopathy with shorter axon length and abnormal branching phenotypes (Laird et al., 
2010).  Both wild-type and mutant overexpressed TDP43 localise to cell nuclei. Injecting TDP43 
constructs also results in motor deficits and deletion experiments show that the C-terminus of 
TDP43 is required for pathogenicity (Kabashi et al., 2010). In worms, wild-type and mutant 
overexpression models have been generated with both being pathogenic. Overexpressing wild-
type TDP43 is toxic requiring RNA-binding and the C-terminal region (Ash et al., 2010). Multiple 
models including worms show GABAergic deficits and interestingly, mutating serines 409 / 410, 
that are hyperphosphorylated residues in human pathology, ameliorates the motor deficits 
(Liachko et al., 2010).  
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In the fly, models have been generated overexpressing TBPH and human TDP43. TBPH 
overexpression causes a sensory neuron branching axonopathy (Lu et al., 2009). Human 
mutant TDP43 overexpression (Q331K and M337V) also causes dendritic branching 
phenotypes (Lu et al., 2009). Overexpression of wild-type TDP43 in flies causes retinal 
degeneration, axonal loss in mushroom bodies and motor neuron death. It has pathogenic 
effects on axonal branching and neuromuscular junctions (NMJs) (Hanson et al., 2010; Li et al., 
2010). Mutating phenylalanines at positions 147 / 149 which are necessary for RNA-binding 
reduces overexpression induced toxicity producing mild motor deficits (Voigt et al., 2010). Full 
length overexpressing TDP43 mutants show that TDP43 localises to the nucleus to induce 
pathogenicity so there is no nuclear depletion as seen in human patients. Mild abnormalities in 
the eye are also worsened when mutating the nuclear localisation signal (NLS) (Miguel et al., 
2011). Considering full length TDP43 and modified forms, there are no aggregates or 
cytoplasmic mislocalisation phenotypes. However, there is toxicity. Overexpressing full length 
TDP43 in flies is toxic to neuronal cells, but overexpressing C-terminal fragments has been 
shown as less toxic (Li et al., 2010; Voigt et al., 2010). These overexpression models overall 
show significant motor axonopathy with wild-type overexpression localising more to nucleus 
and TDP43 mutant forms localising slightly more to the cytoplasm. This is also reflected in 
rodent models discussed below, showing that pathogenicity in neuronal systems in these 
models does not occur through identical mechanisms seen in human patients and that 
overexpression is toxic. 
 
Rodent models (Rattus norvegicus and Mus musculus) 
Multiple transgenic mouse models overexpressing TDP43 have been generated. A variety of 
wild-type and mutant forms of TDP43 have been expressed with different neuronal and 
promoters with ubiquitous expression. These have been reviewed (Joyce et al., 2011) and 
show that overexpression of either wild-type or mutant TDP43 forms (such as A315T) generally 
results in dose dependent toxicity.  Various motor and cognitive phenotypes are also observed 
in different models. Mice overexpressing TDP43 with a deleted nuclear localisation signal (Igaz 
et al., 2011) show behavioural abnormalities and neurodegeneration, however endogenous 
TDP43 is still expressed in the nucleus. With overexpression of TDP43 over a certain threshold 
of exogenous protein production the endogenous protein is downregulated by auto-
regulation. Overexpression models may support a gain of function model however when 
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considering individual models, the degree of endogenous protein down regulation (due to 
TDP43 auto-regulation) must be considered as this may confer elements of loss of function. 
In transgenic rats wild-type and mutant (M337V) overexpressers have been generated (Zhou et 
al., 2010). Wild-type transgenic rats do not show early paralysis but overexpressing TDP43 
M337V results in an early paralysis phenotype. This supports increased mutant TDP43 toxicity, 
which is not always reflected in other models / species. In rodent models, overexpressed 
TDP43 localises to the nucleus and is toxic. In both the mouse and rat, endogenous protein in 
all of the rodent models has not been completely depleted from the nucleus. Despite this, 
some transgenic rodents do show TDP43 positive inclusions but they are rarely seen 
(Wegorzewska et al., 2009; Shan et al., 2010; Stallings et al., 2010; Wils et al., 2010; Xu et al., 
2010; Igaz et al., 2011). Some transgenic mice also contain TDP43 negative mitochondrial 
aggregates (Wegorzewska et al., 2009; Shan et al., 2010; Stallings et al., 2010; Wils et al., 2010; 
Xu et al., 2010), suggesting abnormal alterations in metabolic pathways. When overexpressing 
truncated TDP43 (C-terminal fragments) this results in cytoplasmic aggregates that are 
hyperphosphorylated and polyubiquitinated (Dormann et al., 2009; Igaz et al., 2009; Nonaka et 
al., 2009; Zhang et al., 2009). Rodent models overexpressing TDP43 have also been shown to 
have lower molecular weight TDP43 fragments (Wegorzewska et al., 2009; Shan et al., 2010; 
Stallings et al., 2010; Tsai et al., 2010; Wils et al., 2010; Xu et al., 2010).  Levels of these lower 
molecular weight fragments increase with disease progression in some models (Wegorzewska 
et al., 2009; Stallings et al., 2010; Wils et al., 2010). TDP43 C-terminal fragments are also 
soluble when extracted from tissue (Wegorzewska et al., 2009; Tsai et al., 2010; Wils et al., 
2010; Xu et al., 2010) and are in the nuclear fraction, which does not reproduce what is seen in 
human ALS patients (Wils et al., 2010). Furthermore not all transgenic rodents show C-terminal 
fragments (Shan et al., 2010; Igaz et al., 2011) but still show selective neurodegeneration. An 
alternative approach using a bacterial artificial chromosome (BAC) to express wild-type TDP43 
in all mouse tissues has been completed replicating many of the major pathological hallmarks 
of human TDP43 ALS (Swarup et al., 2011a). With this more subtle overexpression approach, 
mice showed age dependent TDP43 positive ubiquitinated inclusions, C-terminal fragment 
production, axonopathy and neuroinflammation. Despite these features, overt motor neuron 
degeneration was not present. Overall, TDP43 transgenic rodents in many cases do 
recapitulate aspects of the phenotypes observed in human TDP43 proteinopathies although 
few show progressive motor neuron degeneration. Transgenic overexpressing mice show 
selective motor neuron degeneration and motor phenotypes accurately reflecting motor 
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changes in human patients. The complexity of the underlying pathology driving these changes 
in humans are not all observed, however multiple aspects are recapitulated.  
 
Non-human primate model 
More recently a non-human primate model of ALS has been generated (Uchida et al., 2012). By 
overexpressing wild type human TDP43 in cynomolgus monkey (Macaca fascicularis) spinal 
cord through viral injection of a transgene, these monkeys develop progressive motor 
weakness. They show muscle atrophy and distal hand fasciculation.  At a molecular level there 
are cystatin C positive cytoplasmic aggregates and TDP43 mislocalisation from the nucleus of 
specific motor neuron subsets (lateral nuclear group). This study did not see cleavage 
fragments or recapitulate all features of human ALS; however they argue that this model is 
“superior” to mouse models because they recapitulate aspects of the human condition not 
seen in rodent models. This model is further support that overexpressing wild-type TDP43 
protein is toxic. 
 
1.4.4. Summary of models and disease 
 
The overall picture from TDP43 models across cells and species is that TDP43 plays a critical 
role in survival and neuronal function. Too little or too much TDP43 results in toxic outcomes 
indicating that TDP43 auto-regulation may be a critical factor in pathology. Within TDP43 
proteinopathies and specifically ALS, multiple hallmarks of pathology are present. Expression 
levels of TDP43 encoding RNA are upregulated in human ALS / FTLD-TDP one and a half fold as 
measured by quantitative real time PCR (Mishra et al., 2007; Gitcho et al., 2009) and there are 
a series of modifications to TDP43 protein. It is unknown whether TDP43 protein levels are 
upregulated, although one study has shown increased levels in cerebrospinal fluid of ALS 
patients (Kasai et al., 2009). If so, it is not known if that protein is available for normal function, 
or whether the amount of functional TDP43 is downregulated (potentially sequestered in 
inclusions). It is also yet to be determined whether many TDP43 modifications cause aggregate 
formation and toxicity or are normal responses to pathology. Within models that show 
selective neuronal vulnerability or relevant phenotypes, aspects of the human condition are 
recapitulated. For example hyperphosphorylation, which is seen in human ALS, is not required 
43 
 
for toxicity in some models, with TDP43 cleavage or aggregation in cells (Dormann et al., 2009; 
Zhang et al., 2009). Furthermore, cytoplasmic inclusions can form when overexpressing C-
terminal fragments or an NLS TDP43 mutant (Igaz et al., 2009; Nonaka et al., 2009).  But 
toxicity often occurs without these features in many models, where overexpressing both 
nuclear and cytoplasmic TDP43 is toxic. Data from models supports both loss and gain of 
function mechanisms leading to neuronal abnormalities and degeneration. Dissecting species 
differences in TDP43 function will be necessary to delineate whether models can accurately 
reproduce the human condition. The high degree of conservation of TDP43 and the consistent 
axonopathy phenotypes show that existing models are very useful tools. They can be used to 
understand TDP43 function and dysfunction in human pathology and alongside alternative 
models must be used to address hypotheses behind TDP43 pathology. 
 
1.4.5. Hypotheses for TDP43 pathology 
 
Importance of TDP43 levels in toxicity 
Across animal models, toxicity is generally increased as a dosage response effect rather than 
wild-type versus mutant TDP43 overexpression. Higher expression levels in transgenic mice 
can also downregulate endogenous mouse TDP43 (Xu et al., 2010; Igaz et al., 2011) which 
correlates highly with neurodegeneration. This shows in vivo the impacts of TDP43 on auto-
regulation / down regulation of TDP43 protein, potentially causing or contributing to neuronal 
phenotypes. When TDP43 is removed or highly downregulated in various models, neuronal 
health and survival are compromised.  
TDP43 auto-regulation is thought to occur in the nucleus (Polymenidou et al., 2011). TDP43 
regulates its own RNA transcript by binding to its 3’ UTR (Ayala et al., 2011; Polymenidou et al., 
2011; Tollervey et al., 2011). There is emerging evidence that a disruption of TDP43 auto-
regulation may be important in pathology with models linking auto-regulation disruption and 
pathology having been proposed (Lee et al., 2012). Both loss and gain of auto-regulation 
models rely on a disruption of TDP43 in regulating its transcript levels. Further characterisation 
in various cell and animal models is required to determine the relevance of different proposed 
auto-regulation mechanisms (Ayala et al., 2011; Polymenidou et al., 2011) with assessment of 
whether human pathogenic mutations directly alter the dynamics of this process.  
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Importance of RNA metabolism 
Alongside the potential importance of auto-regulation, there is emerging data that TDP43’s 
roles in RNA metabolism may be crucial to TDP43 proteinopathies. A variety of genes are 
associated with ALS and atypical motor neuron disease with roles in RNA metabolism. Shortly 
after the identification that mutations in TDP43 cause ALS, mutations in FUS were identified 
(Kwiatkowski et al., 2009; Vance et al., 2009). FUS is structurally highly similar to TDP43 and 
has since been shown to directly bind TDP43 (Ling et al., 2010) and act downstream of TDP43 
in common pathways (Wang et al., 2011). This further enhanced the potential importance of 
perturbations in RNA metabolism potentially being responsible for diseases such as ALS. 
Overall, TDP43 is part of an extensive RNA metabolic network, as would be expected with it 
being an hnRNP. Down regulation of TDP43 has been shown to alter 30% of the murine 
transcriptome (Polymenidou et al., 2011). With such extensive interactions with RNA and a 
diversity of functions (as shown in Figure 1.6) mutations in TDP43 may disrupt RNA 
metabolism through multiple proposed mechanisms.  Assessment of this is a viable hypothesis 
to being a causal mechanism behind TDP43 proteinopathies (Johnson et al., 2009; Lagier-
Tourenne et al., 2010; Strong & Volkening, 2011). 
 
Emergence of the prion hypothesis 
TDP43 has a C-terminal prion like domain (Johnson et al., 2009; Fuentealba et al., 2010; Gitler 
& Shorter, 2011; Guo et al., 2011) and in cell culture this promotes features such as 
aggregation. In vitro TDP43 is naturally prone to aggregation (Johnson et al., 2009) and a novel 
hypothesis has emerged regarding TDP43 being prion-like. In the case of diseases such as ALS, 
there is a focal initiation of disease with symptoms progressing. Under this hypothesis, TDP43 
spreads in a prion-like manner sequestering wild-type protein and steadily progressing through 
specific neural pathways. A human pathogenic change has been shown to increase aggregation 
ability (Guo et al., 2011) potentially supporting human mutations altering the properties of 
TDP43 in the prion hypothesis context. 
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1.5. ENU approach (considering pathology): An allelic series of Tardbp 
mutations to understand TDP43 biology 
 
TDP43 is a widely expressed protein with extensive roles in RNA metabolism. These roles 
continue to be focused on in driving forward TDP43 proteinopathy research. TDP43 is likely to 
have critical roles in other aspects of biology that are yet to be defined. With such diverse roles 
already characterised, it remains a major challenge to determine how these roles relate to 
human pathology. Understanding this will provide a clear understanding of the mechanisms 
driving TDP43 proteinopathies and ultimately provide the targets for effective treatments and 
a potential cure for these devastating diseases. 
Loss of function and transgenic overexpressing models have been discussed and show across 
species that both elements may be relevant to neuronal health and pathology. Of those 
presented, various aspects of human pathology have been recapitulated but no model has 
shown all the major hallmarks of ALS or FTLD-TDP.  
Although the aim is to replicate human conditions as best as possible, models that recapitulate 
certain aspects of disease remain powerful tools for understanding elements of pathology as 
well as normal protein function. For example, in the case of rodent transgenic models TDP43 
positive inclusions are rare yet some lines of mice still show selective motor neuron 
degeneration and many changes relevant to the human condition, such as inflammatory 
changes and astrogliosis (Wegorzewska et al., 2009; Wils et al., 2010; Zhou et al., 2010). 
For the work described in this thesis, one nonsense and nine missense mutations have been 
identified in mouse Tardbp. These are endogenous mutations that are expressed in an 
identical fashion to human pathogenic mutations. The nonsense mutation (Q101X) acts in a 
similar fashion to the knockouts and is characterised alongside the K160R mutation, which may 
also show a partial loss of function. These mutations were originally re-derived due to their 
identification from the MRC Harwell archive. They represent the first mice of a potential allelic 
series for deconstructing the biology of TDP43 in the mouse. They are complementary models 
to knockouts and transgenic mice asking questions that these alternative models are less able 
to at an endogenous level. 
Alongside the Q101X and K160R mutations all alleles were functionally assessed with F210I 
showing a strong deficit in RNA-binding and RNA functions. It is a strongly hypomorphic allele 
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with its identification and characterisation presented in this thesis. This provides an alternative 
loss of function allele particularly relevant to addressing auto-regulation and TDP43’s roles in 
RNA metabolism. All of the animal models generated and hypotheses proposed in reviews may 
support auto-regulation and RNA metabolism alterations as being key processes in TDP43 
proteinopathies. Certainly at an endogenous level in the mouse, F210I is a hypomorphic allele 
that can contribute to evaluating this. It will also provide a model in which to determine the 
impact of loss of function on post mitotic neurons, which has yet to be assessed. There is data 
for loss of function being critical to pathology and the F210I allele in the mouse provides an 
ideal tool to assess the relevance of loss of RNA-binding function and its impacts in disease. 
Outside of the data for mutations presented in this thesis, recent data from the laboratory on 
the M323K mutation supports it being a gain of function allele. This result is not a component 
of this thesis, but it shows how an allelic series provides an array of mutations that can show 
multiple effects, whether they are complete loss, gain, hypomorphic or dominant negative 
effects.  
By being completely random, ENU is hypothesis generating and has no a priori assumptions. 
The generation of multiple random mutations in TDP43 requires an assessment of each of 
these mutations which is the aim of the work of this thesis. This provides novel alleles that can 
be used as tools to deconstruct TDP43 biology, and this is needed to further understand TDP43 
function.  A complementary approach is to generate knock-ins. However, this can be difficult 
and lengthy in process. The allelic series has been characterised and mutations in previously 
uncharacterised residues show clear effects, providing a series of mutations that will be useful 
to understanding TDP43 biology in the future. Characterisation of a number of lines continues 
with the aim of deconstructing TDP43 biology and potentially modelling pathology.  
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1.6. Aims of the work presented in this thesis 
 
The aims of the data presented in this thesis are to utilise an allelic series of endogenous 
mouse TDP43 mutations as a complementary approach to knock-out and transgenic 
overexpression mouse lines. Ten point mutations spanning all major domains of mouse TDP43 
were identified with the aim to determine their functionality in deconstructing TDP43 biology 
and potential dysfunction in pathology. In order to address this, the Q101X and K160R 
mutations, which were the first mutations identified, have been derived as mice without a 
priori data on their functionality, which has been assessed longitudinally at the behavioural 
level. Once all ten mutations were identified, an in vitro CFTR mini-gene assay was used to 
assess all mutations in order to guide further work during the PhD. F210I, a mutation in the 
second RNA recognition motif was shown as having deficient splicing activity of the CFTR mini-
gene and the degree of loss of function was further characterised in vivo. The bullet points 
below summarise the aims assessed. 
 To  rederive and generate mice harbouring TDP43 Q101X and K160R mutations and 
assess animal viability 
 To perform a longitudinal behavioural characterisation of Q101X and K160R mice. 
Phenotypic tests include: SHIRPA, grip strength, rotarod, startle response and open 
field 
 To generate compound (TardbpQ101X/K160R) mutants and perform a behavioural 
characterisation to assess for additive or interactive effects and to assess in vivo the 
ability of K160R to auto-regulate 
 To molecularly characterise mutant TDP43 using both RNA and protein analysis 
 To assess in vitro whether any of the mutations identified from the MRC Harwell and 
RIKEN ENU archives show any functional alterations (loss or gain of function) using the 
CFTR mini-gene assay (of which the mutant F210I was deficient) 
 To determine the mechanism of F210I CFTR mini-gene splicing functional deficits 
 To rederive and generate mice harbouring TDP43 F210I and confirm altered 
functionality in vivo 
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2. Materials and Methods 
 
2.1. Behavioural phenotyping 
 
2.1.1. License 
 
All mice were phenotyped in accordance with conditions stated on Home Office project license 
30/2758, held by Professor Elizabeth Fisher. My personal license in completing this work is 
30/8612 (L285). Mice were maintained at MRC Harwell, following all Home Office conditions as 
specified in project and personal licenses. All mice that were sick were assessed by the Named 
Animal Care and Welfare Officer (NACWO). All procedures were recorded for Home Office 
records. 
 
All behavioural tests were completed blind. This was achieved through applying a numbering 
system for every mouse on the reverse of the card where the genotype was hidden. This 
allowed staff to continue to maintain the colonies whilst simultaneously allowing the assessor 
to be blind to the genotype when completing tests. All tests were individually completed at 
approximately the same time of the day to minimise behavioural variation associated with 
circadian rhythms. 
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2.1.2. SHIRPA 
 
SmithKline Beecham, Harwell, Imperial College, Royal London Hospital, phenotype assessment 
(SHIRPA) was used as a first line screening test. Mice were assessed using the SHIRPA set up 
shown in Figure 2.1. 
 
 
Figure 2.1: Photograph of SHIRPA equipment. To the left is a viewing jar on an elevated platform. The mouse is 
then transferred to the main arena for a series of tests before being assessed on a grid shown in front of the SHIRPA 
arena. 
The SHIRPA equipment consists of: 
 Clear perspex cylindrical viewing jar (14 cm diameter, 18 cm height) 
 Tripod (7.5 cm height). 
 Plastic sheet [sandpapered down to create a surface that is not smooth] (20 cm x 20         
cm) 
 Clear perspex arena (60 cm length, 37 cm width and 18 cm height). In the floor of the 
arena is a perspex sheet. A grid (40 cm x 20 cm) with 12 mm mesh (approximate) is secured 
across the top of the width of the box 
 Institute of hearing research (IHR) click-box (generates a brief 20 KHz tone at 90 dB) 
 Clear perspex tube (3 cm diameter, 20 cm length) 
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2.1.3. Modified SHIRPA procedure 
 
Mice were placed in the assessment room and allowed to acclimatize to the room for more 
than fifteen minutes. The area was wiped clean with alcohol and allowed to dry before use to 
prevent any smell being detected by the mice. Under a biological safety cabinet, the viewing 
jar was placed upright on top of the plastic sheet. The mouse was removed from its home cage 
and placed into the viewing jar where highlighted behaviours were recorded without 
disturbing the mouse. These behaviours included body position, respiration rate and tremors. 
The mouse was then transferred to the centre of the arena inside the viewing jar, using the 
plastic sheet underneath the jar to contain the mouse. The plastic sheet was removed from 
underneath the viewing jar at approximately 25 cm above the arena floor. A sequence of 
further behaviours were then scored including locomotor activity, gait and startle response. 
The mouse was then removed from the arena gripping the tail between the thumb and 
forefinger. It was suspended 20 cm above the arena to identify whether the mouse struggled 
when held by its tail. The colour gradations of the plantar surface and digits of forelimbs were 
noted as well as forward curling (i.e. head to abdomen) of the mouse when held by the tail. 
The mouse grasping its limbs when held by the tail was also scored. It was then placed on the 
grid above the arena allowing front paws to grip bars. Whilst holding rear paws elevated, the 
body tone of the mouse was assessed. The mouse was then scruffed to assess limb tone. Limb 
grasping when suspended by the tail and body tone are shown in Figure 2.2 and Figure 2.3. 
 
 
 
 
 
Figure 2.2: Limb grasping.  Photograph showing normal (left) response by a wild-type mouse when suspended by 
the tail. Limbs and digits on paws are extended. Limb flapping when suspended is also normal. Right panel (a 
compound heterozygote Tardbp
Q101X/K160R 
mouse) shows rear limb grasping when suspended. Rear limbs are not 
continuously splayed, with foot and digit curling. Limb grasping is also seen in front paws which instead of being 
extended outwards grasp each other. 
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Figure 2.3: Body tone assessment.  Photograph showing mouse spread on grid above SHIRPA arena. Thumb and 
index finger are used to feel rear body tone. There is a basal muscular tone with an elicited response. The mouse 
must be calm as it may reflexively hunch its rear body completely which is not a body tone response. 
 
The mouse was then placed into the clear perspex plastic tube with the tube rolled slowly until 
the mouse inside it was upside down to observe the righting reflex. The grid was then placed 
vertically on top of the SHIRPA arena with the mouse placed at the top of grid to assess its 
ability to climb down the grid to the horizontal base. The mouse was made to travel down 
vertically and straight or replaced at top of grid if it tried to turn sideways or upwards. At the 
end of the SHIRPA, scores were made for whether or not the mouse bit during the screen and 
whether the mouse was vocal during the screen.  
The basis of the SHIRPA protocol has been adapted from the EMPRESS phenotyping screen 
(empress.har.mrc.ac.uk). This protocol has been modified to match the protocol completed by 
myself. A scoring sheet for all scored behaviours is given in the Figure 2.4 with typical scores 
and explanations given. 
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            COMMENTS
Operator
Date of Birth (dd/mm/yy)
Animal
Sex
Weight
VIEWING JAR
Body Position 0-5 3 Sitting or standing
Spontaneous Activity 0-4 2 Vigorous scratch, moderate movement
Respiration Rate 0-3 2 Moderate
Tremor 0-2 0 Absent
Defecation n 1 Number
Urination n 1 Size - small
Bizarre Behaviour etc.(comments)
ARENA
Transfer Arousal 0-6 3 Brief freeze then active movement
Locomotor activity n 6 Movement around arena
Palperebral Closing 0-2 0 Eyes wide open
Piloerection 0-1 0 None
Gait 0-3 0 Fluid movement
Pelvic Elevation 0-3 2 Normal (3mm)
Tail Elevation 0-2 1 Elevated, not stiff
Startle Response 0-3 2 Jumps less than 1 cm
Touch Escape 0-3 2 Flees prior to touch
Positional Passivity 0-4 0 Struggles when held by tail
TAIL SUSPENSION
Limb Grasp 0-1 0 None
Limb Grasp-OTHER 0-1 0 None
Visual Placing 0-4 2 Upon vibrissae contact
Grip strength 0-4 2 Moderate grip, effective
Body Tone 0-2 2 Extreme resistance
Pinna Reflex 0-2 -
Corneal Reflex 0-2 -
Toe Pinch 0-4 -
Abnormal big toe 0-1 -
Wire Manoeuvre 0-4 0 Active grip with hind legs
SUPINE RESTRAINT
Body Length (mm) n
Heart Rate 0-2 1 Normal
Limb Tone 0-4 2 Moderate resistance
Abdominal Tone 0-2 1 Slight resistance
Provoked Biting 0-1 0 None
TEST AREA
Righting Reflex 0-3 0
Contact Righting Reflex 0-1 0 Normal, lands on four legs
Catelepsy(-ve geotaxis) 0-4 0 Normal grip
Fear 0-1 0 None
Irritabiity 0-1 0 None
Aggression 0-1 0 None
Vocalization 0-1 0 None
Date
 
Figure 2.4: SHIRPA sheet. SHIRPA sheet components scored with normal values for a wild-type mouse given. 
Explanation of the normal value is also provided. Additional comments are noted during SHIRPA for any other 
abnormal behaviour. 
 
54 
 
2.1.4. Rotarod 
 
The accelerating rotarod test assesses balance and motor coordination. An accelerating 
rotating rod (UgoBasile, France) starting at four revolutions per minute (rpm) increased to 40 
rpm over 300 seconds with the time that each mouse could stay on recorded. 
Equipment: 
Commercially available rotarod apparatus modified with rubber foam coating. Dimensions of 
the apparatus: rotating rod diameter is 5 cm, made of hard plastic material covered by grey 
rubber foam (cut from insulation material to provide better grip for the mice); lane width is 5 
cm with five lanes. 
Protocol: 
Mice were acclimatised in the test room for 15 minutes. Up to five mice from the same cage 
only were placed on the rotarod with a steady speed of 4 rpm. All mice were stably on the 
rotarod before beginning the run.  The programme was then started which steadily increased 
the rotation speed. If a mouse held on to the rod and spun rather than running, three spins 
were allowed then the time was stopped for that mouse. Times were recorded as mice fell off, 
up to 300 seconds. Once completed mice were returned to their cages and the rotarod cleaned 
with 70% ethanol, which was allowed to dry before a repeat run with the next cage. All mice 
were tested then repeated from the first tested cage again (once more than 15 minutes had 
passed). Three measurements per mouse per day over three days were recorded, using the 
average of all nine values for analysis.  
 
2.1.5. Grip strength 
 
Grip strength (Coupan, BioSeb) is used to measure muscle strength. Forelimb strength is 
measured twice with an average value recorded, followed by total limb (fore and hind) 
measurements. 
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Grip strength equipment: 
A BioSeb grip strength meter was used. The system is supplied with a single grid (400 x 180 x 
200 mm), which connects to the sensor, shown in Figure 2.5. 
 
 
 
 
 
 
 
Figure 2.5: Forelimb grip strength assessment. 
Protocol: 
The unit of measurement of the sensor was delivered in grams mode. The mouse was removed 
from its cage, gripping the base of the tail between the thumb and the forefinger. It was gently 
lowered over the top of the grid so that only its front paws could reach and grip the grid. 
Keeping the torso horizontal the mouse was pulled back steadily (not jerking) until the grip was 
released down the complete length of the grid. When the animal released the grid, the 
maximal grip strength value of the animal was displayed on the screen, which was recorded. 
This procedure was repeated to obtain a second forelimb grip strength measurement, taking 
the average of the two values for analysis. Then all four limbs were assessed.  
This protocol has been edited from EMPRESS phenotyping (empress.har.mrc.ac.uk). 
 
2.1.6. Startle and pre-pulse inhibition 
 
Startle response requires normal hearing to detect the startle tone which elicits a 
sensorimotor jump response, which is measured relative to weight. Pre pulse inhibition 
assesses sensory inhibition. A series of pre-pulses which are weaker acoustic stimuli precede 
the startle tone. These pre-pulses should dampen the startle response.  
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Equipment: 
Med Associate startle boxes were used. Twelve sound proof boxes allowed assessment of 
twelve mice per run. The experimental apparatus is an outer chamber containing a sound 
proofed acoustic chamber with a load cell platform and an amplifier. A sound generator and 
the appropriate software regulate pulses from the amplifier (Med Associates Inc equipment). 
Protocol: 
Sound calibration and movement sensor calibration were completed monthly. Test animals 
were transported to the phenotyping room and left undisturbed for 30 minutes prior to the 
test to acclimatise. The computer was switched on setting up the experimental design to 
complete the following:  
 An initial acclimation period of 5 minutes without a pre-pulse stimulus, an inter-trial 
interval of 50 msec and a pulse of white noise 110 (dB) / 40 msec. 
 A pre-pulse inhibition session of 10 different trial types:  
 A trial in which only an acoustic startle pulse is presented as white noise 110 dB / 40 
msec. Pulses should be presented ten times in pseudorandom order with an inter-trial delay 
varying between 20 and 30 seconds. 
 Eight different pre-pulse trials, of 10 msec duration, of 70, 80, 85, or 90 dB white noise 
stimuli presented alone or preceding the pulse by 50 msec. 
 A trial in which only background noise 65 dB is presented to measure baseline 
movement of the animal in the chamber. Pulses should be presented ten times in 
pseudorandom order with an inter-trial delay varying between 20 and 30 seconds.  
 Startle response recorded every millisecond for 65 msec after the onset of startle. 
Each mouse was removed from its home cage and placed onto the load cell platform inside the 
acoustic chamber and then the door closed. Additional mice in the remaining boxes were then 
loaded before running the experimental session. Once complete, each mouse was carefully 
removed from the acoustic chamber and placed into its home cage. The acoustic chamber was 
wiped clean with 70% alcohol following each session and allowed to dry before subsequent 
sessions were run. The recorded data was saved for analysis. 
This protocol has been modified from EMPRESS phenotyping (empress.har.mrc.ac.uk). 
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2.1.7. Open field 
 
Mice were placed in an empty arena and ambulation was assessed. A camera from above was 
used to measure ambulation for interpretation as locomotor activity, exploratory drive, 
neophobia and agoraphobia. Aspects of fear and anxiety were also measured. If locomotor 
activity was the same between mice then alterations were interpreted as being driven by fear 
or increased exploratory drive. 
Equipment: 
The open field is a 44 x 44 cm square arena. The walls are opaque (so that animals cannot see 
the room) and approximately 50 cm high. The arena floor is not completely smooth allowing 
the mice to move freely. The base colour of the open field is light grey. Light grey (RAL 7035) 
compensates for various coat colours, for Ethovision Noldus software video tracking.  
Procedure: 
Mice were moved into the testing room and left for 30 minutes, to acclimatise. Ethovision 
software was opened and the programme loaded. A mouse was placed into each arena and 
the door to the room closed before starting the trial. A standard trial run was 30 minutes. After 
30 minutes video tracking the trial was saved and the mice returned to their cages.  All arenas 
were cleaned with 70% ethanol allowing the arena to dry before beginning the next run. Four 
mice were analysed at the same time, always using mice from the same cages. 
 
2.2. Genotyping mice 
 
For the Tardbp mutations, genotyping assays were completed for Q101X, K160R and F210I 
mutations. For SOD1G93A, the transgene was genotyped as described below. Q101X and K160R 
samples were genotyped using a Qiagen Pyro Sequencer. F210I was genotyped using an 
Idaho® LightScanner and SOD1 G93A was genotyped by PCR band assessment on an agarose gel. 
 
For all genotyping methods DNA was extracted from tissue using the following protocol.  Ear 
clips (or other tissue) were placed in a microcentrifuge tube with 200 μl TENS buffer (amounts 
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were scaled to tissue size). 10 μl Proteinase-K (20mg / ml) (P6556, SIGMA) was added, mixed 
and incubated overnight at 55°C. The microcentrifuge tube was centrifuged for 5 minutes at 
maximum speed (>13,200 x g) at 4°C to pellet non-digested tissue. The supernatant was 
passed to a new tube and 200 μl isopropanol (BP2618-212, Fisher) was added, the tube 
capped and shaken. The tube was the centrifuged for 10 minutes, maximum speed (>13,200 x 
g) at 4°C. The supernatant was carefully discarded and then left for 1 hour to allow excess 
alcohol to evaporate leaving a pellet. The pellet was then resuspended in an appropriate 
volume of H2O (100 μl). The recipe for TENS buffer is given in Table 2.1. 
Components 
Final 
Concentration 
Tris 1M (pH 8) (BP-12-5 
Fisher) 
100 mM 
EDTA (BP1339-1 Fisher) 5 mM 
NaCl (AC42429-0050 Fisher) 200 mM 
SDS (BP166-100 Fisher) 0.20% 
  
Table 2.1: TENS buffer recipe 
 
2.2.1. Q101X and K160R 
 
DNA at 5 ng / μl was prepared for PCR using primers, mix and PCR as outlined in Table 2.2, 
Table 2.3 and Table 2.4.  Following the PCR the sample was run on a Qiagen Pyro Sequencer. 
During this process the PCR product is added to a mixture of enzymes, DNA polymerase, ATP 
sulfurylase, luciferase, and apyrase as well as the substrates adenosine 5' phosphosulfate (APS) 
and luciferin. The mix is heated to separate the template double strand and anneal the 
sequencing probe. A dNTP is then added and if it matches the template strand it binds 
releasing pyrophosphate (PPi) which is converted by ATP sulfurylase to ATP. This drives 
conversion of luciferin to oxyluciferin generating light which is detected by the machinery. 
Apyrase then degrades the free dNTP and the next one is added, slowly sequencing from the 
probe. Deoxyadenosine α-thio triphosphate (dATP·S) is used as a substitute for the natural 
deoxyadenosine triphosphate (dATP). 
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Primer ID Sequence 5’ – 3’ 
K160R-II-F-biot AAGGGTTTGGCTTTGTTCG 
K160R-II-R GCCCATCTATCATATGTCGTTGT 
K160R-II-Seq-R CATATGTCGTTGTGACATT 
Q101X-F CAAAAGGAAAATGGATGAGAC 
Q101X-R-Biot AGTTGTTTTCCAGGGGAGAC 
Q101X-Seq-F GAAAGTGAAAAGAGCAGTC 
 
Table 2.2: Pyro sequencing primers and probes.  Primers and probes for Q101X and K160R genotyping. 
Sequencing primer contains “Seq” in name. 
Components 
Q101X K160R 
(μl) (μl) 
Qiagen PCR mix (201445, Qiagen) 5 5 
H2O 2.6 2.4 
Forward Primer (10 μM) 0.2 0.2 
Reverse Primer (10 μM) 0.2 0.2 
DMSO (D159-4 Fisher) 0 0.2 
DNA (5 ng / μl) 2 2 
  
Table 2.3: PCR set-up for pyro sequencing Q101X and K160R. 
Temp (°C) Time 
95 5 minutes 
Cycle 44 times   
95 30 seconds 
55 30 seconds 
72 15 seconds 
End cycle   
72 5 minutes 
 
Table 2.4: Pyro PCR conditions for Q101X and K160R. 
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2.2.2. F210I 
 
The F210I SNP was genotyped using the Idaho ® system, which uses high resolution melting for 
sample genotyping. The primers used, mix for PCR and PCR conditions are shown in Table 
2.5, Table 2.6 and Table 2.7. The PCR was run in an Idaho® LightScanner compatible PCR 
plate (4ti-0771, 4ti). Following the PCR the plate was placed in the LightScanner and the 
samples were melted from 55 to 98°C, where the high resolution melt curve was assessed for 
genotyping. The temperature at which the probe falls off the wild-type and mutant alleles 
varies (giving different melt curves) to distinguish wild-type, heterozygous and homozygous 
F210I samples. 
Primer ID Sequence 5’ – 3’ 
TDP43_F210I_F GAAAGGTGTTTGTTGGACGTT 
TDP43_F210I_R TCTGAATGGTTTGGGAATGAAGAC 
TDP43_F210I_PrF GCTTCAGCAGATTTTCTGTCAGTATGGAG 
 
Table 2.5: F210I  primers and probe.  Table showing sequence for forward and reverse primers, with the third panel 
showing the probe sequence. The probe was manufactured with an amino C3 modification at the 3' end.  This works 
the same as a 3' phosphate (but lasts longer) and blocks extension of the probe. 
 
Components µl 
HotShot master mix (HRLS-ASY- 0002 Idaho 
Tech) 
5 
LCGreen (BCHM-ASY- 0005 Idaho Tech) 1 
TDP43_F210I_F (20ng / µl) 0.1 
TDP43_F210I_R (20ng / µl) 0.5 
TDP43_F210I_PrF (20ng / µl) 0.5 
DNA (5ng / μl) 2 
ddH2O 0.9 
 
Table 2.6: F210I PCR mix.  Table showing the reagents used to set up the F210I genotyping PCR reaction. 
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Temp (°C) Time 
95 2 minutes 
Cycle 55 times   
95 30 seconds 
60 30 seconds 
72 30 seconds 
End cycle   
95 30 seconds 
25 30 seconds 
15 30 seconds 
 
Table 2.7: F210I PCR programme.  PCR programme used to amplify F210I fragment for analysis. 
 
2.2.3. SOD1G93A 
 
All mice carrying the SOD1G93A transgene underwent a mating regime that maintained the 
transgene in heterozygosis (such that SOD1G93A mice were not inter-crossed). The primers, PCR 
mix and normal PCR programme run are shown in Table 2.8, Table 2.9 and Table 2.10.  
Amplification was from genomic DNA and band products were assessed on an acrylamide gel. 
 
Primer ID Sequence 5’ – 3’ Amplicon Length 
IMR113 CATCAGCCCTAATCCATCTGA 
236 bp 
IMR114 CGCGACTAACAATCAAAGTGA 
Snca4R AGAAGACCAAAGAGCAAGTGACA 
130 bp 
Snca4L ATCTGGTCCTTCTTGACAAAGC 
 
Table 2.8: SOD1
G93A
 primers.  Primers used to detect SOD1
G93A
 (IMR113 / 114) amplify a product of 236 base pairs 
when the transgene is present. Snca primers are control primers for mouse Snca amplifying a 130 base pair 
fragment. PCR product was loaded on a 2% agarose gel and run at 120 V (60 mA) for 30 minutes or until complete 
band separation. Samples with 2 bands are SOD1
G93A
 heterozygotes. 
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Components μl 
H2O 16.8 
10X buffer 2.5 
DMSO 2.5 
dNTPs (2.5 mM) 2 
Primers (25 μM) 1 
Taq polymerase 0.2 
DNA 1 
 
Table 2.9: SOD1
G93A
 genotyping PCR mix.  Mix used to set up SOD1
G93A
 transgene genotyping PCR. 
 
Temp (°C) Time 
94 3 minutes 
Cycle 35 times   
94 30 seconds 
60 30 seconds 
72 45 seconds 
End cycle   
72 10 minutes 
 
Table 2.10: SOD1
G93A
 PCR conditions.  PCR conditions to amplify SOD1
G93A
 fragment. 
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2.3. Constructs 
 
2.3.1. pcDNA 3.1 V5 / HIS constructs  
 
All V5 / HIS mammalian expression vectors were pcDNA 3.1 (K4800-01 Invitrogen). They 
contain mouse TDP43 encoding cDNA inserted using BamHI / XbaI restriction sites. The 
backbone and Tardbp cDNA insert is 6.688 kilo bases (kb), as mapped in Figure 2.6. 
 
 
 
 
 
Figure 2.6: Schematic representation of pcDNA3.1 vector containing Tardbp cDNA.  Note that this is a mammalian 
expression vector with a CMV promoter in advance of the T7 promoter, not indicated on the map. Map generated 
using Ape software. 
The V5 / HIS plasmids containing mouse TDP43 encoding cDNA were generated by Dr Peter 
Joyce who also generated the allelic series of point mutations through site directed 
mutagenesis (SDM). Two additional mutant constructs were generated by myself through site 
directed mutagenesis (protocol at end of section) using the primers shown below (Table 2.11). 
Highlighted regions show the mutant residues for the respective encoding amino acid changes. 
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Primer ID Sequence 5’ – 3’ 
TDP_D169G_F cgacatatgatagGtgggcgatggtg 
TDP_D169G_R caccatcgcccaCctatcatatgtcg 
TDP_F147L / F149L_F CTCGAAAGGGcttggccttGTTCGATTTACAG 
TDP_F147L / F149L_R CTGTAAATCGAACaaggccaagCCCTTTCGAG 
 
Table 2.11: Site directed mutagenesis primers for TDP43 point mutations. Table showing the primer sequences to 
generate the point mutations D169G and F147L / F149L in mouse Tardbp cDNA. 
 
2.3.2. Human TDP43 construct and CFTR mini-gene 
 
Human TDP43 was gifted from Dr Emanuele Buratti. The construct was pFLAG TDP43 siRNA-
resistant wild-type cloned HindIII / KpnI pFLAG-CMV2. Silent mutations were introduced using 
standard PCR procedure (SDM) in order to make them resistant to anti-TDP43 siRNA. The 
primers used to achieve this are shown below (Table 2.12). The CFTR mini-gene construct 
C155T TG11T5 was also gifted by Dr Emanuele Buratti. 
Primer ID Sequence 5’ – 3’ 
siTDP_KOFW taattctaagcagtcccaggatga 
siTDP_KOREV tcatcctgggactgcttagaatta 
 
Table 2.12: Human TDP43 silent mutation primers. Primers used by the Buratti / Baralle laboratory to generate 
silent mutations in order to allow the construct to express human TDP43 protein despite siRNA treatment which 
downregulates endogenous cellular protein. 
 
2.3.3. GST tagged constructs - pGEX5X3 GST fusion vectors 
 
GST tagged mouse TDP43 constructs were sub cloned from the pcDNA 3.1 vectors. pcDNA 
constructs containing wild-type and each of the TDP43 mutant alleles were sub cloned into 
pGEX5X3 GST fusion vectors. These are the bacterial expression vectors used to purify wild-
type and F210I mouse TDP43 protein. 
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2.3.4. Generation of TDP43 D169G, F147L / F149L by site 
directed mutagenesis 
 
Site directed mutagenesis was performed as per the manufacturer’s conditions (200519, 
Stratagene). The procedure was carried out on ice. The PCR was set up on ice as shown below 
in Table 2.13, with the PCR run as shown in Table 2.14. 
Reagent μl 
10 X Buffer 5 
10 – 50 ng plasmid DNA X 
125 ng FW primer 1 
125 ng REV primer 1 
dNTPs 1 
Quick Solution 3 
PFU Turbo DNA Polymerase 1 
Up to 50 μl H2O X 
 
Table 2.13: Stratagene SDM mix for PCR. 
 
Temperature (°C) Time 
95oC 1 minute 
Cycle 18 times   
95 oC  50 seconds 
60 oC  50 seconds 
68 oC   1 minute 
End cycle   
68 oC  7 minutes 
Store at 4 oC   
 
Table 2.14: SDM PCR cycling conditions. 
 
Following the PCR, 1 μl DpnI enzyme was added and incubated at 37oC for 1 hour. 
Transformation of the mutagenized plasmid followed using 45 μl XL competent cells provided. 
2 μl β-mercaptoethanol (M3148 Sigma) was added and incubated on ice for 10 minutes flicking 
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the tube to mix every 2 minutes. 2 μl reaction product was added to the cells and incubated on 
ice for 30 minutes. The cells were heat shocked at 42oC for 30 seconds before returning to ice 
for 2 minutes. 500 μl pre warmed (37oC) SOC medium (15544-034 Invitrogen) was then added 
and the mix was incubated at 37oC for 1 hour in the shaking incubator. 250 μl transformed 
cells was spread on a pre-warmed Lysogeny Broth / Ampicillin (LB-Amp plate) (100 μg / ml 
ampicillin, 11593-027 Invitrogen) and incubated overnight at 37oC. Individual colonies were 
picked the following day, grown overnight in LB-Amp and the following day mini prepped 
(27104, Qiagen). Plasmids (pcDNA 3.1) were sequenced using the following primers to confirm 
SDM (Table 2.15). 
 
Primer Name Sequence 5’ – 3’ 
T7 TAATACGACTCACTATAGGG 
Pj23 GAAAGTGAAAAGAGCAGTCCAG  
Pj24 CTTCATTCCCAAACCATTCAGAG  
Pj25 CATGTTAGCCAGCCAGCAGAAC  
 
Table 2.15: Primers used to sequence insert region for pcDNA 3.1 TDP43 vectors.  These primers are designed to 
sequence the full length of the TDP43 encoding cDNA transcript inserted into the V5 / HIS plasmid. There is 
significant sequence overlap from the T7 sequence to beyond the C-terminal tags and STOP site. 
 
2.3.5. Plasmid amplification and extraction 
 
Plasmids were extracted using Qiagen mini / midi / maxi (endotoxin free) kits (27106, 12143, 
12362 Qiagen). When working in the Buratti / Baralle laboratory, plasmids were grown up 
using JetStar (210025 Gmbh) mini / midi / maxi kits. The JetStar protocol is outline below. 
E coli DH5α (18263-012, Invitrogen) cells were thawed on ice and 3 μl plasmid (10ng / μl) was 
added to 30 μl cells. The cells were incubated on ice for 20 minutes, then placed at 42°C for 2 
minutes in a water bath and returned to ice for 5 minutes. All 30 μl of the cells were spread on 
pre-warmed agar plates (at 200 μg / ml Ampicillin) and left to incubate overnight at 37°C, agar 
side up. The following day, single, isolated colonies were selected and put into 500 ml LB + 500 
μl of 1000 X ampicillin stock. This was incubated at 37°C on a shaker (speed 140) for 16 hours. 
The bacterial cells were then pelleted at >3700 x g for 20 minutes and frozen at -20°C until 
required.  
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Mini / Midi / Maxi preps were completed using the JetStar Plasmid purification system 
(210025, GENOMED Gmbh). Jet Star purification solutions (provided by the manufacturer) are 
given below with solutions 2-6 stored at room temperature. 
Solution 1 – (cell resuspension) 50 mM Tris + 10 mM EDTA + HCl to pH 8 (add extra RNAse and 
store at 4°C) 
Solution 2 – (cell lysis) 200 mM NaCl + 5% SDS (w / v) 
Solution 3 – (Neutralization) 3.1 M potassium acetate + acetic acid to pH 5.5 
Solution 4 – (Column equilibration) 600 mM NaCl + 100 mM sodium acetate + 0.015% Triton X-
100 + acetic acid to pH 5.5) 
Solution 5 – (column washing) 800 mM NaCl + 100 mM sodium acetate + acetic acid to pH 5.0 
Solution 6 – (DNA elution) 1500 mM NaCl + 100 mM sodium acetate + acetic acid to pH 5.0 
 
Midi preps were carried our as per the manufacturer’s instructions. A column was equilibrated 
with 10 ml solution 4, which was allowed to flow through by gravity. Bacterial cells were 
harvested by pelleting for 20 minutes at 3700 x g and removing all traces of medium 
(completed at the end of plasmid amplification step). Cells were suspended in 4 ml solution E1. 
10 μg / ml of extra RNAse inhibitor (50 μl to 4 ml) was added. Solution 2 (4 ml) was then added 
and mixed gently by inversion until a homogeneous lysate formed. The lysate was incubated at 
room temperature for 5 minutes before adding solution 3 (4 ml) and mixing immediately by 
multiple inversions until a homogeneous lysate formed. This was filtered through thin filter 
paper and then the supernatant was added to the equilibrated JetStar column. The column 
was washed with 10 ml solution 5 twice and the DNA then eluted with solution 6 (5 ml). The 
DNA was precipitated with 0.7 volumes isopropanol (3.5 ml) and then centrifuged at 4°C at 
12,000 x g for 30 minutes. The pellet was washed with 70% ethanol and centrifuged at 12,000 
x g. The pellet was then air dried for 10 minutes and re dissolved in 200 μl H2O. 
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2.4. Culturing cells, transfections, add-back assay and labelling 
 
All cells were grown in Heraeus Cell culture incubators at 37°C in humidified conditions with 
5% CO2. All media used were pre-warmed to 37°C before cell exposure unless otherwise 
stated. All cell culture work was completed in class two biological safety cabinet. 
 
2.4.1. HeLa cells 
 
HeLa cells were grown using standard cell culture practise. Cells were grown in complete 
media containing DMEM (31966, Gibco) supplemented with 10% FBS (10082147, Invitrogen) 
and 1% pen / strep (10378016, Invitrogen). Cells were split at 80-90% visual confluence (being 
split 1:5) and maintained following standard practise in 10 cm dishes (664160 Greiner). 
 
2.4.2. Mouse Embryonic Fibroblasts (MEFs) 
 
Complete medium for MEFs was identical to that used for HeLa cells but was also 
supplemented with 3 ml Ultraglutamine II (BE04-684E Lonza). MEFs were obtained from 
embryos using the following protocol. 
PBS-Gelatin (0.1%) (Gelatin, S-006-100 Invitrogen) was added to a 10 cm (664160 Greiner) cell 
culture dish, with 10 ml in one dish per embryo. Dishes were pre warmed (37°C) in cell culture 
incubators until needed. Embryos were harvested from E14.5 dpc pregnant females. The 
female was culled by schedule one procedure and embryos were removed and stored in PBS 
on ice.  Each embryo was dissected from the maternal sac and assessed for visual defects.  The 
head, limbs and organs were removed from each embryo. Individual carcasses were then 
processed in parallel in separate dishes. From this step, all work was completed in a class two 
biological safety cabinet. Each carcass was transferred to a 5 cm dish (628160 Greiner) with 3 
ml pre-warmed trypsin (25300062, Invitrogen).  The carcass was roughly chopped using two 
10a sterilised scalpel blades (Swan Morton). The trypsin / cell solution was homogenised by 
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pipetting up and down ten times with a 5 ml pipette and then transferred to a 50 ml Falcon 
tube (352070, BD). Each Falcon tube was incubated at 37°C in a water bath with agitation for 5 
minutes. Following incubation, the trypsin / cell solution was returned to the 5 cm dish and 
syringed up and down five times (using a 10 ml syringe). Pre warmed cell culture dishes were 
taken from the incubator and 7 ml of PBS-Gelatin was removed.  10 ml pre warmed (37°C) 
complete media was then added to the dish. The trypsinized cell mix was then added drop 
wise and the plate swirled gently. The presence of cells was confirmed under a light 
microscope and the cells were left in the culture incubator overnight (5% CO2, 37°C). 
Once cells reached 80% visual confluence, which was usually after one to two days, the cells 
were passaged at a 1:3 ratio. In between passages, cells were washed with PBS and fresh 
growth media added.  
 
2.4.3. Transfection with Effectene 
 
Effectene (1008430, Qiagen) was used for HeLa cell transfections. The following solutions were 
made for each transfection: 300 μl EC buffer, 3 μg plasmid and 16 μl enhancer. The samples 
were then vortexed for 10 seconds and left to incubate for 5 minutes at room temperature. 20 
μl Effectene was then added and vortexed for 20 seconds followed by incubation for 10 
minutes at room temperature. During this time, the cells were washed with 10 ml PBS and 9 
ml complete medium was added (cells were in 10 cm dishes, at 80% confluence). After the 10 
minute incubation, 600 μl complete medium was added to the mix. The mix was then added to 
the cells drop wise and the cell culture dish was swirled to distribute evenly. After 24 hours the 
cells were harvested. This was scaled down for six well dishes in the add-back assay as 
described later. 
 
2.4.4. Electroporation (CFTR mini-gene) 
 
Electroporation was used to insert the CFTR mini-gene into MEFs. Wild-type and F210I mutant 
P1 MEFs were grown to 80% confluence (in a 10 cm dish) and then split into a T75 flask 
(658975 Greiner). Once at 80% confluence (normally up to two days), the MEFs were 
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electroporated with 4 μg maxi prepped CFTR mini-gene plasmid using the Lonza Amaxa system 
(DPD-1005, Lonza), programme T20, solution one. For MEFs, a choice of two programs and 
solutions were available, with T20 / solution one providing a transfection efficiency for a GFP 
control plasmid of 50%. Electroporation was completed following the manufacturer’s 
instructions. MEFs were grown to 80% confluence in a T75 flask.  They were washed once in 
PBS and trypsinized for 3 minutes at 37°C. Cell detachment was confirmed and the cells were 
centrifuged at 200 x g for 10 minutes. The cell pellet was resuspended in 100 μl nucleofector 
solution (room temperature). 100 μl cell solution was combined with 4 μg CFTR plasmid. The 
cell / DNA suspension was transferred into a certified cuvette and the cap closed. Programme 
T20 was selected and the cuvette inserted into the holder before applying the programme. 
Once complete the cuvette was removed (approximately 3 seconds) then 500 μl complete 
medium was added to the cuvette. The contents were transferred to a 10 cm dish and 9 ml 
complete media was added. The MEFs were grown overnight and harvested after 24 hours. 
Control electroporation of no CFTR plasmid, or no solution one was also run alongside 
samples. 
 
MEFs were harvested by being washed in 10 ml PBS and then trypsinized in 3 ml trypsin in the 
cell culture incubator. Following detachment, 7 ml complete media was added to deactivate 
the trypsin and the cells were pelleted in a 15 cm Falcon tube at 1000 x g, for 5 minutes. The 
supernatant was removed and the cell pellets snap frozen.  
 
2.4.5. Add-back assay 
 
To prevent interference with the transfection reagent (Effectene) antibiotic was not added to 
the complete medium used to culture the HeLa cells. All solutions were pre-warmed to 37°C 
including complete medium, trypsin (R-009-50, GIBCO) PBS, optimem (S1985, GIBCO) and EC 
buffer (Qiagen). A four day protocol was completed as described below: 
Day 1: HeLa cells were plated into 6 well plates (3516, Costar) at 180 000 cells per well. 
Day 2: First day of siRNA against endogenous human TDP43. The following mix per well was 
prepared: 13 μl optimem + 3 μl oligofectamine (Qiagen). This was incubated at room 
temperature for 5 minutes. In another tube 180 μl optimem + 2.5 μl siRNA (40 mM, 
GCAAAGCCAAGAUGAGCCUdTdT, ThermoSci Dharmacon) was prepared and after five minutes 
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was mixed with the first tube. The combined solutions were resuspended and then incubated 
for 20 minutes. While waiting, cells were washed in PBS (2 ml) and then suspended in 1.5 ml 
optimem. The siRNA solution was then added to the wells drop wise with gentle plate swaying 
to ensure even distribution. 4-6 hours after this 200 μl of FBS was added.  
Day 3: Repeated day 2 (this was the second round of siRNA against endogenous TDP43). 
Day 4: Transfection of plasmid. EC buffer was pre-warmed (Qiagen). For each well 150 μl EC 
buffer, 0.5 μg Plasmid, 0.5 μg CFTR mini-gene and 4 μl enhancer (Qiagen) were added to an 
microcentrifuge tube. Following a 2 second vortex the mix was then incubated for 5 minutes at 
room temperature. 5 μl Effectene was then added, the mix vortexed again for 10-15 seconds 
and then incubated for 10 minutes at room temperature. While waiting, cells were washed 
with PBS (2 ml) and then 1.5 ml complete medium was added. After 10 minutes, 600 μl 
complete medium was added to the microcentrifuge tube with the plasmid mix, resuspended 
with a pipette and then added drop wise to the plate. The plate was then swirled to ensure 
even distribution. 
The following day cells were washed in PBS (2 ml) before adding trypsin (300 μl). They were 
incubated for 5 minutes at 37°C. Once detached, 700 μl complete medium was added to the 
cells, which were then resuspended and divided into two microcentrifuge tubes equally. The 
microcentrifuge tubes were centrifuged at 200 x g for 10 minutes at room temperature; the 
supernatant removed with the cell pellet frozen either for Western blotting or reverse 
transcription PCR (one microcentrifuge tube for each). 
 
2.4.6. Nuclear / Cytoplasmic fractionation 
 
Following HeLa cell transfection with wild-type and F210I V5 / HIS tagged plasmids using 
Effectene, two 10 cm dishes of HeLa cells were harvested. Solutions needed for nuclear / 
cytoplasmic fractionation are given in Table 2.16. 
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Buffer N Buffer N + NP40 Solution 1 Solution 2 
15 mM Tris HCl pH7.5 
Buffer N + 0.6% NP40 
(NC9807780 Fisher) 
10 mM Hepes pH 
7.9 (AC21500-
1000 Fisher) 
10 mM Hepes pH 
7.9 
60 mM KCl (AC19677-
0010 Fisher) 
  10 mM KCl 10 mM KCl 
15 mM NaCl   1.5 mM MgCl2 1.5 mM MgCl2 
5 mM MgCl2 
(AC41341-5000 Fisher) 
  
0.1 mM EGTA 
(ICN213293 MP 
Bio) 
0.1 mM EGTA 
1 mM CaCl2 (AC34961-
0250 Fisher) 
  0.1 mM DTT 0.1 mM DTT 
1 mM DTT (AC32719-
0010 Fisher) 
  0.5 mM PMSF 
5% glycerol 
(AC15892-2500 
Fisher) 
250 mM sucrose 
(AC17714-0050 Fisher) 
    400 mM NaCl 
2 mM sodium 
vanadate (S454-50 
Fisher) 
    0.5 mM PMSF 
1 mM PMSF (AC21574-
0500 Fisher) 
      
1X Protease Inhibitor 
(Roche) 
      
 
Table 2.16: Nuclear / Cytoplasmic fractionation solutions.  Recipes for all components required for nuclear / 
cytoplasmic fractionation. 
 
2.4.7. Fractionation protocol  
 
HeLa cells (in 10 cm dishes) were washed twice with PBS. 5 ml PBS was added and the cells 
were then scraped and transferred to a microcentrifuge tube which was centrifuged at 200 x g 
for 5 minutes at 4°C. The cells were resuspended with buffer N (five times the volume of the 
pellet – 500 μl). Then the same volume of buffer N + NP40 (to break the cytoplasmic 
membrane) was added. This was mixed using a tip (with the end cut off) and incubated on ice 
for 5 minutes. The mix was centrifuged for 5 minutes at 200 x g, 4°C. The supernatant was 
stored at -80°C (cytoplasmic fraction). The nuclei (pellet) were resuspended in 1 ml solution 1 
using a tip with a cut off end. This was then centrifuged for 5 minutes at 4°C, 200 x g. The 
supernatant was discarded and the pellet resuspended in solution 2 (1X the volume of the 
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pellet – 100 μl was added). Solution 2 breaks the nuclear membrane and extracts nuclear 
proteins. The solution was mixed (with a cut tip end) and incubated for 30 minutes on ice, 
swirling every 5 minutes. This was followed by 30 minutes centrifugation at maximum speed at 
4°C, taking the supernatant for storage at -80°C (nuclear fraction). Everything was done at 4°C 
and when mixed this was done gently to avoid causing damage that could ruin the 
fractionation process. 20 μl of each fraction was then loaded on an acrylamide gel with 5 μl 
SDS 5X loading buffer. This stage is described later. 
 
2.4.8. Immunofluorescence  
 
MEFs were cultured as previously described. On the penultimate passage, cells were 
trypsinized and split into dishes containing sterile glass coverslips to which the cells adhere. 
MEFs were grown for 24-48 hours to achieve a desirable visual degree of confluence. Cells 
were washed twice with an appropriate volume of PBS to the culture dish size, before PBS 
removal and 4% PFA (fix) (158127 Sigma) addition for 10 minutes at room temperature. 
Following incubation, the PFA was removed and the fixed cells were washed in PBS to remove 
PFA traces. All cells were then permeabilized. PBS was removed and the cells submerged in ice 
cold methanol (A456-212 Fisher) for 15 minutes at room temperature. Methanol removal was 
followed by a PBS wash. The cells were then put in blocking (PBS, 5% BSA BP617-10 Fisher) for 
one hour. After blocking, an appropriate volume of blocking per coverslip was prepared with 
primary antibody added at the desired concentration (1:200). The primary antibody in blocking 
was added as a drop on parafilm (S37441 Fisher), placing the coverslip with cells face down on 
the drop to cover the surface of the coverslip. Incubation for 1 hour at room temperature was 
followed by removing the coverslip and face up, washing in PBS for 3 X 5 minutes. The cover 
slip with cells was then incubated with fluorescently tagged secondary antibodies in blocking, 
as completed with the primary antibody. Incubation took place in the dark and then PBS 
washes were repeated. The slide was then prepared with DAPI self-hardening mounting 
medium (H1500, Vector Labs). The coverslip was placed face down on mounting medium to 
cover the surface completely. Coverslip edges were sealed with nail varnish or DPX. This was 
allowed to air dry in the dark for more than three hours at room temperature then stored at 
4°C. Samples were visualized on a confocal microscope (SP5 Leica) for up to two weeks, 
although the signal faded through time. The antibody used is shown in Table 2.17. 
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Table 2.17: Immunofluorescence antibody conditions.  Primary and secondary antibodies used for 
immunofluorescence with concentrations used. 
 
2.5. RNA 
 
2.5.1. Extracting RNA from MEFs, embryo head and adult 
brain 
 
RNA extraction was completed using TRIzol. RNAse free filter tips (732-2223 VWR) were used 
and all bench space and equipment were sterilised using 70% ethanol. Cells or tissue were 
homogenised in 1 ml TRIzol (15596-026 Invitrogen) per 50 – 100 mg tissue. This was incubated 
at room temperature for 5 minutes, before adding 0.2 ml chloroform (AC42355-0040 Fisher). 
The microcentrifuge tube was capped and shaken for 15 seconds before incubation at room 
temperature for 25 minutes. The microcentrifuge tube was centrifuged for 15 minutes at 
12,000 x g at 4°C. The aqueous top phase was transferred to a new microcentrifuge tube. 500 
μl isopropanol (AC41279-0025 Fisher) was added and incubated for 10 minutes at room 
temperature. This was then centrifuged for 10 minutes at 12,000 x g at 4°C. The supernatant 
was removed and the RNA pellet washed with 1 ml 75% ethanol. The microcentrifuge tube was 
vortexed briefly at low intensity and then centrifuged for 5 minutes at 7,500 x g at 4°C. The 
supernatant was removed and the pellet air dried briefly (1-3 minutes) and then re dissolved in 
50 μl RNAse free water. The RNA concentration was measured on a N8000 spectrophotometer 
(Thermo) with a ratio of absorbance at 260 nm and 280 nm of approximately two. 
Primary antibody Primary Concentration Secondary antibody 
Secondary 
Concentration 
anti-TDP43 
(Protein Tech) 
1:200 
Alexa488 anti-rabbit 
(A-11008, Invitrogen) 
1:500 
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2.5.2. Quantifying RNA and converting to cDNA 
 
1 μg RNA was DNAse treated using the Invitrogen DNAse I kit (18068-015, Invitrogen). A mix of 
1 μg RNA sample, 1 μl 10X DNAse reaction buffer and 1 μl DNAse (up to 10 μl with H2O) was 
prepared. The mix was incubated for 15 minutes at room temperature then 1 μl 25 mM EDTA 
was added and heated for 10 minutes at 65°C (to deactivate the DNAse). 
Following DNAse treatment, cDNA was generated using the Invitrogen Superscript 3 First 
strand cDNA Synthesis kit (18080-200 Invitrogen). A mix of 1 μg RNA, 2 μl RT enzyme mix, 10 μl 
2 X RT reactions mix (containing Oligo dT) was made up to 20 μl with H2O. The mix was run on 
the thermo programme given below in Table 2.18. The cDNA was then stored at -20°C until 
required. 
Temp (°C) Time 
25 oC 10 minutes 
50 oC 30 minutes 
85 oC 5 minutes 
1 l of E. Coli RNAse H was added and mixed 
37oC 20 minutes 
 
Table 2.18: cDNA thermo programme. 
 
2.5.3. Splicing reactions and band separation by agarose 
gel electrophoresis 
 
cDNA was generated from MEFs, embryonic head and adult brain. For splicing primer 
reactions, 1 μl of cDNA was used in the PCR. The PCR was set up and run as indicated in Table 
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2.19, Table 2.20 and Table 2.21. PCR product was run on Tris-acetate-EDTA / Tris-Borate-EDTA 
(TAE / TBE) agarose gels. TAE and TBE gels were made and run in their respective buffers. 10X 
TAE buffer (48.4 grams of Tris base [tris(hydroxymethyl)aminomethane], 11.4 ml of glacial 
acetic acid (17.4 M), 3.7 grams of EDTA disodium salt, deionized water up to 1 L) was diluted to 
1X in ddH2O. For a 100 ml gel, 100 ml of TAE was added to the appropriate amount of agarose 
(T4382 Sigma) or NuSieve 3:1 (4618727 Fisher) to make the desired percentage gel (for 
example 2 grams for a 2% gel). The mix was heated in a microwave for approximately 2 
minutes until the powder dissolved. It was allowed to cool then 4 μl ethidium bromide 
(AC17096-0050 Fisher) or gel red (BT41001 Biotium) was added. Once cool the mix was poured 
into a sealed mould and gel combs added. Once the gel had solidified in the biological safety 
cabinet it was placed in a tank and submerged in 1X TAE buffer. Loading buffer added (B7022S, 
NEB) to the PCR product followed by loading an appropriate volume in the gel. NEB 100 bp or 1 
kb ladder (N3231 / N3232, NEB) was also loaded to estimate the product size. The gel was run 
at 100 - 120 volts (50 mA) for an appropriate time to achieve band separation and visualised 
on a BioRad chemidoc. In order to quantify bands, photos saved as tif images were opened 
using ImageJ software and measured (which measures pixel intensity to show band intensity). 
For quantification purposes, PCRs were completed with fewer cycles to avoid producing 
saturated bands which would skew the results interpreted by the ImageJ software. Splicing 
primer gels were 3.5% NuSieve 3:1 agarose gels. The PCR mix, programme and primers used 
are given in Table 2.19, Table 2.20 and Table 2.21.  
 Reagent μl 
Qiagen Mix (201445) 5 
H2O 3.6 
Primer-F (10 μM) 0.2 
Primer-R (10 μM) 0.2 
cDNA 1 
 
Table 2.19: Mix for splicing reactions. 
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Temp (°C) Time 
94 3 minutes 
Cycle 34 times   
94 45 seconds 
55 45 seconds 
72 45 seconds 
End cycle   
72 10 minutes 
 
Table 2.20: PCR for splicing reactions. 
 Gene Primer ID Primer Sequence 5’ – 3’ Exon 
Dnajc5  Dnajc5-F_SPLI_DC CTCTATGTGGCGGAGCAGTT 3 
   Dnajc5-R_SPLI_DC GCTGTATGACGATCGGTGTG 5 
Pdp1  Pdp1-F_SPLI_DC GTGCTGAGTGAGGGAAGGAC 5’ UTR 
   Pdp1-R_SPLI_DC TGCAGTGCCATAGATTCTGC 2 
Poldip3  Poldip3-F_SPLI_DC CATTGGGACTGTAACCCCAG 2 
   Poldip3-R_SPLI_DC TGCAAACTTCATCTGCTTGG 4 
Sort1 Mouse Sort1-F CAGGAGACAAATGCCAAGGT 17 
  Mouse Sort1-R TGGCCAGGATAATAGGGACA 19 
TDP43 TDP43-NMD2-L: AAGAAGTGGAAGATTTGGTGGT 6 
  TDP43-NMD2-R: GCGTGATGACGAATTCTTGG 3’ UTR 
 
Table 2.21: Primers used for splicing reactions. 
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2.5.4. Add-back assay reverse transcription PCR 
 
Reverse transcription PCR was used to assess exon 9 mini-gene splicing. This protocol was 
completed in the Buratti / Baralle laboratory. Once RNA was extracted the concentration was 
measured and the RNA was converted to cDNA. For each sample a mix was made (Table 2.22). 
The mix was heated at 70°C for 5 minutes and then left on ice for 5 minutes. While waiting a 
separate mix per sample was made (Table 2.23). The second mix was added to the first mix 
with the RNA and incubated for 1 hour at 37°C. Following the 1 hour incubation the cDNA was 
ready for PCR. The following mix per tube was made (Table 2.24), 23 μl mix + 2 μl cDNA were 
added together for PCR (Table 2.25). Following PCR, 5 μl sample + 1 μl loading dye were loaded 
onto a TBE agarose gel (1.8%) with ethidium bromide in 1X TBE. 3 μl ladder (1 kb, N3232 NEB) 
was also loaded. Once the gel had run (at 100 volts / 60 mA, until sufficient band separation), 
the product was photographed and quantified using ImageJ software as previously described. 
Components μl 
1 μg RNA (make up to 10 μl with H2O) 10 
Random primers (100ng / μl) (C118A 28320210 Promega) 1 
dNTPs (5 mM) 1 
 
Table 2.22: Part 1 of cDNA generation in Buratti / Baralle laboratory. 
Components μl 
5X reaction buffer (Y02321 Invitrogen) 4 
0.1mM DTT  2 
Reverse Transcriptase Mlv (RT) (28025-013 Invitrogen) 0.5 
 
Table 2.23: Part 2 of cDNA generation in Buratti / Baralle laboratory. 
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Components μl 
Buffer (NEB Biolab) 2.5 
α23 primer (20 μM) CAACTTCAAGCTCCTAAGCCACTGC 1 
Bra primer (20 μM) TAGGATCCGGTCACCAGGAAGTTGGTTAAATCA 1 
dNTPs (5 mM) 1 
Taq (M0273L NEB) 0.52 
H2O 17.435 
 
Table 2.24: CFTR mini-gene PCR set up. 
Temp (⁰C) Time 
94 5 minutes 
Cycle 20 times   
94 30 seconds 
55 30 seconds 
72 30 seconds 
End cycle   
72 7 minutes 
4 hold 
 
Table 2.25: CFTR mini-gene PCR cycling conditions. 
 
2.5.5. Real time PCR using cDNA  
 
Real time PCR was used to quantify RNA transcripts using primers designed to produce a 
product spanning exons. Real time PCR used SYBR Green Fast mix (4385616, Applied Bio) with 
an ABI 7500 Fast Real Time System, using the cycling programme, mix and primers shown in 
Table 2.26, Table 2.27 and Table 2.28. Primer amplification efficiency was optimized and the 
control gene used was S16, with the amplification efficiency between target and control genes 
being confirmed as not being significantly different. For this, the difference between the 
amplification slopes was less than 0.1. This confirms that control and target gene primers 
amplify equally efficiently. Levels were measured through calculating ΔΔCT showing fold 
change normalized to the reference gene S16. The amount of target gene normalised to S16 is 
represented in the formula 2-ΔΔCT. All samples per plate were then normalised to a reference 
sample.
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Temp (°C) Time 
95oC 20 seconds 
Cycle 40 times   
95oC 3 seconds 
60 30 seconds 
End cycle   
 
Table 2.26: PCR programme for real time PCR. 
 
Component μl 
Fast SYBR Green Master Mix (2X) (4309155 ABI) 10 
Forward Primer (2 μM) 1 
Reverse Primer (2 μM) 1 
H2O 5 
cDNA (1 / 10 dilution) 3 
 
Table 2.27: PCR mix for real time PCR. 
 
Gene Primer ID Primer Sequence 5’ – 3’ 
Cdk6 Cdk6_p4_SyGr_F CCAGCAGTGGACAGATAAAGC 
Cdk6 Cdk6_p4_SyGr_R CTGGACTGGAGCAGGACTTC 
Grn PGRN_F_2_M_SyGr AAGCCTCAAGGGAAGTTGG 
Grn PGRN_R_2_M_SyGr ACGGGAGGCTGGATAAAATC 
Fus FUS_F_1_SyGr GTTTTGGCCCTGGCAAGAT 
Fus FUS_R_1_SyGr CTGGGTACAGGAAGAGTTCCA 
Cadps Cadps_FW_ex28_SyGr TGCAGCTCCACATTTACCAG 
Cadps Cadps_RV_ex29_SyGr CCTCCACAGTGAGACGGTTT 
TDP43 tdp_exon2_F GGAATCCCGTGTCTCAGTGT 
TDP43 tdp_exon3_R AGGAAGCATCTGTCTCATCCA 
 
Table 2.28: Primers used for real time PCR. 
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2.6. Protein 
 
2.6.1. Protein extraction 
 
To extract protein from cells, embryonic head or adult brain, cells / tissue were obtained from 
-80°C storage or freshly extracted. Cells were placed in an appropriate amount of RIPA buffer 
(Table 2.29) containing 1X protease inhibitor (11873580001 Roche) and if required, 
phosphatase inhibitor (04906837001 Roche). For tissue, samples were placed in RIPA within a 
lysis column (116540434, MP Bio) containing beads and homogenised until all tissue was gone, 
using a sample homogenizer. With cells, homogenization was achieved by pipetting up and 
down on ice. Following homogenization samples were transferred to a microcentrifuge tube 
and centrifuged at >14,000 x g for 15-30 minutes. The supernatant was removed into a new 
microcentrifuge tube (RIPA soluble fraction) and the pellet stored (RIPA insoluble). Soluble 
extract was kept on ice and aliquoted. To measure concentrations a Bradford assay was 
completed as described below. 
Components Amount 
1M Tris pH 7.5 10 ml 
NaCl 
1.753 
grams 
10% SDS 2 ml 
10% Sodium-Deoxycholate (AA B2075914 Fisher) 10 ml 
NP-40 2 ml 
H2O 176 ml 
 
Table 2.29: RIPA buffer recipe. 
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2.6.2. Bradford assay 
 
The Bradford assay was completed using 1:5 diluted RIPA, as RIPA affects the Bradford 
reagent. Bradford reagent (B6916 Sigma) was mixed gently and incubated on the bench to get 
to room temperature (from 4°C storage). BSA standards were prepared: 2 μg, 1 μg, 0.5 μg, 
0.25 μg and 0.125 μg. 20 μl BSA (10 mg / ml 90001, NEB) was added to 80 μl 1:5 diluted RIPA. 
This was vortexed for 10 seconds and centrifuged, giving the 2 μg standard. 50 μl of this was 
added to 50 μl RIPA (1:5), vortexed and centrifuged. The serial dilution was then continued. 
Having made the standards, the samples were diluted 1:5 in ddH2O. The Bradford assay was 
prepared by loading the standard curve in triplicate, 5 μl per well in a 96 well plate (265302 
NUNC). RIPA 1:5 and H2O controls were also loaded. The samples were then loaded in 
triplicate. Following sample loading 200 μl Bradford reagent was added to every well. The 
plate was mixed on a rocker for 5 minutes then read on a KC Junior plate reader (Biotek). 
Results were exported to excel (which accounted for the dilution). Bradford standard curves 
always had an R greater than 0.98 to be acceptably accurate. Also, if sample concentrations 
were significantly higher than 2 μg per μl, in not matching curve values, the sample was diluted 
further and re-measured. 
 
2.6.3. Western blotting 
 
Protein samples were run by SDS Page using Invitrogen Novex BisTris gels, either 4-12% or 10% 
(WG1401A / NP0301PK2 Invitrogen). Either mini or midi gels were run with varying numbers of 
combs providing flexibility in sample volumes and numbers that were loaded per gel. All 
samples were run under reduced conditions and prepared as indicated below using a mini gel 
example. 
Samples were prepared by adding X μl of protein, 2.5 μl NuPage LDS sample buffer (4X) 
(NP0007 Invitrogen), 1 μl NuPage Reducing agent (10X) (NP0004 Invitrogen) and made up to 
10 μl with ddH2O. Samples were heated at 70°C for 10 minutes, or 95°C for 5 minutes (to 
denature the protein). The gel was submerged in 1X SDS running buffer in the tank (prepared 
by adding 50 ml 20X NuPage MOPS buffer (NP0001 Invitrogen) to 950 ml deionized water). For 
reduced samples, 500 μl NuPage antioxidant (NP0005 Invitrogen) was added to the inner 
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chamber. Samples were loaded into wells alongside the See Blue plus 2 ladder (LC5925 
Invitrogen). The gel was electrophoresed at 200 volts (60- 125 mA) for 55 minutes. 
 
Following the run the gel was semi-dry blotted. Two thick filter papers (3030-6185, Whatman) 
were pre-soaked in transfer buffer (Table 2.30) and the PVDF membrane (IPFL00010 Millipore) 
was activated in methanol for 5 seconds before also being placed in transfer buffer. A thick 
filter paper, the PVDF membrane, the gel and then a final thick filter paper were layered as a 
“sandwich”. The chamber was closed for the semi dry blotter and protein transferred from the 
gel to the membrane at 15 volts (100 mA) for 90 minutes. At the end of the run, the 
membrane was removed and placed into 10 ml blocking (PBS, 0.2% tween, 5% milk powder) 
(tween is BP337-100 Fisher, Milk powder is Marvel). 
 
Component Amount 
Tris 11.64 grams 
Glycine (G48-12 Fisher) 5.88 grams 
10% SDS solution 7.5 ml 
100% Methanol (A456-212 Fisher) 400 ml 
H2O 1 592.5 ml 
 
Table 2.30: Transfer buffer recipe. 
For antibody labelling the membrane was initially blocked (PBS, 0.2% tween, 5% milk) for 1 
hour at room temperature shaking, or at 4°C overnight. This blocking reduces non-specific 
antibody labelling. The membrane was then incubated in 10 ml blocking with primary antibody 
(at a defined concentration) for 1 hour at room temperature shaking. After primary antibody 
incubation, the membrane was washed for 3 X 20 minutes on the belly dancer platform (in 
PBST – PBS 0.2% tween), then the secondary was added (at a defined concentration) in 
blocking with shaking for 1 hour. During fluorescent secondary antibody incubation the 
membrane container was covered in foil to block light bleaching the secondary fluorophore. 
Following secondary incubation, 3 X 20 minutes washes on the belly dancer ensued (in PBST 
0.2%). The membrane could then be stained for ECL visualisation (with secondary HRP 
antibodies) or dried for Li-Cor odyssey visualisation. 
 
Where secondary HRP antibodies were used, the membrane was removed from wash solution 
and placed on film, tipping of excess wash solution. Pierce ECL (32106 Pierce) was added and 
the membrane covered. It was incubated for 3 minutes and then excess ECL was tipped off. A 
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top seal of film was placed over the membrane for visualisation with a Chemi Doc (UVP). 
Complete band quantification used ImageJ software. 
 
Where fluorescent secondary antibodies for the Li-Cor Odyssey visualisation system were 
used, the membrane was dried in a dark box on white tissue. The membrane was then placed 
in the Li-Cor Odyssey machine and visualized accordingly. Band quantification was completed 
using Odyssey software. 
 
For both visualisation methods, membranes were stripped and re labeled with alternative 
antibodies. Stripping was completed by shaking the membrane in 10 ml stripping solution 
(21059, Thermo) (for 10-20 minutes), then washing for 3 X 10 minutes in PBST, re blocking for 
1 hour and repeating antibody labelling. 
 
2.6.4. Alternative Western blotting protocol 
 
When working in the Buratti / Baralle laboratory, Western blotting was completed using 
individually cast gels rather than the pre-cast Invitrogen system. This technique is presented in 
detail below. Acrylamide gels were run at 80-100 volts (100 mA) through stacking, then at 150 
V (80 mA) for the remainder of the run. Gel components are shown in Table 2.31, Table 2.32, 
Table 2.33 with loading buffer in Table 2.34. Following antibody staining and ECL visualisation 
membranes were stripped using the solution in Table 2.35, to allow for further antibody 
labelling. 
Acrylamide / bis 40% 29:1 Catalogue details % 
Acrylamide 1138 Gerbu 38.7 
N,N'-Methylenebisacrylamide 1138 Gerbu 1.33 
Water   60 
 
Table 2.31: Making acrylamide / bis 40%. 
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Components 8% 10% 12% 
Acrylamide / bis (40%) - 29:1 4 ml 5 ml 6 ml 
Tris HCl 1.5 M pH 8.8 5 ml 5 ml 5 ml 
H2O distilled 11 ml 10 ml 9 ml 
SDS 10% 200 μl 200 μl 200 μl 
APS 10% (AC40116-0250 Fisher) 200 μl 200 μl 200 μl 
TEMED (BP150-20 Fisher) 20 μl 20 μl 20 μl 
 
Table 2.32: Making acrylamide gels for Western blotting. 
 
Stacking Volume 
Acrylamide / bis (40%) 0.42 ml 
Tris HCl 0.5M pH 6.8 2.5 ml 
H2O 2 ml 
SDS 10% 50 μl 
APS 10% 50 μl 
TEMED 10 μl 
 
Table 2.33: Making stacking gels for Western blotting. 
 
Component 
Final 
Concentration 
Tris-HCl pH6.8 250 mM 
SDS 10% 
Glycerol 30% 
β-mercaptoethanol (or 0.5 M DTT) 5% 
Bromophenol blue (AC40315-1000 Fisher) 0.02% 
 
Table 2.34: 5X SDS loading sample buffer. 
 
Component Volume 
β-mercaptoethanol  175 μl 
Tris pH 6.8 3.125 ml 
SDS 10% 5 ml 
H2O 16.7 ml 
 
Table 2.35: Stripping solution. 
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Membrane transfer to PVDF membranes was completed in a wet tank blotter. 10X transfer 
solution: 30g Tris, 147g glycine in 1 litre of H2O was made. For a 1X solution, 100 ml of 10X 
stock was added to 800 ml H2O and 100 ml methanol.  A “sandwich” was made containing a 
spacer material, the PVDF membrane, the gel and another spacer material. The sandwich was 
placed in a chamber containing 1X transfer solution, with the current passing through the gel 
and then membrane to transfer the protein to the membrane. Proteins were transferred onto 
PVDF Hybond C membrane (RPN303E Amersham Biosciences). 
 
Visualisation of gels without transfer was completed by staining with Coomassie blue staining 
solution (B-0149 SIGMA) (50% H2O, 40% methanol, 10% acetic acid, 0.2% Coomassie powder). 
The gel was left in Coomassie solution shaking at 65°C for 2 hours and then destained with the 
same solution without the Coomassie, shaking at room temperature.  
 
2.6.5. EMSA gels / Band shift 
 
The band shift experiment was completed using an electrophoretic mobility shift assay 
(EMSA). The EMSA gel (5% acrylamide) was made up of 2.5 ml acrylamide / bis (40%), 200 μl 
APS, up to 20 ml in 0.5X TBE with 20 μl TEMED. The gel was run at 4°C and was pre chilled in a 
cold room for a minimum of 2 hours. It was electrophoresed in 0.5 X TBE, with different 
concentrations of TBE affecting how the gel runs. SDS was prevented from contacting any 
equipment or buffers. Band shift samples of 20 μl were loaded per well using the binding 
buffer, EMSA mix and loading buffer shown in Table 2.36, Table 2.37 and Table 2.38. 
 
Component 
Final 
Concentration 
HEPES pH 7.5 200 mM 
EDTA 2 mM 
DTT 5 mM 
Glycerol 60% 
 
Table 2.36: B10X Binding Buffer. 
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Components Volume 
UG6 1 μl (0.5ng / μl) 
B10X binding buffer  2 μl 
Purified protein 0.25, 0.5, 1, 2 μg 
H2O Up to 20 μl 
 
Table 2.37: EMSA mix. 
 
Component Amount 
TBE 0.5X 700 μl 
Glycerol 300 μl 
Bromophenol blue 0.0025% 
 
Table 2.38: Loading buffer 3X (used 1X). 
 
The binding buffer was mixed with the purified protein and water, followed by incubation on 
the bench for 5 minutes. Labelled RNA (by γ32P as described below) was then added with 1 μl 
loading dye. The contents were mixed and loaded immediately on the pre-cooled gel (2 hours 
at 4°C) which had been pre-run for 30 minutes. The gel was run at 100 volts (up to 60 mA) at 
4°C.  After the run was complete the gel was placed on a thick 3MM Whatman filter paper and 
covered in cling film. It was dried for 1 hour 30 minutes (583 Gel Dryer BioRad) and visualized 
using X-OMAT film or auto radiographic XAR film (F5763 Sigma / Kodak). 
The radioactive labelling of the RNA solution was completed by Dr Mauricio Budini. For 
oligonucleotide preparation he used 2 μl oligonucleotide (0.1μg / μl) – total 200 ng. 2 μl PNK 
buffer 10X and 1 μl T4-PNK was then added. 2 μl radioactive γ-ATP was then added on top of 
13 μl H2O. This was left at 37°C for 1 hour before adding 2 μl sodium acetate 3M pH 5 and 80 μl 
100% ethanol to precipitate the RNA. This was left on dry ice for 20 minutes then centrifuged 
at maximum speed for 30 minutes. The supernatant was carefully removed and the pellet 
washed in 100 μl ethanol (100%). This was then centrifuged at maximum speed for 5 minutes 
and then resuspended in 400 μl ddH20 (giving a concentration of 0.5ng / μl). The labelled RNA 
was used within one month accounting for the radioactive half-life decreasing through time. 
Oligonucleotides were labelled by phosphorylation with (γ32P) ATP and T4 polynucleotide 
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kinase (PNK, Stratagene) for 1 hour at 37°C and then precipitated with 0.3 M sodium acetate 
pH 5.2, and three volumes of ethanol. 
 
2.6.6. GST overlay / Far Western 
 
For the GST overlay experiment 10% acrylamide gels were used.  20 μl HeLa nuclear extract 
and 20 μl cytoplasmic extract were loaded into 10% acrylamide gels. The gels were run as in 
normal Western blots: 80- 100 volts (100 mA) through stacking and 150 volts (60 mA) 
afterwards. Transfer onto PVDF membrane was completed in the same way. The membrane 
was stained with 10 ml Ponceau solution (P7170 Sigma) for 10 minutes, at room temperature 
whilst shaking. The Ponceau was then washed off using water followed by 10 minutes shaking 
with PBST (0.2%). This was to confirm protein extract presence. The membrane was then 
blocked overnight at 4°C shaking. The following day the membrane was cut to split nuclear and 
cytoplasmic fractions for exposure to wild-type or F210I GST-TDP43 purified proteins and to 
probe the membranes. The membrane was placed in 10% milk in PBST and 2 μg GST purified 
protein added (wild-type TDP43 or F210I) with incubation at room temperature, shaking for 1 
hour. This was followed by four washes in PBST 0.2%, 10 minutes per wash, shaking at room 
temperature, then incubation for 1 hour at room temperature shaking with primary anti-GST 
(27-457701 Health care) 1:2000, in blocking solution. After primary incubation, four more 
washes were completed, each 10 minutes at room temperature in PBST 0.2% followed by 
incubation in anti-Goat HRP 1:2000 in blocking for 1 hour, room temperature. Finally, washes 
for 10 minutes (four times) at room temperature in PBST were completed, before 5 minutes 
ECL exposure. 
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2.6.7. Antibodies 
 
A summary of all antibodies used is given below (Table 2.39). 
 
Antibody Conc Incubation Source Species Used 
Anti-
TDP43  
1:2000 1hr RT  
In house, Baralle 
lab 
Rabbit 
Add-back assay, 
Nuclear Cytoplasmic 
localisation 
Anti-V5  1:2000 1hr RT 
Invitrogen, R960-
25 
Mouse 
Add-back assay, 
Nuclear Cytoplasmic 
localisation 
Anti-p84  1:2000 1 hr RT Abcam, Ab487 Mouse 
Nuclear Cytoplasmic 
localisation 
Anti-
Tubulin  
1:80000 1hr RT  
In house, Baralle 
lab 
Mouse 
Add-back assay, 
Nuclear Cytoplasmic 
localisation 
Anti-GST  1:2000 1hr RT 
Healthcare, 27-
457701 
Goat GST Overlay 
Anti-
TDP43  
1:5000 1hr RT 
Cosmo, CAC-TIP-
TD-P07 
Rabbit Q101X fragment 
Anti-
TDP43  
1:1500 1hr RT 
Protein Tech, 
10782-2-AP 
Rabbit 
Immunofluorescence, 
HeLa auto-regulation 
Anti-
TDP43 
1:2000 1hr RT 
Abcam N term, 
ab50930 
Rabbit Q101X fragment 
Anti-Sort1 1:50 1hr RT 
Alomone, ANT-
009 
Rabbit MEFs localisation 
Anti-Actin 1:80000 1hr RT AC-15, Abcam Mouse HeLa auto-regulation 
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Anti-
rabbit 
1:2000 1hr RT Dako, P0448   HRP secondary 
Anti-
mouse 
1:2000 1hr RT Dako, P0448   HRP secondary 
Anti-goat 1:2000 1hr RT 
GE Healthcare, 
P0448 
  HRP secondary 
Anti-
mouse 
 1:10000  1hr RT 
Li-Cor IRDye 
680RD / 800CW 
  
Fluorescent 
secondary 
Anti-
rabbit 
 1:10000  1hr RT 
Li-Cor IRDye 
680RD / 800CW 
  
Fluorescent 
secondary 
 
Table 2.39:  Antibodies.  List of antibodies used and conditions. 
 
2.6.8. GST purification 
 
GST purification was required for band shift and GST overlay experiments. GST plasmids (wild-
type and F210I mouse TDP43) were transformed into BL21 DE3 E. Coli cells, provided by the 
Buratti / Baralle laboratory. Cells (50 μl) were left on ice for 20 minutes after adding 1 μl of 
plasmid (10ng / μl), heated at 42°C for 2 minutes, placed back on ice for 5 minutes and then 
streaked onto plates with 75 μg / ml ampicillin. To express the protein the following day, a 
colony was picked and put in a solution at room temperature of 500 ml “terrific” broth + 50 ml 
SOL TB (KH2PO4-K2HPO4) + 500 μl ampicillin (from 1000 X stock). This was placed in a conical 
flask and grown at 37°C on a shaker at 140 rpm. After 8 hours 150 μl IPTG (1M) (AB-0481, 
Fisher) was added to induce protein production and left on a shaker overnight at room 
temperature (IPTG protein induction was checked by running 25 μl on a gel with loading buffer 
before and after IPTG addition). The next day, the bacterial cells were pelleted in a Sorvall 500 
ml tube at 3500 x g / room temperature (at this stage the pellet was frozen). The pellet was 
then resuspended in 45 ml PBS-triton 1% (by vortexing and pipette mixing) (triton, AC21568-
0010 Fisher). One proteinase inhibitor pellet (M0273L Roche) was then added. The 
resuspended pellet was left on ice for 30 minutes. To purify the protein, the solution was then 
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sonicated, in cycles of 30 seconds on, 30 seconds off at 100% amplitude for 10 cycles. 
Following centrifugation, the supernatant was transferred to a new Falcon tube. Glutathione 
Sepharose 4B beads were then prepared (17-0756-01 Amersham Biosciences / 635610 
Clonetech beads) by taking 500 μl, washing in cold PBS-triton 1% (10 ml), centrifuging briefly, 
and then adding beads to the supernatant. The supernatant was then placed with beads on a 
rotator at 4°C for 2 hours. The supernatant was then centrifuged for 10 minutes at 500 x g at 
4°C. The beads were washed with bound protein three times in cold PBS-triton 1% (20 ml per 
wash) and centrifuged for 10 minutes, 500 x g at 4°C after each wash. Before the third and 
final wash, the beads were put with PBS-triton 1% on the rotator in the cold room for 10 
minutes. Then after the final wash, when removing the PBS-triton 1%, 1 ml was left and the 
beads were moved into a 2 ml microcentrifuge tube. This tube was centrifuged for 5 minutes 
at room temperature followed by removal of as much of the supernatant as possible. During 
the washes the following elution buffers given in Table 2.40 and Table 2.41 were made. 
Component μl Preparation 
Glutathione 250 mM  30 
Prepare in warm water at 37°C. Store at 
-20°C 
DTT 1 M  1.5 Should be stored at -20°C 
Protease Inhibitor (25X)  120 1 tablet in 2 ml H2O is 25X (store -20°C) 
Tris 100 mM pH 8.8 1350   
 
Table 2.40: 5 mM elution buffer. 
 
For 10 ml solution (1 sample) μl 
Glutathione 250 mM 400 
DTT 1M 10 
Protease Inhibitor (25X) 800 
Tris 100 mM pH 8.8 8800 
 
Table 2.41: 10 mM elution buffer. 
 
For protein elutions 1 ml 5 mM elution buffer was added to the beads, with 5 minutes 
incubation on a rotator at 4°C, followed by a 5 minute centrifugation at 500 x g at 4°C. For 
elutions two and three, 1 ml 10 mM elution buffer was added and rotated for 20 minutes at 
4°C, then centrifuged for 10 minutes at 500 x g at 4°C. For elutions four and five the same 
process was completed but incubated on the rotator for 10 minutes. Then 1 ml elution buffer 
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was added and the microcentrifuge tube rotated overnight for the sixth elution by 
centrifugation for 10 minutes 500 x g at 4°C. The next morning the final protein elution was 
stored at -80°C (all previous elutions were frozen when obtained). 20 μl per elution was run on 
a gel (with 5 μl 5X SDS loading dye) to check that protein had been successfully extracted and 
to quantify against BSA. A representative image of the protein elutions is shown in Figure 2.7. 
 
 
Figure 2.7: Purified TDP43 protein stained by Coomassie.  Image showing a typical run of GST-purified TDP43. 
Protein has been loaded on a 12% acrylamide gel and stained with Coomassie blue. First three lanes contain BSA 
(66.5 kDa) and following six lanes contain TDP43 elutions. GST-TDP43 runs at a height of 69 kDa as the mass of GST 
is 26 kDa. This image can also be used to quantify protein amounts as comparing band intensity to known loaded 
amounts of BSA allows for protein concentration calculation. 
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3. Results: Q101X and K160R mutations identified from the 
MRC Harwell ENU archive 
 
3.1. Mouse lines and genetics 
 
All coding exons of the MRC Harwell archive were screened for mutations in Tardbp. A 
nonsense and two missense mutations were identified. They are Q101X, K160R and T153A 
shown in Chapter 1, Figure 1.1. These mutations were found prior to the beginning of my PhD 
when there were no published TDP43 models in September 2008. The aim was to re-derive 
mice carrying each of the mutations for phenotypic assessment. These mice were 
behaviourally assessed to determine whether the mutations were functional and whether they 
resulted in pathology relevant to known TDP43 proteinopathies. 
At TDP43 amino acid position 101, glutamine is mutated to a stop codon (Q101X). This 
truncates the protein producing a potential null allele. The two missense mutations T153A and 
K160R lie in the first RNA recognition motif (RRM), which is a domain that is necessary and 
sufficient for RNA-binding (Buratti et al., 2001; Giordana et al., 2010). At residue 153, a 
threonine is mutated to an alanine (T153A). Threonine is a neutral polar amino acid with the 
change to a neutral non-polar amino acid. The phosphorylation of this threonine may be 
important in TDP43 function however this residue is not highly conserved across species 
(Figure 1.1), but it does appear to be phosphorylated (Hasegawa et al., 2008). At position 160, 
there is a lysine to arginine change. This lysine is more highly conserved than the threonine at 
position 153 (although it is not conserved in Drosophila, where TDP43 is generally not highly 
conserved in this species). 
The first lines to be re-derived from the sperm archive by IVF were Q101X and K160R. The 
initial IVF to rederive the T153A mutant failed and therefore resulted in a delay for these mice 
to be generated. These mice continue to be phenotyped and are not presented as part of the 
work in this thesis. The genetic backgrounds of the phenotyped Q101X and K160R mice are 
given in Figure 3.1. 
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Figure 3.1: Q101X and K160R mice. Schematic showing the genetic background and ENU mutations carried by the 
Q101X and K160R phenotyping cohorts. Q101X cohorts were a mixture of BC3 and BC4 C57BL/6J mice, carrying all 
ENU mutations in heterozygosis as they were generated through a backcross. This is because Q101X homozygotes 
are not viable. K160R mice are OC mice with a more mixed genetic background than Q101X mice. There may be 
other ENU mutations in homozygosis as the phenotyping cohort was generated though inter cross matings. The 
starting genetic makeup of the Q101X and K160R mice is different because the mutagenesis regime changed 
through time as the Harwell centre progressed. Overall, the aim with all lines is to get the mutations congenic on a 
C57BL/6J background as this is the background in which the group studies most mutations. 
Following generation of the initial Q101X and K160R cohorts, further crosses were used to 
produce compound and double mutants. Q101X heterozygotes were crossed to K160R 
heterozygotes to generate compound heterozygotes (TardbpQ101X/K160R). Q101X heterozygotes 
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were also crossed to low copy SOD1G93A transgenic mice to generate double mutants. Figure 
3.2 summarises the genetic makeup of each of the lines with the number of backcrosses 
completed. 
 
Figure 3.2: Q101X double and compound mutants. Schematic showing the generation of Q101X/ SOD1G93A double 
mutants and compound Tardbp
Q101X/K160R
 TDP43 compound mutants. The Q101X / SOD1
G93A
 double mutants are 
BC4 C57BL/6J mice crossing Q101X heterozygous mice to SOD1
G93A
 transgenic heterozygous mice. SOD1
G93A
 
transgenic mice were congenic, therefore in this schematic this mating is considered as a backcross. Compound 
Tardbp
Q101X/K160R
 double mutants were generated through crossing Q101X male BC2 C57BL/6J mice to K160R OC 
females. Note that as these mice carry unique arrays of ENU mutations, no other ENU mutations are in 
homozygosis. 
 
The cross to generate compound mutants (TardbpQ101X/K160R) was used to assess the impact of 
having one full length encoding K160R allele versus two in K160R homozygotes 
(TardbpK160R/K160R). The aim was to assess whether there were any effects at a behavioural level 
when comparing one and two full length encoding alleles. Q101X heterozygotes were also 
crossed to SOD1G93A low copy transgenic mice to assess for modifying effects on SOD1G93A 
induced phenotypes. Both males and females were aged to end stage which due to the 
SOD1G93A transgene is 31-38 weeks (Alexander et al., 2004; Acevedo-Arozena et al., 2011). In 
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this SOD1G93A model, the disease course is highly consistent with onset from 22- 24 weeks 
progressing to death by humane endpoint. The SOD1G93A mice are a well characterised model 
of ALS, overexpressing around 8-10 copies of the human SOD1G93A transgene. They recapitulate 
many of the major hallmarks of SOD1 induced ALS seen in humans showing a progressive 
motor neuron degeneration disease course. Mutations in both SOD1 and TDP43 cause ALS. 
SOD1 induced ALS results in TDP43 negative inclusions and when mutations in TDP43 as well 
as other causative genes cause ALS they result in SOD1 negative inclusions. Despite this lack of 
overlap in these misfolded proteins aggregating, there is convergence of the effects of 
mutations in both genes resulting in ALS and therefore there could be commonality in the 
mechanism through which selective neurodegeneration occurs. Considering the well 
characterised nature of the SOD1G93A model, these mice were crossed to Q101X heterozygotes 
to assess for potential interactive effects up to end stage. A summary of the crosses for the 
compound (TardbpQ101X/K160R) and SOD1G93A double mutants is given in Figure 3.2 with a 
summary schematic of all lines phenotyped shown in Figure 3.3. 
 
 
 
Figure 3.3: Mouse lines phenotyped. Schematic showing genotypes of mice phenotyped for each mutant line with 
littermate controls. Q101X homozygotes are not viable as presented below. More than ten mice per sex per 
genotype were assessed for all tests where possible. 
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A phenotyping regime containing a variety of behavioural assessments was developed to 
characterise the mutant mice. For the Q101X, K160R and compound (TardbpQ101X/K160R) lines 
this included SHIRPA, grip strength and rotarod as well as other tests aimed at providing a 
comprehensive assessment of mouse health and behaviour with a focus on motor capabilities. 
For the first six months, phenotyping was carried out on a monthly basis.  Once initial 
phenotypes were detected, the programme was revised.  Due to the subtle nature of the 
phenotypes observed, the phenotyping continued on a two to three monthly basis. Most tests 
have been completed every two to three months. The aim was to complete a comprehensive 
behavioural assessment characterising health, cognitive and motosensory ability. The 
phenotyping tests applied were focused on assessing motor capabilities, considering TDP43’s 
central role in amyotrophic lateral sclerosis (ALS). Mouse cohorts of more than ten mice per 
sex per genotype were generated in order to provide cohorts with significant numbers to 
assess phenotypes and potential sex differences. The generation of each mouse cohort was 
staggered for phenotypic assessment in order to allow for a comprehensive phenotypic 
assessment of large numbers of animals.  
For the Q101X, K160R and compound (TardbpQ101X/K160R) mice, based on the phenotypic 
characterisation throughout the first year, it was decided that at one year the male mice from 
each cohort would be culled to assess for pathology. These males were perfused or had tissue 
snap frozen to use for pathology or biochemical assessment. Behavioural characterisation of 
the female cohorts continued to end stage or two years of age, before harvesting tissues for 
further assessment. 
Results are presented for the Q101X, K160R and compound (TardbpQ101X/K160R) lines together. 
The Q101X cross to SOD1G93A is presented separately. 
 
3.2. Viability 
 
Following the IVF for Q101X and K160R mice, Q101X heterozygote inter crosses were set up to 
determine homozygote viability. No Q101X homozygotes were present from the original inter 
cross matings using BC2 and BC3 mice (Figure 3.1). Inter cross matings were set up to 
determine at what stage during development Q101X homozygotes could be identified (Table 
3.1). No homozygous Q101X mice were identified at the developmental stages assessed 
indicating early embryonic lethality. 
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Genotype 
Timed 
mating (dpc) 
N +/+ -/+ -/- Resorptions 
E7.5 - 11.5 
dpc 
47 12 21 0 14 
E6.5 dpc 25 9 11 0 5 
  
Table 3.1: Q101X homozygote viability. Table showing genotyped embryos from selected developmental time 
points. No homozygous Q101X embryos were identified at any time point. Resorptions were at a stage where they 
were unable to be genotyped. At 6.5 dpc χ2 = 8.3, p =  0.0158 versus an expected 1:2:1 WT: heterozygote: 
homozygote ratio. 
Following this result, three independent TDP43 knock out studies showed that knockout mice 
are not viable in homozygosis, dying between E3.5- 8.5 dpc (Kraemer et al., 2010; Sephton et 
al., 2010; Wu et al., 2010) supporting Q101X being a null allele. Crosses to generate K160R 
homozygotes (TardbpK160R/K160R) and compound mutants (TardbpQ101X/K160R) were successful in 
producing genotypes at the expected Mendelian ratio.  
 
3.3. Phenotyping regime 
 
A comprehensive pipeline of tests has been applied to phenotype all mutant lines. In order to 
avoid bias, all mice were phenotyped blind to their genotype. Additionally, all mice 
phenotyped were weighed on a two weekly schedule until mice were culled for tissue or at 
end stage. Following complete characterisation, survival of each mouse cohort was also 
analysed. 
The phenotyping tests used were SHIRPA, grip strength and rotarod. SHIRPA is a first line 
phenotyping screen consisting of multiple elements. Mice were scored for behavioural activity 
as well as being assessed physically. An example SHIRPA sheet is included in Figure 2.4 in 
Chapter 2. 
All elements of the SHIRPA were assessed. However, data analysis has focused on: gait, startle 
response, limb grasp, grip strength, body tone and negative geotaxis. The SHIRPA set up is 
shown in Figure 2.1. One week after the SHIRPA test, rotarod and grip strength were assessed 
as described in methods.   
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At selected time points, startle response and open field were also measured. Startle response 
assesses motosensory response gating and open field measures aspects of locomotor activity 
and fear. Startle response is measured in the SHIRPA, with a score given for the jump response 
to a 90 dB tone. This semi-quantitative assessment was also completed using Minnesota 
medical development Inc (MMDI) boxes to a give a fully quantitative readout, providing an 
arbitrary value. Startle response to a 110 dB tone was measured in the quantitative system. 
Pre-pulse inhibition (PPI) was also measured, where pre tones of varying intensity are used 
which should dampen the mouse’s response to a successive startle tone. This test models 
sensorimotor gating with PPI deficits being linked to schizophrenia and psychosis (Geyer, 1999; 
Geyer et al., 1999; Ouagazzal et al., 2001a; Ouagazzal et al., 2001b). In applying this test the 
assessment aims were twofold, to determine normal sensorimotor gating in the startle 
response as well as any PPI deficits. As well as startle, mice were assessed in the open field 
arena. Mice were placed in a grey arena for 30 minutes and their activity was recorded using 
Noldus Ethovision software. Parameters analysed included total distance moved, duration 
moving, velocity, rearing frequency and time near the edge or centre of the arena. This data 
can represent features such as locomotor activity, neophobia, agoraphobia, exploratory drive 
and aspects of anxiety and fear (Crawley & Paylor, 1997; Choleris et al., 2001). The software 
itself measures ambulation. 
 
3.4. TardbpQ101X/+, TardbpK160R/K160R, TardbpQ101X/K160R phenotypes 
 
 
3.4.1. Survival 
 
 
Female cohorts from all lines were aged to end stage to assess survival. End stage was defined 
by 20% weight loss from maximum weight, mice being found dead or if the animal was sick as 
defined by the Named Animal Care and Welfare Officer (NACWO). Mice that were injured due 
to wounds from handling or fighting with other mice were not included in this study. Q101X 
heterozygous (TardbpQ101X/+) mice show no significant differences in survival (Figure 3.4). 
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K160R Survival Females 
 
 
 
 
 
 
 
 
 
Figure 3.4: Q101X survival. Plot showing the Q101X phenotyping cohort survival. Animals included were those that 
died for health or severe weight loss reasons. Mice that were culled due to reasons such as fight wounds from other 
mice were not included. Only female cohort aged to end stage n = 9 WT, 15 HET. Mean survival was WT = 709 days, 
HET = 643 days. No significant differences in survival observed p = 0.235 Log rank statistic, Kaplan Meier Analysis.  
In the K160R line, wild-type, heterozygote (TardbpK160R/+) and homozygote (TardbpK160R/K160R) 
female survival was approximately two years (Figure 3.5). No significant differences in survival 
were observed between genotypes. 
 
 
 
 
 
 
 
Figure 3.5: K160R survival. Survival plot showing the K160R phenotyping cohort. Animals included were those that 
died for health or severe weight loss reasons. Mice that were culled due to reasons such as fight wounds from other 
mice were not included. Only female cohort aged to end stage, n = 10 WT, 13 HET, 11 HOM. No significant 
differences in survival observed. Mean survival was WT = 762 days, HET = 649 days, HOM = 759 days. No significant 
differences between genotypes observed p > 0.05 Log rank statistic, Kaplan Meier Analysis. Overall p = 0.245 (log 
rank). 
Q101X Survival Females 
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Significant differences in survival were observed in the compound heterozygote 
(TardbpQ101X/K160R) line. Q101X heterozygotes and compound heterozygotes reached end stage 
significantly earlier (Figure 3.6) than littermates. Mean wild-type (Tardbp+/+) survival was 749 
days, Q-Het (TardbpQ101X/+) was 693 days, K-Het (TardbpK160R/+) was 642 days and Q/K-Comp 
(TardbpQ101X/K160R) was 689 days. Mice that reached end stage earlier due to weight loss or poor 
health condition were perfused for full pathological assessment which continues to be 
assessed. So far, there appear to be no genotype specific causes of death indicating that as 
mice naturally reach end stage the TardbpQ101X/K160R and TardbpQ101X/+ mice in this cohort were 
more susceptible to natural causes of death at an earlier age. 
 
 
 
 
 
 
 
 
 
Figure 3.6: Compound TardbpQ101X/K160R survival. Survival plot showing the compound TardbpQ101X/K160R 
phenotyping cohort survival plot. Animals included were those that died for health or severe weight loss reasons. 
Mice that were culled due to reasons such as fight wounds from other mice were not included. Only female cohort 
aged to end stage n = 10 WT, 6 Q-Het, 6 K-Het, 9 Q/K-Comp. Mean survival was WT = 749 days, Q-Het = 693 days, K-
Het = 642 days, Q/K-Comp = 689 days. WT versus Q-Het p = 0.007, WT versus K-Het p = 0.133, WT versus Q/K-Comp 
p = 0.049, Log rank statistic, Kaplan Meier Analysis. Overall p = 0.134 (log rank statistic). 
 
3.4.2. Weights 
 
Weight measurements were taken from between five and seven weeks, on a two weekly basis 
as shown in Figure 3.7, Figure 3.8 and Figure 3.9. No significant differences in weight are seen 
in the Q101X and K160R lines (Figure 3.7 and Figure 3.8). There is increased variability in 
Q101X/ K160R Survival Females 
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weight in the compound heterozygote line, potentially due to the mixed genetic background of 
the mice. Through time female compound heterozygotes are significantly smaller. This is 
significant by repeated measures ANOVA (overall p = 0.025) from 28 weeks in females using 
the least significant difference (LSD) test statistic (Figure 3.9). Repeated measures analysis up 
to one year shows no significant differences in males. 
 
 
 
Figure 3.7: Q101X weights. Graphs showing male and female Q101X weights through time. N is more than ten per 
sex per genotype, until individual mouse end stage for female cohort. No significant differences in weight are 
observed through repeated measures (where possible) or 1 way ANOVA analysis (p > 0.05). Error bars show 
standard deviation. 
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Figure 3.8: K160R weights. Graphs showing male and female K160R weights through time. N is more than ten per 
sex per genotype, until individual mouse end stage for female cohort. No significant differences in weights are 
observed through repeated measures (where possible) or 1 way ANOVA analysis Bonferroni post hoc analysis (p = 
0.05). Error bars show standard deviation. 
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Figure 3.9: Compound TardbpQ101X/K160R weights. Weights (grams) measured approximately every two weeks. No 
significant differences are observed in male compound Tardbp
Q101X/K160R
 mice. Female compound Tardbp
Q101X/K160R
 
mice are significantly smaller than wild-type littermate controls from 28 weeks onwards (repeated measures 
ANOVA up to one year, followed by multivariate GLM with LSD test statistic). From 28 weeks, wild-type versus 
Tardbp
Q101X/K160R
 p < 0.05. Repeated measures GLM could not be used for analysis at end stage due to mice dying 
resulting in uneven data point collection. Error bars show standard deviation. 
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3.4.3. SHIRPA 
 
SHIRPA was completed every two months in all lines. All lines show significant differences in a 
number of SHIRPA endophenotypes. Male mice were assessed by SHIRPA up to one year of 
age, starting from seven weeks. Female cohorts were assessed up to two years of age. There 
were significant differences in a number of SHIRPA endophenotypes as detailed below. Male 
mice were culled for pathological assessment and protein / RNA analysis at one year. 
 
3.4.4. Gait 
 
In the SHIRPA arena, a small proportion of Q101X heterozygote mice showed a more 
pronounced and less fluid gait compared to littermate controls. The lack of motion fluidity was 
subtle but consistantly present in mice showing the phenotype. This was observed through 
time at a mean age of 67 weeks, with no wild-type mice showing an abnormal gait. The 
combined proportion of heterozygous mice showing an abnormal gait across sexes was over 
20% in both sexes (Figure 3.10). 
 
 
 
 
 
 
 
 
Figure 3.10: Q101X Gait. Onset plots showing the presence of abnormal gait observed in the SHIRPA arena, 
through time, plots shown by sex. Y axis shows proportion of mice with lines for each genotype decreasing from 1, 
where no mice show the phenotype. N = female WT 12, HET 15. N = male WT 16, HET 16. Mean age at which gait 
was shown for both sexes combined was WT = no phenotype, HET = 67. WT versus HET p = 0.014, Kaplan Meier Log 
Rank Statistic. Overall p = 0.014 (log rank) with no significant differences between sexes p = 0.954. 
Abnormal gait was also observed in the compound heterozygote line. Wild-type males up to 
one year showed normal gait as did nearly all wild-type females up to two years. More than 
50% Q101X heterozygotes and compound homozygote males showed abnormal gait (versus 
Q101X Gait - Females Q101X Gait - Males 
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wild-type p = 0.001 Log rank statistic), with 25% female compound mutants showing abnormal 
gait (Figure 3.11). 
 
 
 
 
 
 
 
 
Figure 3.11: Compound TardbpQ101X/K160R Gait. Onset plots showing the presence of abnormal gait observed in the 
SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1 where 
no mice show the phenotype. N = female WT 11, Q-Het 8 , K-Het 6, Q/K Comp 11 . N = male WT 12, Q-Het 7, K-Het 
10, Q/K Comp 11. Mean age at which gait was shown for both sexes combined was WT = no phenotype, Q-Het = 58 
(more than 50% females), K-Het = 66 (more than 50% females), Q/K Comp = 63 (more than 50% males). WT versus 
Q-Het p < 0.0001, WT versus K-Het p = 0.013, WT versus Q/K Comp p = 0.001, Kaplan Meier Log rank statistic. 
Overall p = 0.002 with no sex differences by genotype up to one year of age (p > 0.05). There was a trend in a 
compound heterozygote sex difference (p = 0.07). 
 
3.4.5. Limb grasp 
 
 
Limb grasping was assessed when the mouse was suspended by the tail or hanging from a wire 
In the Q101X line, heterozygous males were culled at one year and did not overtly show this 
phenotype. In females the phenotype developed at a mean age of 61 weeks, which was not 
observed in the littermate controls (p = 0.002, Log Rank Statistic, Kaplan Meir Analysis) shown 
in Figure 3.12. 
 
 
 
 
Q101X/ K160R Gait Females Q101X/ K160R Gait Males 
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Figure 3.12: Q101X Limb grasp. Onset plots showing the presence of limb grasp observed in the SHIRPA arena, 
through time. Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1, where no mice 
show the phenotype. N = female WT 12, HET 15. N = male WT 16, HET 16. Mean age at which limb grasp was shown 
for both sexes combined was WT = no phenotype, HET = 61. WT versus HET p = 0.002, Kaplan Meier Log Rank 
Statistic. Overall p = 0.002 with a significant difference in Q101X heterozygote sex up to one year, p = 0.046. 
In the K160R line, more than 50% K160R homozygotes limb grasped in both sexes (Figure 
3.13). Beyond 60 weeks, almost 80% K160R homozygote females were limb grasping when 
suspended by the tail (wild-type versus homozygote limb grasp p < 0.0001 Kaplan Meier Log 
rank statistic). There is a trend for K160R heterozygotes in limb grasping, with almost 50% 
females showing this phenotype however it is not significant. 
Q101X Limb grasp Females Q101X Limb grasp Males 
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K160R Limb grasp Females K160R Limb grasp Males 
 
 
 
 
 
 
 
 
Figure 3.13: K160R Limb grasp. Onset plots showing the presence of gait observed in the SHIRPA arena, through 
time. Plots shown by sex. Y axis shows proportion of mice and each with lines decreasing from 1 where no mice 
show the phenotype. N = female WT 16, HET 22, HOM 17. N = male WT 14, HET 15, HOM 15. Mean age at which 
limb grasp was shown for both sexes combined was WT = no phenotype, HET = no phenotype, HOM = 49 (more 
than 50% females). WT versus HET p = 0.136, WT versus HOM p < 0.0001, Kaplan Meier Log rank statistic. Overall p 
< 0.0001 with no sex differences within genotypes. A trend towards a difference in K160R heterozygotes up to one 
year was seen, p = 0.052. 
 
Limb grasping was also present in the compound heterozygote line. More than 50% of Q101X 
heterozygote and compound heterozygote mice showed a limb grasping reflex (wild-type 
versus Q-Het p = 0.019, wild-type versus Q/K Compounds p = 0.001, Kaplan Meier Log rank 
statistic). This is shown in Figure 3.14.  
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Figure 3.14: Compound TardbpQ101X/K160R Limb grasp. Onset plots showing the presence of abnormal limb grasp 
observed in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice with lines 
decreasing from 1 where no mice show the phenotype. N = female WT 11, Q-Het 8 , K-Het 6, Q/K Comp 11 . N = 
male WT 12, Q-Het 7, K-Het 10, Q/K Comp 11 . Mean age at which limb grasp was shown for both sexes combined 
was WT = no phenotype, Q-Het = 52 (more than 50% females), K-Het = no phenotype, Q/K Comp = 50 (more than 
50% both sexes). WT versus Q-Het p = 0.019, WT versus K-Het p = 0.551, WT versus Q/K Comp p = 0.001, Kaplan 
Meier Log rank statistic. Overall p = 0.001, with no sex differences within genotypes (p > 0.05). 
 
3.4.6. Body tone 
 
Softer rear abdominal body tone was assessed by pressing the rear body (abdomen) of the 
mice with the thumb and index finger as described in methods. Body tone was scored as 
normal (0), soft (1) or severely soft (2). A score of zero was a firm normal tone. A score of 1 
was a significantly soft tone with no elicited tonal reflexive response and a score of 2 was a 
severely soft and flaccid tone with almost absent basal tone with no elicited response. In the 
Q101X line, a softer body tone developed in all genotypes and sexes, but was more prevalent 
with an earlier onset in Q101X heterozygous mice. Up to 20 weeks of age, the body tone in all 
mice remained firm with an elicited response. This progressed into a softer body tone in 
heterozygotes at a mean age of 45 weeks, versus less than 50% having a softer body tone in 
littermate controls. 80% of heterozygous Q101X mice show the soft body tone phenotype with 
only 30% of controls showing this phenotype (Figure 3.15). 
 
Q101X/ K160R Limb grasp 
Females 
Q101X/ K160R Limb grasp 
Males 
111 
 
Q101X Body tone Females Q101X Body tone Males 
 
 
 
 
 
 
 
 
 
Figure 3.15: Q101X Body tone. Onset plots showing the presence of softer body tone observed in the SHIRPA 
arena, through time. Plots shown by sex. Y axis shows proportion of mice and with lines decreasing from 1, where 
no mice show the phenotype. N = female WT 12, HET 15. N = male WT 16, HET 16. Mean age at which body tone 
was shown for both sexes combined was WT no phenotype, HET 90 (more than 50% in both sexes). WT versus HET 
p < 0.001, Kaplan Meier Log Rank Statistic. Overall p < 0.0001, with a trend in sex differences within Q101X 
heterozygotes up to one year, p = 0.07 
 
As well as scoring for body tone, a score for severe softness of body tone was given (2). In this 
score, the previously soft body tone becomes significantly softer such that there is no muscular 
tone felt with a clear ability to feel internal structures and organs. More than 50% of Q101X 
females displayed this and it was increasingly prevalent with age (Figure 3.16). 
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Figure 3.16: Q101X Severe reduction in body tone. Onset plots showing the presence of severely softer body tone 
observed in the SHIRPA arena, through time. Plots shown by sex. Y axis shows proportion of with lines decreasing 
from 1, where no mice show the phenotype. N = female WT 12, HET 15. N = male WT 16, HET 16. Mean age at 
which severe body tone was shown for both sexes combined was WT no phenotype, HET 66. WT versus HET p = 
0.003, Kaplan Meier Log Rank Statistic. Overall p = 0.003 with no significant differences in Q101X heterozygotes by 
sex up to one year (p = 0.621). 
In the K160R line, increasing numbers of mice displayed softer body tone through time in both 
males and females (Figure 3.17). Nearly all K160R homozygotes (more than 90%) showed a 
soft body tone through time in the SHIRPA assessment, which was not seen to the same 
degree in wild-type and heterozygote littermates. As with Q101X, body tone was scored as 0, 1 
or 2. Significantly more heterozygote and homozygote K160R mice showed a severely softer 
body tone (scored as 2) compared to wild-type controls (Figure 3.18).  This occurred with a 
higher prevalence in females, beyond the final age to which males were assessed. 
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Figure 3.17: K160R Body tone. Onset plots showing the presence of soft body tone observed in the SHIRPA arena, 
through time. Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1, where no mice 
show the phenotype. N = female WT 16, HET 22, HOM 17. N = male WT 14, HET 15, HOM 15. Mean age at which 
body tone was shown for both sexes combined was WT= 62, HET = 59, HOM = 38. WT versus HET p = 0.605, WT 
versus HOM p < 0.0001, Kaplan Meier Log rank statistic. Overall p < 0.0001 with no significant differences by sex 
within genotype (p > 0.05). 
 
 
 
 
 
 
 
Figure 3.18: K160R Severe reduction in body tone. Onset plots showing the presence of severely softer body tone 
observed in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice with lines 
decreasing from 1 where no mice show the phenotype. N = female WT 16, HET 22, HOM 17. N = male WT 14, HET 
15, HOM 15. Mean age at which severe body tone was shown for both sexes combined was WT = no phenotype, 
HET = no phenotype, HOM = 62 (more than 50% for both sexes). WT versus HET p = 0.018, WT versus HOM p = 
0.001, Kaplan Meier Log rank statistic. Overall p = 0.003 with no differences within genotype by sex up to one year. 
As with Q101X and K160R lines, in the compound heterozygote line loss of body tone firmness 
was progressive in all genotypes. In wild-type mice assessed, the number of mice showing 
softer body tone was less than 50% (Figure 3.19). More than 50% K160R heterozygotes, Q101X 
K160R Body tone Females K160R Body tone Males 
K160R Severe body tone 
Females 
K160R Severe body tone 
Males 
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Q101X/ K160R Body tone 
Females 
Q101X/ K160R Body tone 
Males 
heterozygotes and compound heterozygotes showed softer body tone. The compound 
mutants showed an earlier onset, particularly in males, versus K160R heterozygotes and wild-
type controls. There is also a trend towards an earlier onset than Q101X heterozygote 
littermate controls. When scoring for a severely soft body tone, Q101X heterozygotes and 
compound heterozygotes showed severely softer body tone. This was most prevalent in 
female mice, where 90% compound heterozygotes showed a severely soft body tone 
compared to less than 40% wild-type controls, p < 0.001 (Figure 3.20). 
 
 
 
 
 
 
 
 
Figure 3.19: Compound TardbpQ101X/K160R Body tone. Onset plots showing the presence of soft body tone observed 
in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice and each with lines 
decreasing from 1 where no mice show the phenotype. N = female WT 11, Q-Het 8 , K-Het 6, Q/K Comp 11 . N = 
male WT 12, Q-Het 7, K-Het 10, Q/K Comp 11. Mean age at which body tone was shown for both sexes combined 
was WT = less than 50%, Q-Het = 41 (more than 50% both sexes), K-Het = 47 (more than 50% both sexes), Q/K Comp 
= 30 (more than 50% both sexes). WT versus Q-Het p < 0.0001, WT versus K-Het p = 0.001, WT versus Q/K Comp p < 
0.0001, K-Het versus Q/K Comp p = 0.009, Q-Het versus Q/K Comp p = 0.105, Kaplan Meier Log rank statistic. Overall 
p < 0.0001, with no differences by sex within genotype (p > 0.05). 
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Figure 3.20: Compound TardbpQ101X/K160R Severe reduction in body tone. Onset plots showing the presence of 
severely softer body tone observed in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion 
of mice with lines decreasing from 1, where no mice show the phenotype. N = female WT 11, Q-Het 8 , K-Het 6, Q/K 
Comp 11 . N = male WT 12, Q-Het 7, K-Het 10, Q/K Comp 11. Mean age at which body tone was shown for both 
sexes combined was WT = no phenotype, Q-Het = 52 (more than 50% of females), K-Het = no phenotype, Q/K Comp 
= 48 (more than 50% both sexes). WT versus Q-Het p = 0.009, WT versus K-Het p = 0.692, WT versus Q/K Comp p < 
0.001, Q-Het versus Q/K Comp p = 0.514, K-Het versus Q/K Comp p = 0.004.  Kaplan Meier Log rank statistic. Overall 
p < 0.0001, with no differences by sex within genotype (p > 0.05). 
 
3.4.7. Negative geotaxis 
 
Negative geotaxis was assessed by placing the mouse on a vertical grid and assessing how 
effectively the mouse was able to climb down to the floor and to what degree the mouse slips. 
Negative geotaxis is a challenge to wild-type mice with increased slipping progressing as the 
mice aged. In the Q101X line, slipping was observed in both sexes however there was a higher 
penetrance and earlier onset (Figure 3.21) in Q101X heterozygotes, age of onset (wild-type less 
than 50%, Q101X heterozygotes was 44 weeks). 
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Figure 3.21: Q101X Negative geotaxis. Onset plots showing the presence of negative geotaxis slipping observed in 
the SHIRPA arena, through time. Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1, 
where no mice show the phenotype. N = female WT 12, HET 15. N = male WT 16, HET 16. Mean age at which 
negative geotaxis was shown for both sexes combined was WT less than 50%, HET = 44. WT versus HET p < 0.0001, 
Kaplan Meier Log Rank Statistic. Overall p < 0.0001 with significant difference by sex within genotype. Wild -type 
females versus males p = 0.02, Q101X heterozygote females versus males p < 0.001). 
In the K160R line, the mean age at which mice began to slip in the task was significantly 
younger in homozygote mice versus controls. Wild-type mice slipped at 42 weeks, 
heterozygote mice on average at 36 weeks with homozygous mice slipping at 24 weeks (Figure 
3.22). 
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Figure 3.22: K160R Negative geotaxis. Onset plots showing the presence of slipping on the negative geotaxis 
observed in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice with lines 
decreasing from 1, where no mice show the phenotype. N = female WT 16, HET 22, HOM 17. N = male WT 14, HET 
15, HOM 15. Mean age at which negative geotaxis was shown for both sexes combined was WT = 42, HET = 36, 
HOM = 24. WT versus HET p = 0.204, WT versus HOM p < 0.001, Kaplan Meier Log rank statistic. Overall p = 0.003 
with no differences by sex within genotype up to one year of age. 
More than 50% of mice from every genotype significantly slipped in the negative geotaxis 
challenge in the compound heterozygote line. The frequency and prevalence of slipping was 
significantly higher with an earlier onset in compound heterozygotes mice versus WILD-TYPE 
controls (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
K160R Negative geotaxis 
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K160R Negative geotaxis 
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Figure 3.23: Compound TardbpQ101X/K160R Negative geotaxis. Onset plots showing the presence of negative 
geotaxis slipping observed in the SHIRPA arena through time. Plots shown by sex. Y axis shows proportion of mice 
with lines decreasing from 1 where no mice show the phenotype. N = female WT 11, Q-Het 8 , K-Het 6, Q/K Comp 
11 . N = male WT 12, Q-Het 7, K-Het 10, Q/K Comp 11. Mean age at which negative geotaxis slipping was shown for 
both sexes combined was WT = 47 (more than 50% both sexes), Q-Het = 35 (more than 50% both sexes), K-Het = 41 
(more than 50% both sexes), Q/K Comp = 32 (more than 50% both sexes). WT versus Q-Het p = 0.135, WT versus K-
Het p = 0.402, WT versus Q/K Comp p = 0.027, K-Het versus Q/K Comp p = 0.016, Q-Het versus Q/K Comp p = 0.488, 
Kaplan Meier Log rank statistic. Overall p = 0.029 with significant sex differences within genotypes. There were 
trends for significant differences between male and female Q101X and K160R heterozygotes (p = 0.078 and 0.073 
respectively) and a significant difference between sexes in compound heterozygotes (p = 0.004) up to one year. 
 
3.4.8. SHIRPA summary 
 
SHIRPA assessment of Q101X, K160R and compound heterozygote lines showed significant 
differences in a number of endophenotypes, common to all lines. The commonality of 
phenotypes in K160R and Q101X lines, despite each line carrying different alternative ENU 
mutations, supports these phenotypes being caused by the TDP43 mutations. A summary of all 
SHIRPA phenotypes is given below, in Table 3.2, with comparisons by sex up to one year shown 
in Table 3.3. 
Q101X/K160R Negative 
geotaxis Males 
Q101X/K160R Negative 
geotaxis Females 
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  Q101X Line K160R Line 
Compound (TardbpQ101X/K160R) 
line 
Gait 
< 50%,  
p = 0.014 
No phenotype 
> 50% Q-het + Q/K Compounds 
(all mutants significant),  
Q/K Comp p = 0.001  
Limb grasp 
> 50% 
(females),  
p = 0.002 
> 50% homozygotes only, 
 Het p = 0.136, Hom p < 0.001 
> 50% Q/K Compounds (Q-Het 
and compounds significant),  
Q/K Comp p = 0.001 
Body Tone 
> 50%,  
p < 0.001 
> 50% all genotypes,  
Het p = 0.605, Hom p < 0.001 
> 50% Q/K Compounds (all 
mutants significant), Q/K Comp p 
< 0.001 
Severe Body 
tone 
> 50% 
(females),  
p = 0.003 
> 50% homozygotes only,  
Het p = 0.018, Hom p = 0.001 
> 50% Q/K Compounds (Q-het 
and compounds significant),   
Q/K Comp p < 0.001 
Negative 
geotaxis 
> 50%,  
p < 0.001 
> 50% all genotypes 
(homozygotes only significant),  
Het p = 0.204, Hom p < 0.001 
> 50% all genotypes (compounds 
significant) 
Q/K Comp p = 0.027 
 
Table 3.2: SHIRPA phenotype summary. Table showing the proportion of mice from each line showing the SHIRPA 
endophenotypes and which genotypes are significantly different from littermate controls. 
 
Table 3.3: SHIRPA sex differences. Table showing significant differences by sex within genotype for those 
endophenotypes were differences were observed. 
    Q101X Line K160R Line 
Compound 
(TardbpQ101X/K160R) 
line 
Gait 
Male No sex 
differences 
No phenotype no sex differences 
Female 
Limb grasp 
Male Significantly in 
females 
No sex differences No sex differences 
Female 
Body Tone 
Male 
Trend to earlier 
onset with 
increased 
prevalence in 
males 
No sex differences No sex differences 
Female 
Severe Body 
tone 
Male No sex 
differences 
No sex differences No sex differences 
Female 
Negative 
geotaxis 
Male 
Significantly 
earlier onset in 
males 
No sex differences 
Significantly 
earlier and more 
prevalent in 
compound males 
with trends in 
heterozygote 
mutants 
Female 
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3.4.9. Startle response and open field 
 
Startle response was used to measure the sensorimotor jump response to a tone stimulus. This 
was tested alongside pre-pulse inhibition to assess sensory inhibition. Open field was also used 
to measure mouse behaviour and locomotor activity in an arena. Both tests were used to 
characterise reflexive and behavioural responses, with both tests potentially assessing motor 
deficits.  
 
Startle response and pre-pulse inhibition were assessed at 10 and 22 weeks of age in all lines 
(number greater than ten mice per sex per genotype). No significant differences in startle 
response or pre-pulse inhibition were present in the Q101X heterozygote line (p > 0.05, 
Multivariate general linear model - GLM). Open field was assessed at 14 and 30 weeks, with no 
significant differences observed (p > 0.05 for all endophenotypes, Multivariate GLM). The 
results for startle response and pre-pulse inhibition are shown in Figure 3.24 and Figure 3.25. 
There were no significant differences between sexes either (p > 0.05, Multivariate GLM). 
 
 
Figure 3.24: Q101X Startle response and pre-pulse inhibition at 10 weeks. N = WT 23, HET 27. Average startle 
response is WT = 989, HET = 829, p < 0.05 Univariate GLM. With no significant difference in startle indicating normal 
hearing and sensorimotor gating, pre pulse inhibition can be analysed. Tones at 65, 70 and 75 dB played before the 
110 dB startle should increasingly dampen the startle response. This occurs for control and mutant mice, with no 
significant differences observed. Error bars represent standard deviation. 
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Figure 3.25: Q101X Open field 14 weeks. Graph showing total distance travelled in Q101X mice and littermate 
controls. N = WT 21, HET 24. Mean distance travelled: WT = 7115.12 cm, HET = 7448.32 cm. p = 0.841 Univariate 
GLM. Error bars represent standard deviation. 
No significant differences in startle response were seen at 10 and 22 weeks of age in the K160R 
line. At 10 weeks, 14 wild-type, 16 heterozygote and 10 homozygote K160R mice were 
assessed. At 22 weeks, 25 wild-type, 33 heterozygous and 22 homozygous mice were assessed. 
Startle response was not significantly different. With a normal startle response, pre-pulse 
inhibition can be assessed, which was also not significantly different (in all cases p > 0.05, 
Univariate GLM, post hoc Bonferroni analysis). Open field activity was assessed at 14 and 30 
weeks. There was a trend to reduced movement duration in K160R heterozygotes versus 
littermate controls at 14 weeks (Figure 3.26). However at 30 weeks, with 17 wild-type, 19 
heterozygous and 18 homozygous mice assessed, no significant differences were present and 
this trend was also absent. For startle response there were no significant differences between 
sexes (p > 0.05) but in the open field females had significantly reduced movement duration 
across genotypes (p = 0.044 Multivariate GLM, Bonferroni post hoc). 
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Figure 3.26: K160R Open field at 14 weeks. Bar chart showing the movement duration (seconds) from a total of 
1800 seconds in the arena, measured using Noldus Ethovision software. Error bars represent standard deviation. N 
= WT 25, HET 30, HOM 42. Movement duration average was WT = 1029.02, HET = 916.32, HOM = 963.11. WT versus 
HET p = 0.06, WT versus HOM p = 0.509, Multivariate GLM, Bonferroni post hoc. 
In the compound heterozygote line, startle response was assessed at 10 and 22 weeks. At 10 
weeks there was a significant difference between K160R heterozygotes (1360) and Q101X 
heterozygotes (830), p = 0.025 Univariate GLM, Bonferroni post hoc analysis. The number of 
mice tested was wild-type 19, K-Het 11, Q-Het 12, Q/K Compounds 18, with an equal male to 
female ratio. At 22 weeks, there was no significant difference between heterozygotes (Figure 
3.27). There was a trend to reduced startle response in compound heterozygotes (versus wild-
type p = 0.06 Univariate GLM, Bonferroni post hoc analysis). Open field activity was assessed at 
14 and 30 weeks. At 14 weeks, no significant differences were observed (n = WT 24, Q-Het 14, 
K-Het 14, Q/K Comp 24). Analysing the data before it was fully complete at 30 weeks, showed 
trends in the movement duration endophenotype. Based on this measurements were taken at 
42 weeks, before the 30 week data set was complete. Once all results at 30 weeks were 
collected no significant differences were observed (n = WT 22, Q-Het 13, K-Het 14, Q/K Comp 
21). As a result the 42 week time point was not completed by all mice however significant 
differences due to K160R heterozygote activity were observed (Figure 3.28). Overall for both 
startle and open field tests no significant differences by sex were observed (p > 0.05 in all 
cases). 
123 
 
 
 
 
 
 
 
 
 
Figure 3.27: Compound TardbpQ101X/K160R Startle response at 22 weeks. Bar chart showing the relative startle 
response to a 110 dB tone, quantitatively measured. Error bars represent standard deviation. N = WT 23, Q-Het 14, 
K-Het 13, Q/K Comp 22. Average startle response was WT = 1260.70, Q-Het = 1195.70, K-Het = 1302.58, Q/K Comp = 
932.64. WT versus Q/K Comp p = 0.06, K-Het versus Q/K Comp p = 0.078, Multivariate GLM Bonferroni post hoc. 
 
 
 
 
 
 
 
 
 
Figure 3.28: Compound TardbpQ101X/K160R Open field at 42 weeks. Bar chart showing the maximum distance 
travelled in a directed movement, measured using Noldus Ethovision software. Error bars represent standard 
deviation. N = WT 16, Q-Het 9, K-Het 10, Q/K Comp 17. Average distance moved was WT = 2.74, Q-Het = 3.17, K-Het 
= 3.73, Q/K Comp = 2.94. WT versus Q/K Comp p = 1, WT versus K-Het = 0.002, Q/K Comp versus K-Het p = 0.02, 
Multivariate GLM Bonferroni post hoc. 
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3.4.10. Rotarod and grip strength 
 
Rotarod was assessed at time points indicated in Figure 3.29, Figure 3.31 and Figure 3.33, 
initially once per month and later every two months.  No significant differences in overall 
performance were seen up to 64 weeks of age in the Q101X heterozygote line with no 
significant differences due to sex (p > 0.05) (Figure 3.29).  
 
Figure 3.29: Q101X longitudinal rotarod. Graph showing average WT and HET time on the accelerating rotarod, 
with error bars representing standard deviation. Rotarod measurements were taken in triplicate over three days 
(nine values per mouse), with the average of total performance recorded. There are no significant differences in 
rotarod performance between WT and Q101X HET mice observed up to 64 weeks (p > 0.05, Repeated measures 
ANOVA wherever possible and Standard GLM).  
Grip strength analysis followed the rotarod assessment in the same week. No significant 
differences were observed in Q101X male cohorts up to one year and female cohorts up to 
two years, as summarised in Figure 3.30. Mean force generated in mutants and controls 
remained around 200 grams, slightly decreasing in later age beyond 80 weeks. Weight was not 
accounted for in the analysis as there were no significant differences in weight between 
genotypes up to one year of age, with no significant differences by sex (p > 0.05, Multivariate 
GLM).  
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Figure 3.30: Q101X longitudinal grip strength. Graph showing average WT and HET grip strength, with error bars 
representing standard deviation. Measurements represent average force (g) generated in duplicate over four limbs. 
There are no significant differences in grip strength between WT and Q101X HET mice observed up to 64 weeks 
with males and females, or up to 104 weeks with females (p > 0.05, Repeated measures ANOVA wherever possible 
and Standard GLM).  
 
As with the Q101X heterozygote line, in the K160R line no significant differences in 
rotarod performance were seen at any point by genotype or sex (p > 0.05). Because of 
a low average time spent on the rod and large variation, only major differences would 
have been detected (Figure 3.31). Grip strength was assessed at selected time points up 
to 92 weeks as shown in Figure 3.32.   Data includes male and female strength up to 54 
weeks of age, with only female results up to 92 weeks of age. No consistently 
significant differences in grip strength were seen in male and female mice.  
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Figure 3.31: K160R longitudinal rotarod. Graph showing average WT, HET and HOM time on the accelerating 
rotarod, with error bars representing standard deviation. Rotarod measurements were taken in triplicate over three 
days (nine values per mouse) with the average of total performance taken. There are no significant differences in 
rotarod performance between WT , HET and HOM K160R mice observed up to 64 weeks (p > 0.05, repeated 
measures ANOVA wherever possible and Standard GLM, Bonferroni post hoc). 
 
Figure 3.32: K160R longitudinal grip strength. Graph showing average grip strength, with error bars representing 
standard deviation. Measurements represent force (g) generated in duplicate over four limbs. There are no 
consistent significant differences in grip strength between genotypes observed up to 64 weeks with males and 
females, or up to 104 weeks with females (p > 0.05, repeated measures ANOVA wherever possible and Standard 
GLM Bonferroni post hoc). At 24 weeks, WT grip strength is significantly higher than mutants (p < 0.05) but this is 
not repeated. Error bars represent standard deviation. 
No significant differences were seen in either rotarod and grip strength in the compound 
heterozygote line, by sex or genotype as shown in Figure 3.33 and Figure 3.34. 
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Figure 3.33: Compound TardbpQ101X/K160R longitudinal rotarod. Graph showing average time on the accelerating 
rotarod, with error bars representing standard deviation. Rotarod measurements were taken in triplicate over three 
days (nine values per mouse), with the average of total performance measured. There are no consistently significant 
differences in rotarod performance between genotypes observed up to 64 weeks (p > 0.05, repeated measures 
ANOVA wherever possible and Standard GLM). 
 
 
Figure 3.34: Compound TardbpQ101X/K160R longitudinal grip strength. Graph showing average grip strength, with 
error bars representing standard deviation. Measurements represent average force (g) generated in duplicate over 
four limbs. There are no significant differences in grip strength between genotypes observed up to 64 weeks with 
males and females, or up to 92 weeks with females (p > 0.05, repeated measures ANOVA wherever possible and 
Standard GLM).  
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3.5. Q101X and K160R cognitive assessment 
 
A separate cohort of female compound (TardbpQ101X/K160R) and K160R (TardbpK160R/K160R) 
homozygote mice were generated, with respective littermate controls. These mice were sent 
to the Department of Psychology, Oxford University for cognitive assessment. Dr Sam Line and 
Dr Rob Deacon assessed these mice with a pipeline of cognitive tests. The aims of these 
experiments were based on FTLD-TDP being part of a spectrum of disease with ALS (Liscic et 
al., 2008). The aim was to determine if there were deficits in multiple aspects of cognition in 
these mice, indicative of the changes seen in dementia. 
Significant differences were seen in two cognitive tests, the light-dark box test and the black-
white alley test. The light dark box test and black white alley test both measure multiple 
aspects of anxiety based phenotypes. In the light-dark box test, a smaller dark box is adjacent 
to an illuminated box with the mouse having the ability to move between the boxes. Mice 
have an aversion to the illuminated box and the activity of the mice starting from the dark or 
light box over time is measured. The test is used to predict anxiolytic and anxiogenic-like 
behaviours through measuring time in each compartment and transitions. Similarly, in the 
black-white alley test, a long alley box which is half black and half white is used. The mouse is 
placed facing the black wall which is less aversive and it is timed to enter the white half of the 
alley. In both tests the white area represents a mild stressor to the mice. 
Compound heterozygotes (TardbpQ101X/K160R) in the light-dark box test spend more time in the 
dark versus littermate controls (Figure 3.35). Overall, the significant differences observed in 
these two tests indicate that the compound heterozygotes are more anxious and show lower 
emotionality. This is not seen in heterozygous mutants or K160R homozygotes when compared 
to their littermate controls. The numbers of mice assessed were approximately ten per 
genotype, so this result is preliminary. A second cohort is being aged to re-assess whether 
these mutations result in anxiety related phenotypes. 
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Figure 3.35: Compound TardbpQ101X/K160R cognitive assessment. Cohorts of mice (n = WT 8, Q/K Comp 7, all other 
genotypes 9) were generated for cognitive assessment. Compound Tardbp
Q101X/K160R
 mice in the light dark box 
showed increased time in the dark: p = 0.001 versus WT, a trend in dark latency: p = 0.105 versus WT, and reduced 
transits: p = 0.010 versus WT. 
 
3.6. Pathology 
 
Pathology was assessed at one year of age for all mutant lines. Pathological assessment was 
required as it often precedes behavioural abnormalities where subtle alterations may not be 
detected at a behavioural level. One year old males were perfused and brains were harvested 
for analysis. Three brains per genotype for the compound (TardbpQ101X/K160R) and K160R 
(TardbpK160R/K160R) cohorts were sent to Dr Sebastian Brandner (UCL) for this assessment. 
Following a standard staining regime including hematoxylin and eosin stain, no overt 
alterations at the light microscopy level was seen in brain at this stage. Brains from two year 
old (end stage) samples are yet to be analysed. 
Pathological assessment showed no overt alterations in the brain at one year of age at the 
light microscope level. At eight months, spinal cords from two wild-type, two Q101X 
heterozygotes and two compound heterozygotes (TardbpQ101X/K160R) were harvested for 
electron microscopy (EM) analysis. This was completed by Constandina Vasiliou in Dr Julian 
Thorpe’s laboratory at the University of Sussex. Spinal cord sections were analysed by 
transmission EM. Immunogold labelling using anti-TDP (ProteinTech) showed small aggregate 
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structures exclusively seen in the cytoplasm of TardbpQ101X/K160R compound neurons (Figure 
3.36). These were not seen in Q101X heterozygote or littermate controls.  
 
 
 
 
 
 
 
Figure 3.36: Compound TardbpQ101X/K160R EM pathology. Image taken in the cytoplasm of a spinal cord neuron 
from a compound mutant. Black dots show anti-TDP43 (ProteinTech) labelled structures which are not seen in 
control samples. Image taken from tissue harvested at eight months. 
 
3.7. Compound TardbpQ101X/K160R molecular characterisation 
 
3.7.1. Q101X auto-regulation 
 
Q101X heterozygous animals only have one full length functional TDP43 allele. Whilst 
phenotyping the Q101X cohort, published knock out papers showed that in heterozygous 
knock outs, protein levels are equivalent to wild-type controls (Kraemer et al., 2010). This 
confirmed in vivo that in heterozygote knock outs TDP43 auto-regulates its protein levels 
equivalently to having two functional alleles. This was initially assessed in the Q101X 
heterozygotes with Westerns blots for six wild-type and six heterozygotes from twelve week 
harvested adult brain. Protein levels normalised to actin were not significantly different. This 
has since been assessed in one and a half year old TDP43 mice, with an equivalent level of 
protein detected when normalised to actin (Figure 3.37). This confirms that in vivo in Q101X 
heterozygous mice, there is TDP43 protein auto-regulation as in knock out heterozygotes. This 
data supports the Q101X mutation being a null allele, alongside the homozygote lethality 
phenotype occurring at the same time as published knockouts. 
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Figure 3.37: TDP43 Q101X levels from mouse brain. N = WT 6, HET 6. Brains were collected for protein and RNA 
analysis. Protein was extracted from half brain and quantified using anti-TDP (ProteinTech) with anti-actin control 
(Abcam). Fluorescent Leica secondary antibodies were used with Leica Odyssey visualisation and quantification 
software. TDP43 is green and actin is red. TDP43 levels were calculated as percentage intensity relative to actin. 
Error shows standard deviation. 
 
Two N-terminally targeted antibodies (Ab50930 Abcam, CAC-TIP-TD-P07 Cosmo) were used to 
detect whether the Q101X allele is expressed at the protein level. Western blots were unable 
to detect the band expected at approximately 18 kDa. This indicates that the Q101X protein is 
either not produced or is rapidly degraded. 
The Q101X encoding RNA transcript was quantified to compare the relative levels against the 
full length protein encoding transcript. Using the same pyro-sequencing assay for genotyping 
Q101X, RNA levels were quantified. RNA was extracted from brain tissue and cDNA generated. 
The Q101X genotyping assay was run and the area under the curve for the wild-type and 
mutant peaks was measured. DNA serves as a control with Q101X heterozygotes having a 1:1 
ratio of wild-type (C) and mutant (T) alleles. From the cDNA, the wild-type allele is highly 
expressed (C = 83.9%) whereas the Q101X encoding transcript relative to the wild-type allele is 
lowly expressed (T = 16.1%). This is shown in Figure 3.38. This was repeated from three 
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independent samples and confirms that the Q101X encoding transcript is reduced and is likely 
to be degraded with minimal protein produced. 
 
Figure 3.38: Q101X transcript ratio. Pyro-sequencer result from the assay used normally to genotype Q101X mice. 
The WT base is a C and the Q101X mutated base is a T. Genotyping from genomic DNA produces an approximate 50 
/ 50 ratio for each allele (left panel). Down regulation of the Q101X allele from RNA converted to cDNA is shown in 
the right panel. The pyro sequencer measures the relative areas under each curve, which can be used as a 
quantified measurement to compare expression levels of the two transcripts to each other. 
 
3.7.2. Protein levels 
 
Data for protein levels has been collected from mouse brain at various time points. There is a 
trend towards reduced TDP43 levels in compound heterozygotes versus wild-type controls. 
Relative to actin, TDP43 levels decrease by a third in compound heterozygotes, from 12 week 
adult brain (Figure 3.39). This Western blot has been repeated. However, there is no significant 
reduction in the protein levels between genotypes. 
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Figure 3.39: Compound TardbpQ101X/K160R three month protein levels. Western blot of protein extracted from 
compound Tardbp
Q101X/K160R
 half brain with littermate controls. TDP43 (ProteinTech) is the green band (Li-Cor Rabbit 
secondary) and actin (Invitrogen) is the red (Li-Cor Mouse secondary). Bands quantified using Li-Cor Odyssey 
software. As a mean percentage of actin band intensity, WT = 66.05%, Q-Het = 53.02%, K-Het = 51.75%, Q/K Comp = 
39.25%. WT versus Q/K Comp p = 0.097, 1 way ANOVA Bonferroni post hoc. Error bars show standard deviation. 
Westerns were also run using samples from one year old male brain. wild-type, Q101X 
heterozygous and compound heterozygous samples were run (3:3:3 per genotype). Figure 3.40 
shows that there is a trend towards reduced Q101X heterozygote protein levels with a trend to 
decreased levels in compound heterozygote protein levels. This matches the trend seen in 
young brain harvested at three months. 
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Figure 3.40: Compound TardbpQ101X/K160R one year Western blot. Top panel shows Western blot using protein 
extracted from one year old snap frozen half brain. TDP43 (ProteinTech) and actin (Invitrogen) were labelled with 
green and red secondaries respectively (Li-Cor rabbit and mouse). Levels were quantified relative to actin and 
plotted in a bar chart. WT versus Q-Het p = 0.11, WT versus Q/K compound p = 0.29 (ANOVA Bonferroni post hoc). 
Error bars show standard deviation.  
As well as the samples assessed at one year of age, males were aged to 18 months. Protein 
was extracted from half brain and assessed by Western blotting (Figure 3.41).There is a trend 
towards significantly reduced protein levels in compound heterozygotes verses wild-type. This 
Western blots were repeated technically as well as from re-extracted samples in order to 
determine whether this difference was significant, however significance was not consistently 
achieved and in some repeats the trend was lost.  
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Figure 3.41: Compound TardbpQ101X/K160R eighteen month Western blot. Top panel shows Western blot using 
protein extracted from 18 month old snap frozen half brain. TDP43 (ProteinTech) and actin (Invitrogen) were 
labelled with green and red secondaries respectively (Li-Cor Rabbit and Mouse). Levels were quantified relative to 
actin and plotted on a bar chart. All other comparisons p > 0.05 (1 way ANOVA Bonferroni post hoc). Error bars 
show standard deviation.  
 
3.7.3. Endogenous splicing target 
 
Alongside characterisation of protein levels, the levels of splicing were assessed in aged adult 
brain. TDP43 has extensively characterised roles in splicing. Sortilin1 (Sort1) exon 18 is spliced 
by TDP43 (Polymenidou et al., 2011). This is discussed in more detail in Chapter 5. RNA was 
extracted from harvested mouse brain and cDNA generated. Sort1 exon 18 spliced and non-
spliced transcripts were amplified and the ratio of band intensity was measured. Promotion of 
exon 18 skipping in Q101X brain and compound heterozygous brain was significantly reduced, 
compared to littermate controls (Figure 3.42 and Figure 3.43). No significant differences were 
seen in K160R homozygous brain (Figure 3.44). 
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Figure 3.42: Compound TardbpQ101X/K160R Sort1 splicing from one year brain. Top panel shows Sort1 spliced 
(bottom band) and unspliced (top band) transcripts. Bar chart shows quantified percentage of top band relative to 
total band intensity. N = WT 3, Q-Het 2, Q/K Comp 2. WT versus Q-Het p = 0.038, WT versus Q/K Comp p = 0.009, Q-
Het versus Q/K Comp p = 0.396, 1 way ANOVA Bonferroni post hoc. Error bars show standard deviation. 
 
 
 
 
 
 
 
 
Figure 3.43: Q101X Sort1 splicing from one and a half year brain. Top panel shows Sort1 spliced (bottom band) 
and unspliced (top band) transcripts. Bar chart shows quantified percentage of top band relative to total band 
intensity. N = WT 3, HET 3. WT versus HET p = 0.006, students two tailed T test. Error bars show standard deviation. 
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Figure 3.44: K160R Sort1 splicing from one year brain. Top panel shows Sort1 spliced (bottom band) and unspliced 
(top band) transcripts. Bar chart shows quantified percentage of top band relative to total band intensity. N = WT 4, 
HET 1, HOM 5. WT versus HOM p = 0.813, students two tailed T test. Error bars show standard deviation. 
 
3.8. Q101X / SOD1G93A double mutant 
 
Q101X heterozygotes (TardbpQ101X/+) were crossed to SOD1G93A transgenic low copy mice, to 
generate double mutants. At the time of generating this cross, the aim was to assess whether 
the Q101X TDP43 mutation could modify the disease of this characterised mouse model of ALS 
(Gurney et al., 1994; Acevedo-Arozena et al., 2011) and vice versa. Mutations in both TDP43 
and SOD1 cause ALS, however the pathological signature between the two induced disease 
courses is different. In SOD1 induced ALS, misfolded SOD1 is found in aggregates without 
TDP43, whereas in TDP43 induced ALS and most forms with mutations in other genes, TDP43 is 
localised to inclusions without SOD1. Despite this independence, mutations in both genes 
result in motor neuron disease supporting potential interactions (Mackenzie et al., 2007; 
Robertson et al., 2007; Turner et al., 2008). 
The low copy transgenic SOD1G93A mice are a well characterised model of ALS. They have been 
characterised previously and within the laboratory (Acevedo-Arozena et al., 2011), with a clear 
understanding of disease onset and progression in the model. By crossing to Q101X, as shown 
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in Figure 3.2, the aim was to phenotype the mice to look for potential modifying effects. 
Carrying 8-10 human copies of SOD1G93A, disease onset begins at approximately 22 weeks, with 
end stage by paralysis or more than 20% weight loss (as defined in the Home Office license 
conditions) between 31-38 weeks. This provided a clear model with a well characterised 
phenotype in which to search for modifying effects. The phenotypes induced by the transgene 
are only discussed here where potential modification occurs. 
 
3.8.1. Survival and weights 
 
SOD1G93A induced paralysis typically occurs at 31-38 weeks (217-266 days). When comparing 
Q101X WT / SOD1G93A mice to Q101X HET / SOD1G93A mice, there were no significant 
differences in survival (Figure 3.45). Being heterozygous for Q101X in both sexes does not 
enhance or decrease SOD1G93A induced survival. 
 
 
 
 
 
 
 
 
Figure 3.45: Double Q101X / SOD1G93A survival. Survival plot showing the Q101X / SOD1G93A phenotyping cohort 
survival. Animals included were those that died due to health (SOD1
G93A
 induced paralysis to humane end point) or 
severe weight loss (more than 20%). Mice that were culled due to reasons such as fight wounds from other mice 
were not included. N = 22 WT / SOD1
G93A
, 19 HET / SOD1
G93A
. p = 0.227, Log rank statistic, Kaplan Meier Analysis. 
 
Mice were culled when they lost 20% of maximum body weight or became paralysed, in 
accordance with Home Office license conditions. SOD1G93A mice showed a significant decrease 
in weight near end stage and this was overtly seen in male mice (Figure 3.46). Q101X HET / 
Q101X / SOD1G93A Survival 
Females 
Q101X / SOD1G93A Survival 
Males 
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SOD1G93A weights were not significantly different to Q101X WT / SOD1G93A littermate controls 
(p = 0.227 Log rank statistic). 
 
 
Figure 3.46: Q101X / SOD1G93A weights. Male and female phenotyping cohorts aged until SOD1G93A induced end 
stage, being weighed up to 34 weeks. WT / SOD1
G93A
 and Q101X HET / SOD1
G93A
 mice show a significant reduction 
in weight near end stage (versus WT / WT, p = 0.002 and 0.004 respectively, Univariate GLM Bonferroni post hoc). 
No significant differences in WT / SOD1
G93A
 versus Q101X HET / SOD1
G93A
 are observed. Error bars show standard 
deviation. 
 
Q101X / SOD1G93A Male weights 
Q101X / SOD1G93A Female weights 
140 
 
3.8.2. Q101X / SOD1G93A SHIRPA 
 
Body tone 
When assessing body tone, Q101X HET / SOD1G93A mice showed softer body tone versus WT / 
SOD1G93A littermates (p = 0.042). This was expected due to characterisation of the Q101X 
heterozygotes in other lines which show a soft body tone phenotype. When comparing Q101X 
HET / WT mice to Q101X HET / SOD1G93A mice, there was no significant difference in the 
proportion of mice showing soft body tone (p = 0.982, Figure 3.47). This shows that this TDP43 
induced phenotyped is not modified by the SOD1G93A transgene. 
 
 
 
 
 
 
 
 
 
Figure 3.47: Q101X / SOD1
G93A
 Body tone. Onset plots showing softer body tone in the SHIRPA test, through time. 
Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1, where no mice show the 
phenotype. N = female WT / WT 10, Q101X HET / WT 5, WT / SOD1
G93A
 14, Q101X HET / SOD1
G93A
 14. N = male WT / 
WT 12, Q101X HET / WT 10, WT / SOD1
G93A
 15, Q101X HET / SOD1
G93A
 14. Mean age at which body tone was shown 
for both sexes combined was WT / WT no phenotype, Q101X HET / WT 32 (more than 50% of females), WT / 
SOD1
G93A
 no phenotype, Q101X HET / SOD1
G93A
 26 (50% for both sexes). WT / SOD1
G93A
 versus Q101X HET / 
SOD1
G93A
 p = 0.042, Q101X HET / WT versus Q101X HET / SOD1
G93A
 p = 0.982, WT / WT versus HET / WT p = 0.006 
Kaplan Meier Log Rank Statistic. Overall p = 0.008 with no significant differences between sexes within genotypes (p 
> 0.05). 
Negative geotaxis 
Mice were assessed on the negative geotaxis challenge. Near end stage, 50% of WT / SOD1G93A 
male mice were significantly slipping on the negative geotaxis, with 90% of Q101X HET / 
  
Q101X / SOD1G93A Body Tone 
Females 
Q101X / SOD1G93A Body Tone 
Males 
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SOD1G93A mice slipping (Figure 3.48). Most females did not slip on the negative geotaxis 
however more than 50% of Q101X HET / SOD1G93A did slip. 
 
 
 
 
 
 
 
 
Figure 3.48: Q101X / SOD1G93A Negative geotaxis. Onset plots showing slipping on negative geotaxis in the SHIRPA 
test through time. Plots shown by sex. Y axis shows proportion of mice with lines decreasing from 1, where no mice 
show the phenotype. N = female WT / WT 10, Q101X HET / WT 5, WT / SOD1
G93A
 14, Q101X HET / SOD1
G93A
 14. N = 
male WT / WT 12, Q101X HET / WT 10, WT / SOD1
G93A
 15, Q101X HET / SOD1
G93A
 14. Mean age at which negative 
geotaxis was shown for both sexes combined was WT / WT = no phenotype, Q101X HET / WT = no phenotype, WT / 
SOD1
G93A
 = 35 (50% of males), Q101X HET / SOD1
G93A
 = 32 (more than 50% of both sexes). WT / SOD1
G93A
 versus 
Q101X HET / SOD1
G93A
 p = 0.005, Kaplan Meier Log Rank Statistic. Overall p < 0.001 with a significant difference in 
male and female Q101X HET / SOD1
G93A
 mice presenting the phenotype (p = 0.025). 
 
3.8.3. Startle response and open field 
 
Startle response was assessed at 10, 18 and 22 weeks. Reduced startle response in SOD1G93A 
mice has been shown previously (Acevedo-Arozena et al., 2011). Smaller cohorts were also 
assessed at 28 and 34 weeks. At 10 weeks, no significant differences in startle or pre-pulse 
inhibition were observed (n = WT-WT 21, Q-Het-WT 17, WT-SOD1G93A 25, Q-Het-SOD1G93A 26). 
No significant differences were seen at 18 weeks (n = WT-WT 16, Q-Het-WT 13, WT-SOD1G93A 
25, Q-Het-SOD1G93A 17) or at 22 weeks, with WT / SOD1G93A versus Q101X HET / SOD1G93A p = 
0.073, Figure 3.49. Smaller cohorts were assessed at 28 and 34 weeks with no significant 
differences in startle response (28 weeks n = WT-WT 9, Q-Het-WT 11, WT-SOD1G93A 9, Q-Het-
SOD1G93A 8, 34 weeks n = WT-WT 11, Q-Het-WT 7, WT-SOD1G93A 4, Q-Het-SOD1G93A 6). There 
were no significant differences in pre-pulse inhibition at any time points or differences due to 
sex.  
Q101X / SOD1G93A Negative 
geotaxis Females 
Q101X / SOD1G93A Negative 
geotaxis Males 
142 
 
  
 
 
 
 
 
 
 
Figure 3.49: Q101X / SOD1G93A Startle response at 22 weeks. Bar chart showing the relative startle response to a 
110 dB tone, quantitatively measured. Error bars represent standard deviation. N = WT / WT 20, Q101X HET / WT 
19, WT / SOD1
G93A
 27, Q101X HET / SOD1
G93A
 23. Average startle response was WT / WT = 971.67, Q101X HET / WT 
= 855.69, WT / SOD1
G93A
 = 1000.63, Q101X HET / SOD1
G93A
 = 878.49. WT / SOD1
G93A
 versus Q101X HET / SOD1
G93A
 p 
= 0.073, Multivariate GLM Bonferroni post hoc.  
 
Open field was assessed at 14 and 30 weeks. At 14 weeks, SOD1G93A mice were pre-
symptomatic, reflected in the open field where there are no significant differences in activity 
compared to wild-type controls. At 14 weeks, there was a trend for reduced Q101X HET / 
SOD1G93A movement duration, WT / SOD1G93A versus Q101X HET / SOD1G93A p = 0.088, Figure 
3.50. There were no significant differences due to sex. 
Q101X/ SOD1G93A Startle response – 22 weeks 
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Figure 3.50: Q101X / SOD1G93A Open field at 14 weeks. Bar chart showing movement duration (seconds) from a 
total of 1800 seconds in the arena, measured using Noldus Ethovision software. Error bars represent standard 
deviation. N = WT / WT 20, Q101X HET / WT 11, WT / SOD1
G93A
 24, Q101X HET / SOD1
G93A
 24. Movement duration 
average was WT / WT = 1022.60, Q101X HET / WT = 982.34, WT / SOD1
G93A
 = 1045.66, Q101X HET / SOD1
G93A
 = 
941.80. WT / SOD1
G93A
 versus Q101X HET / SOD1
G93A
 p = 0.088, Multivariate GLM Bonferroni post hoc.  
 
3.8.4. Rotarod and grip strength 
 
Rotarod was assessed at selected time points, as shown in Figure 3.51. From 8 weeks through 
to 36 weeks, no significant differences in time on the rotating rod were observed as well as no 
differences by sex. No prior training regime and a large variation in performance have masked 
an expected decline in WT / SOD1G93A performance.  
Q101X/ SOD1G93A Movement duration, open field – 14 weeks 
22 weeks 
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Figure 3.51: Q101X / SOD1G93A longitudinal rotarod. Graph showing average time on the accelerating rotarod, 
with error bars representing standard deviation. Rotarod measurements were taken in triplicate over three days 
(nine values per mouse), with the average of total performance taken. There are no consistently significant 
differences in rotarod performance between genotypes observed up to 64 weeks (p > 0.05, Repeated measures 
ANOVA wherever possible and Standard GLM). 
 
As well as rotarod, grip strength was assessed from 8 weeks though to 36 weeks. By 36 weeks, 
Q101X WT / SOD1G93A mice show significantly reduced grip strength versus wild-type littermate 
controls (Figure 3.52). At this stage, WT / SOD1G93A versus Q101X HET / SOD1G93A grip strength 
was not significantly different (p = 0.529). Sex was not significantly different between 
genotypes (p > 0.05). 
Q101X/ SOD1G93A Rotarod  
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Figure 3.52: Q101X / SOD1G93A longitudinal grip strength. Graph showing average grip strength, with error bars 
representing standard deviation. Measurements represent average force (g) generated in duplicate over four limbs. 
There are no significant differences in grip strength between genotypes observed up to 32 weeks with males and 
females. There is a reduction in force at 36 weeks as a result of the SOD1
G93A
 induced ALS phenotype in these mice 
(p = 0.008), but WT / SOD1
G93A
 versus Q101X HET / SOD1
G93A
 mice are not significantly different (p = 0.529, ANOVA 
1 way Bonferroni post hoc).  
 
3.9. Results discussion 
 
3.9.1. Introduction 
 
In this chapter the Q101X and K160R mutations identified from the MRC Harwell ENU archive 
have been characterised in vivo. An extensive longitudinal behavioural screen has been 
completed to determine whether these mutations are functional. This study identified that 
Q101X is homozygous lethal as was subsequently published in knock out studies (Kraemer et 
al., 2010; Sephton et al., 2010; Wu et al., 2010). Q101X heterozygous mice are viable and show 
in vivo TDP43 protein auto-regulation to retain protein levels equivalent to those of wild-type 
mice. These mice also show significant alterations in the SHIRPA assessment. 
Mice which are homozygous for K160R are viable. A phenotyping cohort of more than ten mice 
per sex per genotype was generated with a phenotyping regime matching that of the Q101X 
line. Significant changes in SHIRPA, consistent with the Q101X heterozygotes were seen. 
Finally, compound mutants for TardbpQ101X/K160R were generated, to assess the impact of the 
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K160R allele having to auto-regulate itself. These compound mutants show the SHIRPA 
phenotypes that Q101X heterozygous and K160R homozygous mutants show generally with an 
earlier onset. TardbpQ101X/K160R mice also show EM pathology not seen in Q101X heterozygotes. 
Finally, these mice show preliminary anxiety and emotionality phenotypes not observed in any 
other genotype.  
Q101X heterozygotes were crossed to low copy SOD1G93A transgenic mice to assess for 
potential modifying effects. With a defined disease course as a result of the SOD1G93A 
transgene, mice were phenotyped for phenotypic deviations from this baseline. Q101X HET / 
SOD1G93A mice did show phenotypic deviations in the negative geotaxis test in the SHIRPA, by 
slipping more. A potential trend in reduced movement duration in open field at 14 weeks and 
trend towards reduced startle response at 22 weeks were not replicated at alternative time 
points. This shows that there is no overt impact on the SOD1G93A phenotype from the TDP43 
Q101X mutation, arguing no significant interaction between the genotypes in this context. 
 
3.9.2. Q101X, K160R and Compound TardbpQ101X/K160R mutants 
 
Q101X viability and auto-regulation 
Q101X is homozygous lethal without any embryos being detected at E6.5 dpc (Table 3.1). 
Whilst studying these mice three knock out publications have shown that homozygous TDP43 
knockout mice die between E3.5 – 6.5 / 8.5 dpc (Kraemer et al., 2010; Sephton et al., 2010; Wu 
et al., 2010). Assessment in development from these papers supports lethality being the result 
of impaired inner cell mass proliferation. It is likely that the Q101X mutation is lethal through 
the same mechanism as homozygous knock outs although this has not been assessed directly. 
These results support Q101X being a null allele. 
In heterozygous knock outs, all three studies show that TDP43 levels auto-regulate to wild-
type levels in vivo. This is confirmed in Q101X heterozygotes which at young and aged stages 
show wild-type protein levels. In aged mice up to 18 months, no significant differences in 
Q101X heterozygote protein levels have been shown. 
Out of the three published knockout mice generated two show no significant phenotypes in 
knock out heterozygous mice (Sephton et al., 2010; Wu et al., 2010). The third study (Kraemer 
et al., 2010) which aged mice beyond the first two studies (over one year) shows motor 
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phenotypes in aged mice despite no reduction in TDP43 levels or TDP43 pathology. Only 
beyond one year do motor phenotypes emerge in this knock out model. These mice showed 
reduced grip strength and when upside down on a grid, held on for a significantly reduced 
time. These phenotypes emerge with age but were not progressive. They were also unable to 
detect any overt pathology in brain, spinal cord and selected muscle. The authors speculate 
that subtle non-structural abnormalities may be driving the phenotype, such as changes in 
metabolism. 
The knock out data supports that Q101X is a null allele, mirroring the knock out generated 
mice. The inability to detect Q101X protein by Western blot and the down regulation of the 
transcript relative to the wild-type allele, indicate that the Q101X protein is unlikely to be 
translated. If translated, the Q101X protein is likely to be degraded rapidly. Applying a 
proteasome inhibitor would allow for translation assessment. As with published knock out 
studies, despite a potential trend for reduced protein levels in Q101X heterozygotes, no 
reduction in protein levels versus wild-type was detected by Western blotting. A subtle 
reduction in protein levels may support a mild loss of function driving the observed motor 
phenotypes in heterozygous knock outs and the non-motor phenotypes in Q101X 
heterozygotes. 
 
Q101X and K160R lines: survival and weights 
Female cohorts of Q101X, K160R and compound mutants were aged to end stage. In the 
Q101X and K160R cohorts no significant differences were seen between wild-type and mutant 
survival. In the compound heterozygote cohort, both Q101X heterozygotes and compound 
(TardbpQ101X/K160R) heterozygotes died significantly earlier than littermate controls (Figure 3.6). 
wild-type mean survival was 749 days, where Q101X heterozygotes and compound 
heterozygotes showed a mean survival of 693 and 689 days respectively. Where possible, 
samples have been collected from all end stage mice for post mortem analysis. The cause of 
death continues to be determined and is being investigated. So far a mixture of phenotypes 
have been observed including lymphomas, however no genotype specific phenotypes have 
been identified. This shows that compound heterozygotes may be more susceptible to 
common causes of death in mice at this age versus wild-type mice. As aged mice die for a 
number of reasons, if there is no genotype specific cause then this mutation may result in an 
age dependent susceptibility to natural causes of death. The number of Q101X heterozygotes 
in the survival study was six, which is small. In the Q101X heterozygote specific colony there 
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was a significantly larger number of mice in the survival study, fifteen. In this study, Q101X 
heterozygous mice did not die earlier than littermate controls. This data therefore supports 
only compound heterozygous mice showing shortened survival, but the six Q101X 
heterozygous littermate controls are a more appropriate control than the Q101X heterozygote 
colony with their respective littermate controls due to the genetic similarity of the mice. 
Genetic background may contribute to why an earlier end point is seen for Q101X 
heterozygotes in one line over another, supporting a potential lethality-susceptibility 
phenotype for Q101X heterozygotes on the compound heterozygote genetic background. 
Weights were measured throughout the lifespan of phenotyped mice from 5 to 7 weeks of age 
onwards. Differences in weight are an important phenotype potentially reflecting metabolic or 
structural changes. TDP43 alterations have also been shown to result in weight phenotypes 
and body fat metabolism alterations (Chiang et al., 2010). No significant differences in weight 
were seen in Q101X and K160R lines. In the compound heterozygote colony, female 
compound heterozygote mice were significantly smaller than littermate controls from 28 
weeks onwards (Figure 3.9). Weight loss was also seen in conditional TDP43 knockout mice 
which altered levels of Tbc1d1, a gene controlling fat metabolism and leanness (Chiang et al., 
2010). A potential loss of function in compound mice may affect Tbc1d1 in a similar way to the 
conditional knockout out, ultimately altering fat metabolism resulting specifically in reduced 
fat mass. Levels of Tbc1d1 could be measured to assess this as well as generating further mice 
for fat analysis. 
SHIRPA: Q101X and K160R 
Gait 
In Q101X and compound heterozygote lines, significant differences in gait were seen. Gait was 
visually assessed in the SHIRPA arena. Abnormal gait was associated with low pelvic elevation, 
pronounced limb movement and loss of fluidity. In the Q101X cohort, less than 30% of 
heterozygotes showed abnormal gait in both sexes. In the compound heterozygotes line, more 
than 50% of Q101X heterozygotes and compound heterozygotes showed an abnormal gait, 
indicating that on this background the gait phenotype was more penetrant for Q101X 
heterozygotes. Overall, gait abnormalities are often associated with motor alterations. Gait 
could more quantitatively be assessed using Treadscan gait analysis systems / software. The 
sensitivity of the software to this subtle gait change may be limiting. In assessing these mice, 
gait was variable due to the genetic background, compared to assessing gait in congenic mice. 
Mutants have been scored for a non-fluid gait and this is statistically significant, however 
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further alterations in other phenotypes may have been expected and fully quantitative 
assessment is required. Strong gait abnormalities seen in other ALS models such as SOD1G93A 
are the result of motor unit loss and severe degeneration. The gait phenotype here was a more 
subtle phenotype where mice had lost the fluidity of their movement, potentially indicating a 
finer loss in motor coordination which may have both neuronal and muscular causes. 
 
Limb grasp 
Limb grasping was seen in Q101X, K160R and compound heterozygote lines. In the Q101X 
heterozygote line (Figure 3.12), limb grasping was mainly seen in females with more than 50% 
limb grasping at 80 weeks. In the K160R line, more than 50% homozygote mice limb grasped at 
45 weeks, which was matched in the compound line by compound heterozygous mice. With 
large proportions of mutant mice all limb grasping, this supports that both the Q101X and 
K160R mutations cause limb grasping. As a phenotype, many mutant mice have shown limb 
grasping however the underlying mechanism is poorly characterised. With the general motor 
capabilities of these mice being relatively normal, this implies a limb grasping response being 
driven by a nervous system alteration rather than a muscular defect. These alterations are 
difficult to identify, however this could be anticipated considering TDP43’s role in 
neurodegeneration and neuronal function across organisms. A poor understanding of the 
causative mechanism for limb grasping limits the ability to understand the causative molecular 
change. 
Body tone and severe body tone 
Body tone was commonly softer in all three TDP43 lines. This was measured by feeling the rear 
body of the mouse and assessing muscular tone and elicited tonal response to touch. In the 
Q101X cohort, more than 50% Q101X heterozygotes showed at softer body tone by 30 weeks, 
with a severely softer body tone by 90 weeks, showing a progressive phenotype. In the K160R 
cohort, 50% homozygotes showed a softer body tone by 35 weeks, with a severely softer body 
tone by 65 weeks. In the compound heterozygotes, more than 50% compound TardbpQ101X/K160R 
mice had a softer body tone by 20 weeks, with a severely softer tone by 40 weeks. There was 
also a trend in compound heterozygotes versus Q101X heterozygote littermates for this 
occurring earlier with higher prevalence in the compound mutants (p = 0.105). The high 
penetrance of this phenotype across cohorts provides strong support that it is induced by both 
Q101X and K160R mutations. This phenotype was also seen in the Q101X HET / SOD1G93A 
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cohort of mice. By being present in lines carrying different ENU induced point mutations it 
supports that the body tone phenotype is caused by the Q101X and K160R TDP43 mutations 
and not by alternative ENU mutations. Body tone itself, is a phenotype which is very poorly 
represented in the literature (Ingman et al., 2004; Messaoudi et al., 2005; Duysen et al., 2007). 
Mice require extensive handling to be settled to assess true body tone, which may contribute 
to it not being frequently assessed and reported. With no data indicating the pathological or 
mechanistic changes which drive this reduction in tone, muscle was dissected for 
neuromuscular junction assessment by Dr Gonzalo Blanco and Dr Abraham Acevedo. External 
oblique muscle, internal oblique muscle and transversus abdominis muscles overlay where the 
body tone is felt and the response elicited. Neuromuscular junction staining of compound 
heterozygous mice with soft body tone versus wild-type littermates with normal body tone, 
showed no overt abnormalities. Further characterisation of the muscles is required however 
this result supports this being a non-muscular based phenotype. There may be a potential 
sensory defect in eliciting the tone response or a higher central nervous system processing 
defect. Cohorts of mice are currently being generated for sensory assessment and brain 
imaging to further delineate this poorly defined phenotype. Results support no sensory 
deficits. 
 
Negative geotaxis 
The final SHIRPA endophenotype commonly affected was slipping on the negative geotaxis 
challenge. In the Q101X cohort, more than 50% Q101X heterozygotes slipped at 50 weeks. 
More than 50% K160R homozygotes showed slipping at 25 weeks and this was matched by 
compound heterozygote mutants. Slipping was observed in control mice as this is a 
significantly difficult challenge for wild-type mice. With mutants slipping on the negative 
geotaxis challenge at an earlier age this supports a subtle age associated reduction in 
controlled movement down the grid, but does not support a motor deficit on its own. 
 
Startle and open field 
Startle response and pre-pulse inhibition were assessed in the Q101X, K160R and compound 
heterozygote lines at multiple time points. In the Q101X and K160R lines, no significant 
differences in startle response or pre-pulse inhibition were seen at 10 and 22 weeks. In the 
compound line, there was a trend towards reduced startle response for compound 
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heterozygotes versus wild-type controls (p = 0.06) at 22 weeks (Figure 3.27). Overall, the 
startle response test provides a fully quantitative assessment of reflexive nervous function. 
There is significant variation in the response in these lines, probably due to the mixed genetic 
background of the mice tested. Mice were not retested at older time points as with a large 
C57BL/6J background, loss of hearing due to the age-related hearing (AHL) locus would 
potentially interfere with the results (Gates et al., 1999; Keithley et al., 2004). The AHL locus 
contributes towards age related hearing loss and in C57BL/6J mice this locus results in cochlear 
degeneration and hearing loss around mid-life. 
Open field assessment showed no significant differences in Q101X and K160R cohorts. The 
initial assessment at 14 weeks was used to assess locomotor activity, neophobia, agoraphobia, 
exploratory drive and aspects of anxiety and fear. At the repeated time point, as the mice were 
no longer naive to the test, assessment focused purely on locomotor activity. In the 
TardbpQ101X/K160R line, K160R heterozygous littermates showed increased maximum distance 
travelled per ambulation, compared to littermate controls (Figure 3.28). The number of K160R 
heterozygotes is low, so this should be viewed as a preliminary result. K160R heterozygotes 
from the K160R line did not show this phenotype, supporting that this is unlikely to be a 
significant difference. 
 
Rotarod and grip strength 
In all three lines, rotarod and grip strength were assessed. No significant differences were 
observed. For the rotarod, the mice were not trained in advance of the test and as a result 
many mice consistently performed badly on the test. This resulted in a low average running 
time on the rod with large variation between those that successfully ran versus mice that could 
not or would not. The result is that subtle to medium differences may be masked by the 
variation resulting in a loss of sensitivity to differences. Training mice in advance of the test 
can significantly increase mean time on the rod and reduce variation. In training, mice are 
continuously replaced to achieve a high baseline time on the rod in advance of being tested, 
which they more effectively maintain in future runs. This has since been applied to other lines 
in the laboratory.  
There were no significant differences for grip strength within the three lines assessed. There 
was low variation in grip strength readings supporting a sensitive detection for potential loss of 
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grip strength. This supports that these mutant mice do not showing significant motor deficits 
in their grip strength. 
 
Pathology 
Samples from one year old males were assessed for pathology at the light microscope level. 
Results from Dr Sebastian Brandner show that there was no overt pathology in the brains of 
mutant mice. Samples from end stage two year mice have been collected and will be assessed. 
At the EM level in the spinal cord, Dr Julian Thorpe showed small aggregates of TDP43 in the 
cytoplasm of neurons in compound heterozygote mice. Further samples at end stage have 
been collected to see if this phenotype progresses. Interestingly, at the Society for 
Neuroscience conference in 2011, unpublished data presented by Dr Gitcho (Washington Univ. 
Sch. of Med) from an Alzheimer’s transgenic mouse (APP-PS1), showed similar structures in 
spinal cord cytoplasm, labelled with anti-TDP43-phospho (Cosmo) at eight months. This result 
may indicate that these structures are associated with a general neural process which under 
certain conditions, potentially stress induced in the Alzheimer’s model, promotes TDP43 mini 
aggregate formation in the cytoplasm. Further investigation is required using antibodies 
against phosphorylated and non-phosphorylated TDP43. Overall the data from the compound 
heterozygous mice support a subtle intracellular change at the EM level which is not reflected 
as overt pathology at the light microscopy level. 
 
Protein levels 
Q101X heterozygote protein levels match those of wild-type levels in young and aged mice 
(Figure 3.37). This is consistent with the in vivo auto-regulation seen in knockout mice. In the 
compound heterozygote line, there may be a trend to reduced TardbpQ101X/K160R protein levels. 
This is seen in three month brain, in one year brain and in eighteen month old brain (Figure 
3.39, Figure 3.40 and Figure 3.41).  Littermate Q101X heterozygotes and K160R heterozygotes 
do not show any differences either. K160R homozygote protein levels have not been assessed 
due to time constraints. 
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Q101X and K160R summary 
The Q101X and K160R mutations have been characterised independently and together as 
compound mutants. They show common phenotypes in the SHIRPA surrounding body tone 
softness and limb grasp.  
The compound heterozygotes (TardbpQ101X/K160R) show the strongest phenotypes. The body 
tone phenotype has an earlier mean onset than in Q101X heterozygotes or K160R 
homozygotes, with an earlier onset trend versus a small cohort of Q101X heterozygote 
littermate controls. Compound heterozygote mice also show significantly reduced survival and 
females are significantly smaller than littermate controls from 28 weeks. At 22 weeks, there is 
a trend towards reduced startle response. These behavioural changes are not seen in Q101X 
heterozygotes and K160R homozygotes (not accounting for genetic differences between lines) 
and support more pronounced phenotypes in the compound heterozygotes. This is matched 
by a trend towards reduced protein levels versus wild-type controls and EM pathology seen at 
8 months. The enhanced changes in compound heterozygotes are the result of summing the 
effects of the Q101X and K160R alleles. Q101X heterozygotes show in vivo auto-regulation of 
TDP43 but still show phenotypes. K160R homozygotes also show similar behavioural 
phenotypes however the compound mutants show these phenotypes more overtly. As a 
preliminary result, this is seen in Sort1 splicing and also in cognitive behavioural tests. The 
enhanced and novel phenotypes may be the result of Q101X auto-regulation accentuating a 
mild functional deficit in the K160R mutation, which with two functional K160R alleles is less 
pronounced.  
The commonality of phenotypes between Q101X and K160R mutants supports similar effects. 
Although at the level detectable by Western blots there is no significant difference, if protein 
levels are subtly reduced in Q101X heterozygotes, this would support a loss of function driving 
observed phenotypes. K160R homozygotes also show phenotypes, with heterozygotes usually 
showing no phenotype. This would further support a potential partial loss of function, as 
heterozygotes still have one wild-type allele and the K160R allele me be mildly hypomorphic. 
Sort1 splicing in aged homozygous K160R brain was not significantly different to the wild-type 
allele, so it is not hypomorphic for this splicing function. However in the compound mutant, 
TardbpQ101X/K160R, there was reduced Sort1 splicing function. This result needs further repeating 
with other target genes. 
Although the mechanisms behind softer body tone and limb grasp phenotypes are poorly 
defined, assessment of muscle and motor performance in the phenotyping tests show normal 
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motor capability in all lines. This supports a neurological cause driving these reflexive 
phenotypes as there is no data for muscular force generation deficits (although direct 
assessment of the relevant muscles has not been completed). Overt pathology has not been 
identified at the light microscopy level in these mutants in the brain. In the compound 
mutants, EM pathology has been observed in eight month old spinal cord.  Overall, both the 
Q101X and K160R mutations are functional, with data here supporting mild loss of function. 
Q101X heterozygotes show body tone and limb grasping phenotypes which are not classical 
motor phenotypes. Out of the three knock out TDP43 mice generated, one shows motor 
phenotypes as a grip strength deficit. This may be because these mice were assessed by 
pooling results across multiple ages (Kraemer et al., 2010). Phenotypes indicative of 
neurological defects are present in limb grasping and body tone in compound TardbpQ101X/K160R 
mice, supporting these mutations having clear impacts on mouse reflexes at a behavioural 
level. 
 
3.9.3. TDP43 Q101X / SOD1G93A 
 
Q101X heterozygotes were crossed to low copy SOD1G93A transgenic mice to generate double 
mutants. The aim was to assess whether there was any interactive effect. With a defined 
disease course induced by SOD1G93A, the phenotyping regime focused on searching for 
phenodeviants from the SOD1G93A induced baseline phenotype. 
Q101X HET / SOD1G93A mice did not show altered survival or weight loss versus WT / SOD1G93A 
mice (Figure 3.45 and Figure 3.46). Q101X HET / SOD1G93A mice slipped more on the negative 
geotaxis test, with more than 50% slipping by 30 weeks where as 50% of WT / SOD1G93A mice 
did not slip. There were also trends for reduced startle response at 22 weeks and reduced 
movement duration in the open field at 30 weeks (Figure 3.49 and Figure 3.50). These 
phenotypes could potentially support a mild reduction in motor capabilities of Q101X HET / 
SOD1G93A versus WT / SOD1G93A mice. Rotarod and quantitative grip strength were not 
significantly different. Overall, subtle alterations in Q101X HET / SOD1G93A may be present; 
however there is no significant alteration in the SOD1G93A or Q101X induced phenotypes. This 
supports no accentuation of phenotypes between the Q101X and SOD1G93A mutations. This 
does not rule out potential interactions between SOD1 and TDP43 overall, however in this 
genetic cross no overt interaction was observed.  
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4. Results: Functional assessment of an allelic series of 
TDP43 mutations in vitro 
 
4.1. Introduction 
 
The aim of the work in this chapter is to assess the functional effects of an allelic series of 
mutations identified in mouse TDP43 (as discussed in Chapter 1), using an established in vitro 
system. This work was carried out in the laboratory of Dr Emanuele Buratti / Professor 
Francisco Baralle as part of an EMBO sponsored short term fellowship. The cystic fibrosis 
transmembrane regulator (CFTR) add-back assay was used in order to provide a functional 
assessment of each mutation on TDP43 splicing activity. In humans, CFTR exon 9 skipping is 
regulated by TDP43 through its binding to UG repeats at the 3’ splice site of exon 9. This 
mechanism of CFTR exon 9 skipping and the TDP43 binding site were previously characterised 
by Dr Buratti / Professor Baralle (Niksic et al., 1999; Buratti & Baralle, 2001; Buratti et al., 2001; 
Pagani et al., 2003a; Pagani et al., 2003b; Buratti et al., 2004; Ayala et al., 2006; Buratti et al., 
2007). Following binding to the target sequence, TDP43 interacts with other heterogeneous 
nuclear ribonucleoproteins (hnRNPs) to promote exclusion of exon 9 from the RNA transcript. 
Professor Baralle’s laboratory have created multiple constructs with a mini-gene containing 
CFTR exon 9 where the ratio of exon skipping, regulated through TDP43 binding, is controlled 
by the binding sequence motifs (Pagani et al., 2003a). In the mini-gene, exon 9 skipping activity 
is dominantly driven by the action of TDP43. Characterised mutations in the target binding 
sequence of the mini-gene alter TDP43’s binding and subsequent action in promoting exon 9 
skipping. For this assay the mini-gene construct C155T TG11T5 (D'Ambrogio et al., 2009) was 
used, where endogenous HeLa TDP43 promotes approximately 50% exon skipping. A summary 
schematic of the mini-gene is shown below (Figure 4.1). 
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Figure 4.1: Mini-gene construct with splicing outcomes. The schematic shows the CFTR mini-gene construct used 
in the add-back assay. The mini-gene contains an α-globin promoter, α-globin exons (black boxes), Fibronectin extra 
domain B (EDB) exons (purple boxes) and CFTR exon 9 (orange box). The marked UG sequence is the regulatory 
region that TDP43 binds, subsequently promoting exon 9 skipping (skipping outcomes indicated below blue arrow 
and by dotted red lines). Altering the UG11U5 sequence with the C155T mutation alters the activity of TDP43 in 
driving exon skipping. There is an intermediary outcome for partial exon 9 skipping which also occurs through a 
cryptic splice site. 24 hours post transfection; RNA was extracted from harvested cells and converted to cDNA. The 
degree of exon skipping was determined by PCR using primers α23 and BRA, in the indicated exon regions with 
horizontal blue arrows. PCR product was then run on an agarose gel with ethidium bromide staining for 
visualisation. Band intensity was measured using ImageJ software. 
Each of the missense TDP43 mutations were assessed for their ability to complete mini-gene 
exon 9 skipping in an equivalent fashion to the wild-type protein, assessing whether there was 
a loss or gain of function. The aim was to compare the effects of each of the mutations on 
splicing output of the reporter mini-gene versus wild-type TDP43. This would provide an 
assessment for each of the mutations on TDP43’s functional role in splicing. Each of the 
mutations and their conservation is given in the introduction, Figure 1.1.  
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4.2. Mouse TDP43 can complete CFTR mini-gene splicing 
 
CFTR exon 9 is not spliced by TDP43 in the mouse, instead, exon 9 splicing is regulated through 
an alternative mechanism (Buratti et al., 2001). This is due to the absence of a polymorphic 
regulatory sequence thought to have developed specifically in humans during evolution, which 
is not present in mouse CFTR (Rozmahel et al., 1997; Kazazian & Moran, 1998). Furthermore, it 
had never been shown that mouse TDP43 could promote exon 9 skipping in the mini-gene, 
despite proof that the relatively poorly conserved Drosophila homolog, TBPH, could 
(D'Ambrogio et al., 2009). In order to confirm this ability, the add-back assay was first 
completed, comparing human TDP43 and mouse TDP43 rescue.  
For the add-back assay, HeLa cells were seeded and grown in 6 well plates, before being 
treated with 40 mM siRNA targeted against endogenous TDP43, for two successive days. 
Following this, a flag tagged human siRNA resistant construct (pFLAG TDP), or V5 / HIS mouse 
(pcDNA 3.1 TDP43) construct, was co-transfected into the siRNA treated cells with the CFTR 
mini-gene. The mouse TDP43 construct sequence is two bases different to the endogenous 
HeLa cell TDP43 siRNA targeted sequence (Figure 4.2), therefore this experiment initially 
assessed whether the siRNA degraded the mouse construct transcript. Only if the mouse 
construct expression was not inhibited by the siRNA, could the allelic series of expressed 
proteins be functionally assessed. 
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Figure 4.2: siRNA sequence. The schematic shows the TDP43 cDNA sequence in human and mouse as well as 
encoded protein spanning exons 4 and 5. siRNA (red) was targeted against this sequence with 4 differences 
engineered in the human resistant construct (from Buratti / Baralle lab). The mouse constructs contained two base 
differences to the siRNA targeted sequence. 
 
Following 24 hours post co-transfection cells were pelleted for RNA and protein extraction. 
RNA was converted to cDNA and amplified using α23 and BRA primers (primers targeted to the 
mini-gene exons), before band assessment. Protein was extracted from cell pellets and 
analysed by Western blot to confirm successful down regulation of endogenous protein and 
transfected plasmid expression. The add-back assay is summarised in Figure 4.3.  
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Figure 4.3: Schematic showing the add-back assay. HeLa cells expressing predominantly nuclear TDP43 are 
treated with successive rounds of siRNA to reduce endogenous TDP43 expression to almost non-existent levels,  
routinely greater than 90% (Ayala et al., 2008a) . siRNA resistant mouse TDP43 constructs alongside the CFTR 
reporter mini-gene are then transfected into the HeLa cells, which now express exogenous TDP43 to promote exon 
skipping in the reporter mini-gene. 
 
There is strong expression of the mouse V5 / HIS tagged TDP43 proteins as labelled by their V5 
tags (anti-V5, 377500, Invitrogen), Figure 4.4 panel C. Results show (Figure 4.4) that the mouse 
TDP43 exogenous transcript is not degraded by the endogenous TDP43 targeted siRNA. 
Wild-type mouse TDP43 is able to rescue exon 9 skipping in the HeLa cell add-back assay. 
Without siRNA treatment, HeLa cells promote 43.9% CFTR mini-gene exon 9 inclusion. Treating 
the cells with siRNA significantly reduces endogenous TDP43 (as confirmed by almost complete 
protein band absence in Figure 4.4 panel C), resulting in exon 9 inclusion increasing to 93.8%. 
Following siRNA treatment, where siRNA resistant human TDP43 is added back, exon 9 
skipping function is rescued, restoring exon 9 inclusion to 41.9%. Wild-type mouse TDP43 
protein also rescues skipping to 52.1% inclusion (not significantly different to human TDP43, p 
= 0.603 1 Way ANOVA). This experiment was replicated at least three independent times for 
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each construct (Figure 4.4). Mouse TDP43 was unable to rescue exon 9 skipping following 
siRNA treatment, when amino acid residues F147 / F149 were mutated as a loss of function 
control. This was expected through the characterisation that these phenylalanines in the first 
RNA recognition motif (RRM1) are critical for human TDP43 RNA-binding (Buratti & Baralle, 
2001; Ayala et al., 2005), which has now been confirmed for mouse TDP43. 
 
 
Figure 4.4: Mouse CFTR mini-gene rescue. Add-back assay showing mouse TDP43 can rescue exon 9 skipping, as in 
human TDP43 rescue. Panel A shows cDNA PCR product with CFTR specific PCR primers. Band intensity was 
quantified using ImageJ software. Panel B shows bar chart of exon inclusion measured as a percentage of exon 
included band versus total (included + excluded) band intensity. The cryptic splice site band in between full exon 9 
inclusion and exclusion bands was not included as part of the measurement.  Error bars represent standard error of 
the mean.  Panel C shows Western blots with anti V5 (Invitrogen) labelling mouse TDP43 constructs, anti-TDP43 (in 
house Buratti laboratory antibody) being specific for human TDP43 only and anti-Tubulin control (in house Buratti 
laboratory antibody). 
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4.3. Assessment of TDP43 mutations in the add-back assay 
 
Wild-type mouse TDP43 protein is able to rescue exon 9 CFTR mini-gene skipping function. 
TDP43 V5 / HIS tagged constructs carrying all mutations in the allelic series were assessed in 
the add-back assay, shown in Figure 4.5. This was completed in six well dishes. For each six 
well dish, 180,000 cells were plated per well. In the experiment, one well each contained: no 
siRNA, siRNA alone and siRNA with wild-type TDP43 rescue. In the remaining three wells, 
siRNA with mutant construct rescue (a different mutation per well) was completed. Mutants 
were then compared to wild-type rescue per six well dish to minimise variation between 
dishes. This was repeated for each mutant at least three independent times. There was a 
significant reduction in exon skipping as expected following siRNA knock down of TDP43 
(versus non siRNA treated p < 0.0001, 1 Way ANOVA). Out of all mutations tested, F210I 
showed a significantly reduced ability to rescue exon skipping resulting in higher exon inclusion 
overall (versus wild-type mouse TDP43 rescue p = 0.011, 1 Way ANOVA). This implies a 
functional deficit where F210I is unable to promote efficient exon skipping (Figure 4.5). Control 
Western blots were run for all samples to confirm that all V5 / HIS plasmids expressing each of 
the mutant proteins were to approximately an equal level and that the siRNA had successfully 
downregulated the endogenous HeLa TDP43. 
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Figure 4.5: Allelic series add-back assay. Panel A shows reverse transcription PCR bands with exon 9 inclusion / 
exclusion, following siRNA treatment and TDP43 WT or mutant rescue. Panel B bar chart represents exon 9 
inclusion, as a percentage of total included / excluded band intensity (as measured by ImageJ software). Panel C 
shows transfected protein expression (anti V5, Invitrogen), endogenous protein levels (in house anti TDP43) and 
Tubulin loading control levels (in house anti Tubulin).  All missense mutations in the allelic series were transfected 
into siRNA treated HeLa cells, alongside the CFTR mini-gene reporter. When assessing exon skipping recovery versus 
WT TDP43 (Figure 4.5 panel A and B), F210I shows a significant inability to promote exon skipping.  Western blot 
analysis shows that all mutant constructs were expressed approximately equally and that endogenous TDP43 was 
heavily downregulated by siRNA. 
Wild-type TDP43 rescue of exon 9 skipping was 52.1% (Figure 4.5). Excluding F210I, mutant 
rescue from all other constructs was not significantly different to wild-type rescue. When 
comparing F210I rescue to wild-type rescue from the same six well plates, F210I rescue (71.7% 
inclusion) was significantly reduced compared to wild-type rescue (p = 0.011, 1 Way ANOVA). 
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4.4. F210I localisation 
 
As F210I was the only mutation to show a loss of ability to rescue exon 9 skipping function it 
was further investigated in vitro. Protein localisation was assessed in order to deconstruct the 
potential mechanism through which the F210I allele is unable to recover mini-gene exon 9 
skipping in the add-back assay (Figure 4.5). HeLa cells were transfected with V5 / HIS tagged 
Wild-type or F210I TDP43 and after 24 hours incubation; cells were pelleted for biochemical 
fractionation using lysis buffers and centrifugation into nuclear and cytoplasmic fractions 
(Figure 4.6). They were then analysed by Western blotting. 
TDP43 is predominantly (approximately 95%) localised to the nucleus as is transfected wild-
type mouse TDP43 in HeLa cells. Transfected F210I TDP43 also localises to the nucleus 
indicating that the nuclear versus cytoplasmic localisation is unaffected (Figure 4.6). This 
experiment was repeated independently three times.  
 
 
 
 
 
 
 
 
Figure 4.6: F210I nuclear versus cytoplasmic localisation. HeLa cells transfected with WT or F210I TDP43 were 
harvested 24 hours post transfection and fractionated into nuclear and cytoplasmic compartments. P84, a nuclear 
matrix protein, and Tubulin, were used to label nuclear and cytoplasmic fractions to confirm successful 
fractionation. V5 labelling against the tagged mouse proteins shows no overt differences between WT and F210I. 
Endogenous human TDP43 (as labelled with a human specific in house antibody generated by the Buratti / Baralle 
laboratory) shows a similar pattern. 
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4.5. F210I GST Overlay (far Western) 
 
In order to complete CFTR mini-gene exon skipping, TDP43 must successfully interact with a 
number of proteins, including characterised interactions with hnRNP family members 
(D'Ambrogio et al., 2009). To assess whether major TDP43 protein interactions are affected by 
F210I, a GST overlay experiment was completed. Utilising wild-type and F210I GST tagged 
plasmids; BL-21 bacterial cells were transformed to express the GST tagged proteins for 
subsequent protein purification. HeLa cell nuclear and cytoplasmic fractions were run on a 
12% acrylamide gel before being transferred to a PVDF membrane in the standard Western 
blot protocol. The membranes were either incubated with wild-type or F210I recombinant GST 
protein (2 μg) purified as described in Chapter 2. Standard incubation followed with a GST 
primary antibody (anti GST, Healthcare) and a HRP (Goat) secondary antibody. The binding 
pattern for this experiment has been previously published for human TDP43 (D'Ambrogio et 
al., 2009), allowing for comparison to this result (Figure 4.7). There is no overt difference in the 
protein binding pattern between wild-type and F210I TDP43. The mouse versus human binding 
pattern to HeLa extract is also identical. This experiment was repeated three independent 
times, using purified protein extracted from independent bacterial transformations.  
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Figure 4.7: F210I GST overlay. HeLa cell extracts (nuclear and cytoplasmic) were run on acrylamide gels before 
transfer to PVDF membranes. GST overlay was completed using GST purified WT and F210I TDP43 protein. The 
binding pattern of the WT and F210I mouse proteins, to human HeLa extracts, is similar to the published human 
binding pattern. Indicated bands, are hnRNP family binding members as characterised by the Buratti / Baralle 
laboratory (D'Ambrogio et al., 2009). Band presence / absence is similar for WT and F210I TDP43. Ponceau staining 
shows the smear of proteins at all molecular weights indicative of the extracted protein array from the nuclear and 
cytoplasmic fractions. Binding patterns were visualised following antibody incubation with ECL. 
Wild-type TDP43 predominantly binds a cluster of hnRNPs, shown to bind human TDP43 
(Figure 4.7). These include hnRNPs A3, B1, C, A2 and A1 (D'Ambrogio et al., 2009). F210I TDP43 
also binds these hnRNPs with a similar binding pattern, representing the major affinity 
interactions for TDP43 with HeLa cell extracted nuclear and cytoplasmic proteins. 
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4.6. F210I band shift with UG repeats 
 
An electrophoretic mobility shift assay (EMSA) experiment was completed to assess whether 
F210I shows normal binding affinity to UG6 repeats. Binding to UG repeats is required for the 
CFTR exon 9 skipping function with the EMSA in vitro assessing direct binding affinity to 
labelled UG6 repeats. Recombinant GST purified wild-type and F210I TDP43 were added to 
radioactively labelled UG6 repeats at increasing concentrations and run on 5% acrylamide gels. 
The gels were then dried onto filter paper and visualised by Cyclone (Packard) exposure. F210I 
TDP43 shows a strongly reduced ability to bind UG6 repeats (Figure 4.8) compared to wild-type 
TDP43. 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: F210I band shift. Radioactively labelled UG6 repeats were loaded onto an EMSA 5% acrylamide gel. 
With no binding protein added, a smeared band is seen at the bottom of the gel. As increasing amounts of WT 
TDP43 are added, the protein binds the free UG6 repeats and forms a band shifted complex. Likewise, the amount 
of free labelled RNA decreases as more is bound to TDP43. Conversely, F210I TDP43 shows a strong loss of ability in 
forming the band shift complex. A basal band of low intensity is formed however this is highly reduced compared to 
WT TDP43, with additional F210I TDP43 protein not significantly increasing the formation of the band shift complex. 
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4.7. Results discussion 
 
The mechanism behind CFTR exon 9 splicing has been well characterised (Buratti & Baralle, 
2001; Buratti et al., 2001; Pagani et al., 2003a; Pagani et al., 2003b). In humans, TDP43 plays 
an important role in regulating exon 9 skipping in CFTR. The add-back assay with a CFTR exon 9 
mini-gene was used to assess the functional capability of the allelic array of mouse TDP43 
mutations. 
Like human TDP43, mouse TDP43 is able to rescue CFTR exon 9 mini-gene skipping (Figure 4.4). 
Human TDP43 rescue was 41.9% whereas the mouse rescue was increased by 10% (52.1%), 
but this is not significantly different, p = 0.603, 1 Way ANOVA. This shows a 10% reduction in 
the ability TDP43 to promote exon 9 skipping, compared to human TDP43 rescue. This may be 
affected by the transfection efficiency of the different plasmids. However this does not affect 
the purpose of this assay, in assessing the functional capability of the mutant mouse forms 
versus wild-type TDP43. A recovery rate of 52.1% also provides a sufficiently clear baseline 
from which to assess potential gain of skipping function, below 52.1%, or loss of function 
above 52.1%. 
Mutating two critical phenylalanines in the first RRM of TDP43 (F147L / F149L) abolishes the 
RNA-binding capability of TDP43 to UG repeats and results in the loss of TDP43’s ability to 
promote exon skipping (Buratti & Baralle, 2001). These phenylalanines are conserved across 
species as well as in the mouse. As a result, mouse TDP43 F147L / F149L was unable to 
promote exon skipping (siRNA only treated cells showed 93.8% inclusion, siRNA with F147L / 
F149L showed 91.2% inclusion). This initial experiment showed that the mouse TDP43 
constructs are resistant to the siRNA used to knock down endogenous TDP43. The sequence of 
the siRNA and mouse sequence differs by only two bases and this is sufficient for the 
constructs to express the V5 / HIS tagged TDP43 proteins (Figure 4.4 and Figure 4.5) without 
being significantly degraded at the RNA level. 
Having established TDP43 rescue in the add-back assay, all missense mutant constructs were 
assessed for their ability to rescue exon 9 skipping. All mutant TDP43 alleles were successfully 
able to recover exon 9 skipping, excluding F210I (p = 0.011, 1 Way ANOVA). When comparing 
the five wild-type add-back experiments completed versus the five F210I add-back results 
(with these runs completed in the same six well dishes), wild-type recovery showed an exon 
inclusion average of 52.15%, versus F210I recovery at 71.77% exon 9 skipping. siRNA only 
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treated cells without construct rescue show 93.86% exon 9 inclusion. Therefore, F210I 
recovery is approximately 50% between wild-type recovery levels and no recovery. This in vitro 
result implies a potential reduction in exon 9 skipping function of 50%. 
With F210I showing a reduced ability to rescue exon 9 skipping function, protein localisation 
was assessed.  Biochemical fractionation of transfected HeLa cells showed that both wild-type 
and F210I TDP43 predominantly localised to the nucleus as expected. This matches the 
endogenous pattern of localisation. This result implies that the F210I mutation does not affect 
subcellular localisation of TDP43. Sub nuclear localisation of TDP43 in chromatin fractions has 
not been assessed for F210I, as described for the RRM1 mutant (Ayala et al., 2008b). This 
result implies that F210I TDP43 is not mislocalised and  is free to promote exon 9 skipping, 
however further characterisation for sub nuclear localisation could be assessed. 
To further characterise potential differences between wild-type TDP43 and F210I in vitro in 
HeLa cells, a GST overlay was completed to assess protein interactions. When HeLa nuclear 
and cytoplasmic extract were exposed to GST purified TDP43 protein, the binding pattern was 
not overtly different between wild-type and F210I proteins. The binding pattern had previously 
been established between human TDP43 and HeLa fractions (D'Ambrogio et al., 2009) with this 
result now characterising the mouse protein binding pattern. The two patterns are identical 
and this may be expected considering the 96% amino acid conservation between human and 
mouse TDP43. Both wild-type and F210I TDP43 have a high affinity for binding other hnRNP 
family members, with the same banding patterns visualised. This indicates that TDP43’s major 
protein interactions are not affected by the F210I mutation. This may be expected, as the 
highly characterised protein binding region in TDP43 lies in the C-terminus, downstream of the 
F210I mutation. Furthermore, a recent paper has identified a binding region in the N terminus 
(Swarup et al., 2011b). There is minimal information on the importance of the second RNA 
recognition motif (RRM2) and within it the F210I region as having roles in binding to other 
proteins. It is established in the literature (Buratti et al., 2005; D'Ambrogio et al., 2009) that 
the C-terminus mediates most known protein interactions and it is the C-terminus that is 
critical for binding to many hnRNP family members (Buratti et al., 2005; D'Ambrogio et al., 
2009), making this region potentially less likely to be affected by the F210I mutation. 
The GST overlay is a powerful technique which assesses major protein interactions. It is not 
quantitative as band intensity can vary significantly between repeat runs. A band presence / 
absence assessment effectively identifies whether a new binding partner is present or a major 
existing binding partner is lost. The major bands identified represent the protein binding 
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partners with the highest affinity for TDP43. There are hundreds of other characterised protein 
interactions for TDP43, which have been established and validated through techniques 
including co-immunoprecipitation. The majority of these binding partners are not represented 
here and this characterisation would require alternative approaches which are more 
quantitative, such as immunoprecipitation. As such, it is possible that F210I may affect TDP43’s 
protein interactions in ways that the GST overlay is not able to detect. This result shows that 
major interactions with hnRNP family members are not lost as a result of the F210I mutation. 
The final in vitro assessment of the F210I mutation confirmed that this mutation affects the 
ability of TDP43 to bind UG6 repeats. TDP43 has a high affinity for binding UG repeats (Kuo et 
al., 2009), binding a minimum of six repeats. The binding affinity also increases with more 
repeats (Buratti & Baralle, 2001). There was a striking inability for F210I to match the wild-type 
binding to UG6 repeats. This in vitro assessment conclusively shows that F210I has highly 
reduced UG6 RNA-binding ability. 
Phenylalanine 210 lies in the second RRM. At position 211 there is a second phenylalanine with 
both residues being conserved from human through to zebra fish. The 210 residue is not 
conserved in Drosophila however the 211 residue is. Mutating F210 to an isoleucine creates a 
mutation that may fit an RNA-binding deficient model, considering the mutation lies in the 
second RRM. The in vitro data presented in this chapter further supports that the deficit in 
promoting exon 9 skipping, is likely to be the result of an inability to efficiently bind UG repeats 
in the mini-gene transcript. Major protein interactions seem unaffected and F210I TDP43 
successfully localises to the nucleus, however correct sub nuclear localisation has not been 
shown. F210I TDP43 shows a clear functional inability to promote exon 9 skipping. 
There is clear data that F147 / F149 in the first RRM are critical in enabling TDP43 to bind UG 
repeats and RNA in general (Figure 4.4). For both human and mouse TDP43, further data has 
supported the first RRM being necessary and sufficient for human TDP43 binding to RNA 
(Buratti & Baralle, 2001), with deletion of the second RRM not inhibiting RNA-binding (Buratti 
& Baralle, 2001). As such, it was anticipated that mutations affecting general protein structure, 
or the missense mutations in the first RRM (T153A and K160R), might be the most likely 
candidates to affect CFTR skipping function. Surprisingly, F210I, in the second RRM, shows an 
inability to complete wild-type function. The 50% loss of rescue ability in vitro indicates a 
strongly hypomorphic effect on RNA-binding and skipping function.  
The mechanism through which F210I causes an RNA-binding deficiency remains to be 
determined. RRM2 may play a more important role in RNA-binding than previously thought. 
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Alternatively this specific mutation may impact on RNA-binding in a dimer specific manner. 
TDP43 is thought to function as a dimer (Kuo et al., 2009). F210 could be a critical residue in 
the dimer which physically binds RNA or it may affect the binding of other phenylalanines such 
as 147 / 149. A direct effect on the impact of physical RNA-binding is more likely considering 
the nature of the mutation; however other aspects of TDP43 biology could also be affected. 
This could range through effects on protein structure and stability, subtle protein localisation 
or interactions but this is not supported by the EMSA. Initial assessment of the structure of 
mouse F210I TDP43 could be achieved through modelling the mutational change, circular 
dichroism and running native gels to assess dimer formation. Alternative effects could be 
tested through techniques such as chromatin fractionation to assess nuclear protein 
localisation or through assessing protein turnover rates. Considering these hypotheses, it still 
remains that a mutation in RRM2 affects TDP43’s binding to UG6 repeats and its functional 
ability to promote exon 9 mini-gene skipping. The nature of the mutation implies a direct 
effect on the physical interaction with RNA explaining both phenotypes and establishes the 
importance of RRM2 in affecting TDP43’s functional ability to bind UG6 repeats and promote 
CFTR mini-gene exon 9 skipping. 
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5. Results: In vivo F210I characterization 
 
5.1. Introduction 
 
In Chapter 4 it was shown in vitro that F210I is highly inefficient at promoting mini-gene exon 9 
skipping. This chapter will describe how this phenotype translates in vivo. Following the finding 
that F210I is strongly hypomorphic for UG6 RNA-binding and promoting exon 9 skipping, 
heterozygous F210I mice were imported from RIKEN Japan into MRC Harwell. After a period in 
quarantine, the mice are now available and have continued to be backcrossed to C57BL/6J 
(from an original DBA / C57BL/6J background). A cohort of mice (backcross 5, BC5, to 
C57BL/6J) has been generated for phenotyping as well as timed matings to assess the F210I 
mutation in vivo. This chapter utilizes mice of BC2-4 to preliminarily characterize the cellular 
and molecular changes driven by F210I TDP43 in vivo. A summary schematic of the mice used 
is shown below (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: F210I mouse genetics. Figure shows original G1 mouse carrying the F210I mutation, with its sperm 
from an ENU archive being used to produce BC1 mice. The background of the IVF mouse is 50% C57BL/6J / 50% 
DBA. This line has been backcrossed continuously with C57BL/6J with inter crosses at various generations used for 
timed matings. 
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Upon receiving the mice and completing two generations of backcross to C57BL/6J, intercross 
matings were set up to obtain Mouse Embryonic Fibroblasts (MEFs). The initial aim for MEF 
culture was to replicate the findings in HeLa cells, by electroporating the CFTR mini-gene into 
MEFs. This cellular system allows assessment of exon skipping ex vivo in wild-type, 
heterozygous and homozygous F210I MEFs. 
MEFs were harvested to assess protein and RNA changes. The aim was to confirm ex vivo that 
F210I is a hypomorphic allele for RNA-binding function. In parallel, whole embryonic head from 
the same embryo that the MEFs were generated from was used for protein and RNA analysis. 
Samples of brain, liver and spinal cord from BC2 adult wild-type and heterozygous F210I mice 
(12 weeks of age) were also harvested with the purpose of protein and RNA analysis. 
Following the in vitro identification of F210I, in early 2011, two publications (Ayala et al., 2011; 
Polymenidou et al., 2011) characterized the impacts on the transcriptome when TDP43 is 
downregulated. They showed that TDP43 auto-regulates its protein levels through binding its 
own 3’UTR. It also has critical roles in RNA metabolism affecting more than 6,000 genes in the 
murine transcriptome when downregulated in the striatum of adult mice (many of these 
changes being potentially direct or indirect). Considering the established in vitro effects of 
F210I on RNA-binding, both auto-regulation and the effects on target genes were assessed to 
characterize F210I as a potential hypomorphic in vivo model for RNA-binding function. 
The model of auto-regulation proposed from the Buratti / Baralle laboratory (Ayala et al., 
2011) hypothesizes that when there is excess TDP43 in the cell, it binds a CLIP (Cross Linking 
and immunoprecipitation) identified sequence in its 3’ UTR. It binds this CLIP identified 
sequence with a lower affinity than UG repeats.  The binding of TDP43 subsequently affects 
recognition of multiple poly adenylation sites, affecting the ratio of read through for varying 
transcripts.  This leads to exosome mediated decay of the transcript encoding for further full 
length TDP43 production. This model was established in stably transfected HEK293 cells 
expressing a single copy of tagged human TDP43 with a tetracycline inducible promoter (Ayala 
et al., 2011). Shortly after this publication, the Cleveland laboratory published a model with 
similar principles (Polymenidou et al., 2011) but not based on exosome mediated decay being 
the driving force to protein encoding transcript degradation. Instead, TDP43 binds its own 3’ 
UTR in the CLIP identified sequence and then promotes the inclusion of an exon within the 3’ 
UTR, targeting the RNA for nonsense mediated decay (NMD). These models are not 
antagonistic, with both mechanisms likely to be occurring to a certain degree. With these 
models in place, the F210I allele in vivo may be an ideal model in which to assess auto-
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regulation being dependent on an RNA-binding event, considering the established in vitro loss 
of function. The initial aim was to assess whether F210I can bind the TDP43 3’ UTR CLIP 
identified sequence as efficiently as the wild-type protein (through band shift). This was 
completed by Dr Mauricio Budini in Professor Baralle’s laboratory (shown in Figure 5.6). 
Following this, characterization of changes in Tardbp transcripts at the RNA level and TDP43 at 
the protein level were completed in multiple tissues. 
Alongside proposed auto-regulation models which may be relevant to TDP43 pathology in 
humans, the Cleveland laboratory (Polymenidou et al., 2011) knocked down endogenous 
TDP43 in adult brain. They assessed the consequences across the murine transcriptome 
through RNA sequencing and exon microarrays. The striatum of young adult mice was injected 
with antisense oligonucleotide (ASO) targeted against the Tardbp encoded transcripts. This 
ASO downregulated the TDP43 encoding transcript by forming double stranded RNA 
recognized by RNAse H which in turn completes pre-mRNA degradation.  Two weeks after ASO 
treatment, the striatum, now containing highly downregulated levels of TDP43, was harvested 
for protein and RNA extraction. RNA sequencing was completed and in response to TDP43 
down regulation, changes across 30% of the murine transcriptome were observed. In 
particular, large effects were seen with 601 mRNA level changes and 965 splicing pattern 
changes. Many of these changes were then validated by PCR and quantitative real time PCR. 
This was the first example showing the extent of TDP43’s role in RNA metabolism across the 
transcriptome, which has subsequently been replicated in other models or has been assessed 
using similar methods (Chiang et al., 2010; Shan et al., 2010; Sephton et al., 2011; Tollervey et 
al., 2011). With this in mind, F210I mice are being used to assess the impact of this mutation 
by performing RNA sequencing and proteomics to detect changes across the transcriptome 
and proteome.  The preliminary results from these experiments are not presented as part of 
the work in this thesis. However, the results from the Cleveland group identified multiple RNAs 
which are regulated by TDP43. This provided specific targets to assess the degree of loss of 
function in F210I MEFs and tissues for RNA level and splicing changes, which are presented 
here.  
To assess the effects of the F210I allele on RNA levels and splicing, target genes were selected 
based on published changes. RNA was harvested and converted to cDNA. Primers were 
designed spanning introns and the included / excluded target exon. PCR was completed to 
produce non saturated PCR bands for band quantification and comparison. Likewise, cDNA was 
used in real time PCRs to quantify transcript levels using SYBR Green. All primers used for real 
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time PCRs were assessed for band amplification purity with primers being optimized to optimal 
amplification efficiency (as indicated in methods). 
 
5.2. CFTR mini-gene rescue in F210I MEFs 
 
It was established in vitro in Chapter 4 (Figure 4.5) when transfected in HeLa cells that F210I 
shows a 50% reduction in its ability to promote CFTR exon 9 skipping. This was next assessed 
ex vivo in MEFs derived from E14.5 dpc embryos. MEFs were harvested and cultured as 
described in Chapter 2. At passage 2 (P2), wild-type, heterozygous and homozygous F210I 
MEFs were cultured and electroporated with the CFTR mini-gene. Negative controls included 
electroporation with no mini-gene, or no buffer. From three independent runs, results show 
that F210I heterozygous and homozygous MEFs are less efficient than wild-type in promoting 
exon skipping (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: F210I MEFs electroporated with the CFTR mini-gene. P2 MEFs were electroporated with the CFTR 
mini-gene with RNA harvested following 24 hours. As in Chapter 4, RNA was extracted and converted to cDNA. BRA 
and α23 primers were used to amplify the CFTR exon 9 region and determine exon 9 skipping. Wild-type MEFs 
promote approximately 50% exon 9 skipping whereas heterozygous and homozygous MEFs show a significantly 
reduced ability to promote exon 9 skipping. Top panel shows PCR product run on a 1.8% acrylamide gel stained with 
ethidium bromide. Exon 9 included is the top band and excluded the bottom band. The intermediary band is the 
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result of a cryptic splice site as discussed in Chapter 4. Bar chart shows exon inclusion as a percentage of included / 
excluded total. Bands were quantified using ImageJ software. N = 5 WT, 6 heterozygous, 3 homozygous. Error bars 
show the standard deviation. 
Wild-type MEFs show 54.0% exon 9 inclusion of the mini-gene. Heterozygous F210I MEFs have 
a significantly reduced ability to promote exon skipping with 67.7% exon 9 inclusion (p < 0.001 
1 Way ANOVA). Homozygous MEFs show an almost complete loss of ability in promoting exon 
9 skipping, with 94.8% exon inclusion (versus wild-type and heterozygous MEFs p <0.0001 1 
Way ANOVA). This shows a clear dosage effect from normal CFTR exon 9 mini-gene splicing in 
the wild-type MEFs, to an intermediary loss of ability to promote skipping in the heterozygous 
MEFs (approximately 13% increased exon 9 inclusion). Finally, the homozygous MEFs show an 
almost complete inability to promote exon 9 skipping. 
178 
 
 
5.3. MEFs immunofluorescence 
 
As in Chapter 4, protein localisation was assessed in MEFs. The aim was to determine whether 
the F210I mutation in vivo, impacts upon its nuclear versus cytoplasmic localisation. Further to 
the biochemical fractionation done in vitro, the labelling pattern within the nucleus was 
assessed by immunofluorescence ex vivo. Wild-type, heterozygous and homozygous P2 MEFs 
were grown and stained by immunofluorescence using anti-TDP43 and DAPI labelling.  
 
Figure 5.3: TDP43 stained F210I MEFs. P3 MEFs were grown on cover slips and fixed with 4% PFA followed by 
membrane permeabilization. MEFs were stained using primary anti-TDP43 (Protein Tech) with an AlexaFluor 488 
conjugated secondary. DAPI staining shows that TDP43 localises predominantly to the nucleus in MEFs and that 
F210I does not appear to overtly affect protein localisation ex vivo. Scale bar is 50 μm. 
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 F210I heterozygous and homozygous MEFs do not appear to show mislocalisation of TDP43 
compared to wild-type MEFs (Figure 5.3). MEFs were stained on three independent runs and 
assessed visually using a confocal microscope (Leica SP5) with Z stack imaging to assess for 
variation through visual planes. No overt visual differences were observed although this was 
not quantified. 
 
5.4. F210I homozygote lethality 
 
Intercross matings were set up to assess F210I homozygote mouse viability. This has been 
assessed with females from all backcrosses from the DBA / C57BL/6J founder background 
through to BC5 C57BL/6J mice (Figure 5.1). Data presented represent BC 2-4 mice. 
From intercross litters, a preliminary result of 20 wild-type mice and 23 heterozygous mice 
were born with no homozygotes at weaning. The expected Mendelian ratio is 1 wild-type: 2 
heterozygotes: 1 homozygote. This was assessed using the Chi squared test. No homozygotes 
have been genotyped making the Chi squared significantly different to that expected. 
Furthermore, from heterozygous intercross matings a ratio of 1 wild-type: 2 heterozygous 
mice born are expected, with a trend to fewer heterozygous mice than expected (Table 5.1). 
Category Observed 
Observed 
(%) 
Expected 
Expected 
(%)  
Category Observed Observed (%) Expected 
Expected 
(%) 
WT 20 46.51% 10.75 25% 
 
WT 20 46.51% 14.33 33.3% 
HET 23 53.49% 21.5 50% 
 
HET 23 53.49% 28.66 
66.67
% 
HOM 0 0% 10.75 25% 
   
 
  
Χ2 = 18.814, 2 DoF, two tailed p = 0.0001  Χ2 = 3.365, 1 DoF, two tailed p = 0.066 
Table 5.1: F210I viability. Tables showing the numbers of genotyped mice at weaning from F210I heterozygous 
inter cross matings. Left table shows Chi squared using all three genotypes and right table assumes homozygous 
mice not to be viable. A general policy of collecting newly born pups that die immediately after birth for genotyping 
has been adopted; however there have been no abnormal numbers of post natal deaths and no samples genotyped 
have been homozygotes (data not shown). 
 
There are significant differences in the expected ratio of wild-type versus homozygous mice 
born and genotyped from inter cross matings. There is a trend to fewer heterozygous mice 
180 
 
born than expected and no homozygous mice have been identified at birth or weaning. As 
homozygous mice are not viable, male heterozygotes were crossed to C57BL/6J wild-type 
congenic females to generate a phenotyping colony. From these crosses, a wild-type versus 
heterozygote ratio of 1:1 is expected. Heterozygous males used have been BC2 to BC4. Results 
show that there is no significant difference (p = 0.1835 χ2 test) in the ratio of wild-type versus 
heterozygous mice across males and females (Table 5.2).  
Category Observed 
Observed 
(%) 
Expected 
Expected 
(%) 
WT Female 69 22.19% 77.75 25% 
HET Female 76 24.43% 77.75 25% 
WT Male 94 30.23% 77.75 25% 
HET Male 72 23.15% 77.75 25% 
Χ2 = 4.846, 3 DoF, two-tailed p = 0.1835 
Table 5.2: F210I backcross ratios. Table showing the Chi square test for mice genotyped at weaning using F210I 
heterozygous males crossed to congenic C57BL/6J WT females. There is no significant difference when accounting 
for all four genotype / sex combinations with an expected ratio of 1:1:1:1 from 311 mice. When assessing males 
only, Χ
2 
= 2.916 with 1 degrees of freedom, p = 0.0877. 
5.5. F210I homozygous embryos 
 
Despite homozygote lethality, F210I homozygous embryos remain alive at E14.5 dpc and as 
such, primary cells such as MEFs have been cultured. Timed matings were set up to identify 
the stages at which homozygous embryos are viable and the potential causes of embryonic 
lethality. Embryos were harvested at E14.5 dpc and dissected for assessment of overt 
morphological abnormalities. Representative images of a normal heterozygous versus 
homozygous E14.5 dpc F210I embryos are shown below (Figure 5.4 and Figure 5.5). 
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Figure 5.4: F210I homozygous embryo photo. F210I heterozygous versus littermate homozygous E14.5 dpc 
embryo side image. Photo of heterozygous embryo alongside a littermate homozygous embryo. The photo was 
taken in PBS in a petri dish, following dissection from the embryo sack. The homozygous embryo is around a third 
smaller, with spinal oedema. The eyes also appear less developed however this embryo is still alive. The red staining 
pattern observed in the homozygous embryo is not thought to be a significant phenotype, observed intermittently 
in all homozygous embryos assessed. No scale bar was taken at the time of this photograph. 
 
 
 
 
 
 
 
 
 
Figure 5.5: F210I homozygous embryo photo (zoomed in). F210I heterozygous versus littermate homozygous 
E14.5 dpc embryo. Zoomed in example photo of heterozygous versus homozygous embryo taken on a light 
microscope. The heterozygous embryo appears completely normal for this stage of development. The homozygous 
embryo shows holoprosencephaly and overt oedema. No scale bar was taken at the time of this photograph. 
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Dissection of three homozygous F210I E14.5 dpc embryos identified holoprosencephaly in two 
embryos, under developed eyes in two embryos and oedema in all three embryos. A dissection 
of these embryos assessed all major organs, including heart, liver, gonads and lungs. 
Heterozygous embryos showed completely normal development as did wild-type embryos 
(four assessed per genotype). Homozygous embryos appeared to have formed all major organs 
correctly but the size of the organs was significantly smaller, all proportional to the overall 
embryo size. All homozygous embryos displayed oedema most easily visible in the spinal cord 
area and are smaller in size by approximately a third, as in Figure 5.4. Having dissected more 
than twenty embryos whilst culturing MEFs (and not for pure morphological dissection), the 
holoprosencephaly and retarded eye development appear to have a low penetrance (both 
observed from five in twenty) in homozygous embryos however the spino-oedema is observed 
in all homozygotes. 
5.6. Q101X / F210I 
 
As F210I homozygotes are not viable, the aim was to assess whether TardbpF210I/Q101X mice 
would be viable by crossing F210I heterozygous males to Q101X heterozygous females. F210I 
homozygotes have two F210I alleles whereas in the compound mutant TardbpF210I/Q101X there is 
one F210I allele which must auto-regulate, as discussed in Chapter 3, for Q101X crossed to 
K160R. Crosses to generate the compound mutant TardbpF210I/Q101X were set up. The aim was to 
see whether this compound mutant would progress in development to a different stage versus 
F210I homozygotes, considering the compound mutant has one F210I allele. Having one F210I 
and no wild-type allele also provides an in vivo model in which to assess the effects of F210I on 
auto-regulation versus the increased dosage of F210I homozygotes. 
Although F210I is hypomorphic for RNA-binding function, it is possible that the mutation 
confers some toxic gain of function. It is hypothesized that the Q101X allele may reduce F210I 
expression (if auto-regulation is inefficient) and may rescue the phenotype in development, 
versus being homozygous for F210I. Preliminary crosses indicated that TardbpF210I/Q101X is not 
viable at birth (Table 5.3). 
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WT Q101X / + F210I / + F210I / Q101X 
9 3 1 0 
 
Table 5.3: F210I / Q101X compound mouse viability. Results from three litters indicating that TardbpF210I/Q101X   
mice are unlikely to be viable. 
As shown in Table 5.3 although the numbers are very low, Q101X / F210I compound 
homozygotes preliminarily, are not viable at birth.  Timed matings were therefore set up to 
assess whether compound homozygous mutants were viable across embryonic development.  
No double homozygotes were found at E14.5 dpc however double mutants were found at 
E11.5 dpc, as shown in Table 5.4. 
WT Q101X / + F210I / + F210I / Q101X 
9 10 11 8 
Χ2 = 0.526, 3 DoF, two-tailed p = 0.9131 
Table 5.4: F210I / Q101X E11.5 dpc timed matings. Six timed matings at E11.5 dpc were harvested to assess 
Tardbp
F210I/Q101X 
viability. Compound mutants were genotyped with genotype ratios not significantly different to the 
expected Mendelian ratio of 1:1:1:1. 
All of the eight compound heterozygotes observed (Table 5.4) were significantly smaller than 
their littermate embryos, with five showing visible signs of resorption. No TardbpF210I/Q101X 
embryos were visibly normal compared to littermate controls. Overall this supports that 
compound TardbpF210I/Q101X die earlier than TardbpF210I/F210I mutants, which are alive at E14.5 
dpc. 
 
5.7. F210I levels / Auto-regulation 
 
Auto-regulation was assessed in vitro and in vivo. Following the identification of the CLIP 
identified sequence (Ayala et al., 2011) which TDP43 binds in its own 3’ UTR to auto-regulate 
its protein levels, the binding capability of F210I to this sequence was assessed. This 
experiment was completed by Dr Mauricio Budini in the Buratti / Baralle laboratory. In an 
identical fashion to the band shift experiment completed by myself, Dr Budini used the same 
constructs and protocol to assess binding to the TDP43 3’ UTR CLIP identified sequence. 
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Alongside this run (repeated three independent times), he also repeated my UG6 band shift 
experiment (which had also already been repeated three independent times) (Figure 5.6). 
 
 
 
 
 
 
 
 
 
Figure 5.6: UG6 and CLIP band shift EMSA. Following the protocol completed in Chapter 4, GST purified WT and 
F210I TDP43 was run on a 5% acrylamide gel to assess binding affinity to radioactively labeled RNA. With equal 
amounts of protein, the inability of F210I TDP43 to efficiently bind UG6 repeats, as shown by a lack of the band 
shifted complex, is repeated (left panel). The right panel shows WT versus F210I TDP43 binding to the CLIP 
identified sequence, with F210I showing a highly reduced binding affinity compared to WT TDP43. 
F210I TDP43 shows a reduced ability to bind both UG6 and the CLIP identified 3’ UTR RNA 
sequences (Figure 5.6). TDP43 has a higher binding affinity to UG6 over the CLIP identified 
sequence (Ayala et al., 2011) reflected in Figure 5.6 where more CLIP sequence RNA is loaded 
to form the band shift complex versus UG6 where the free RNA band is greater for the CLIP 
sequence to form the band shift. 
In order to address reduced 3’ UTR CLIP identified sequence binding ex vivo, TDP43 MEFs were 
grown for RNA and protein harvest (n = 3:3:3 per genotype). The RNA was converted to cDNA 
and primers were designed to assess Tardbp transcript splicing and levels (through PCR and 
real time PCR). 
NMD2 (Tardbp targeted) primers were designed to amplify transcript Tardbp-001 (1106bp) 
and Tardbp-002 (147 bp). NMD2 stands for nonsense mediated decay and these primers were 
designed to amplify Tardbp translation and degradation transcripts based on a proposed 
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model of degradation (Polymenidou et al., 2011).  Although the amplicon lengths between the 
two transcripts are significantly different, the aim was to compare the ratio of the two bands 
between wild-type, heterozygous and homozygous MEFs to assess potential differences in 
transcript lengths (Figure 5.7). 
 
Figure 5.7: NMD2 primer amplification in MEFs. RNA harvested from WT, heterozygous and homozygous F210I 
MEFs, was converted to cDNA and amplified using primers NMD2. PCR product was run on a 3.5% NuSieve 3:1 
agarose gel, stained with ethidium bromide. Expected amplification products include Tardbp-001 at 1106 bp and 
Tardbp-002 at 147 bp. A further PCR product was observed at 250 bp, which was gel purified with Sanger 
sequencing identifying an annotated transcript, Tardbp-004. Transcript schematic taken from www.ensembl.org 
showing NMD2 primer locations (red arrows) for each of the amplified transcripts. 
There is an increase in the presence of transcript Tardbp-002 in heterozygous and wild-type 
MEFs compared to homozygous MEFs. This increase is not fully quantitative due to the nature 
of the PCR however it is qualitative (as equal amounts of cDNA were used in the PCR). 
Transcript Tardbp-001 is not present in high abundance. This is due to the transcript being too 
large and unable to compete with the smaller amplification products. There is some detection 
of Tardbp-001 in the homozygote samples and potentially some heterozygote samples. The 
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NMD2 primers also amplified an intermediary band at 250 bases. This band was gel purified 
and sent for Sanger sequencing (by GATC). Alignment of the sequence with the annotated 
transcripts on www.ensembl.org showed that this is a small annotated non coding transcript, 
Tardbp-004. This amplified transcript was not identified by similarly positioned primers in 
other studies (Polymenidou et al., 2011) due to the exact positions of the primers. 
RNA was also extracted from embryonic head (E14.5 dpc) and 12 week old adult brain. Reverse 
transcription PCR using NMD2 primers with these samples showed the presence of transcript 
Tardbp-002 however there was almost no detection of transcript Tardbp-001 at 1106 bp 
(Figure 5.8) or transcript Tardbp-004. 
 
 
 
 
 
 
 
Figure 5.8: NMD2 primer amplification in embryonic head and adult brain. As in Figure 5.7, cDNA generated 
from RNA extracted from embryonic head and adult brain was amplified in a PCR using NMD2 primers. PCR product 
was run on 3.5% NuSieve 3:1 agarose gel. Tardbp-002 is detected at 147 bp, with Tardbp-001 at 1106 being 
undetected. 
Transcript Tardbp-002, at 147 bp, is present in wild-type, heterozygous and homozygous 
samples in MEFs, embryonic head and adult brain (Figure 5.7 and Figure 5.8). In Figure 5.8, 
there is a trend for increasing band intensity from homozygous to heterozygous and wild-type 
samples for transcript Tardbp-002. This is also observed in MEFs (Figure 5.7). However in 
embryonic head and young adult brain, there is almost complete absence of transcript Tardbp-
001, which was barely present in some homozygous and heterozygous samples in MEFs (Figure 
5.7), likely due to it being too large to compete as a PCR with transcript Tardbp-002. Transcript 
Tardbp-004 observed in MEFs may be lowly present in E14.5 dpc head and adult brain (250bp 
band in Figure 5.8).  
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In order to further characterize alterations in TDP43 encoding transcripts, real time PCR was 
completed on cDNA extracted from wild-type, heterozygous and homozygous embryonic head 
(n = 5:5:5 per genotype). Primers in Tardbp exons 2 (F) / 3 (R) were used to assess levels of all 
mRNA transcripts containing these exons. This was quantified against control gene S16, a 
ribosomal protein whose levels have never been shown to be altered by the effects of TDP43 
knock down in any known publication. The primers were assessed prior to the experiment for 
optimal amplification efficiency without significant differences between the Tardbp and S16 
primers. Exon 2F / 3R Tardbp primer based amplification showed significant differences in 
levels between wild-type, heterozygous and homozygous samples (Figure 5.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Tardbp exon 2F / 3R real time PCR from E14.5 dpc embryonic head. Top panel: Window from Applied 
Bio systems real time PRC programme, showing PCR amplification run as measured by SYBR Green. Red arrow 
shows S16 amplification, yellow arrow shows Tardbp amplification and blue arrow shows control samples with no 
RNA used in RT reaction and H2O controls. All samples were run in triplicate with a 0.1 CT value replication range, 
showing a consistent level of pipetting. Bottom panel: bar chart showing the relative levels of WT, heterozygous and 
homozygous exon 2-3 transcript levels as calculated from the CT values by ΔΔCT (n = 5:5:5). WT versus heterozygous 
p = 0.027, WT versus homozygous p < 0.0001, ANOVA with Bonferroni post hoc analysis. Error bars shown are 
standard deviation. 
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Levels of exon 2F / 3R Tardbp transcripts are significantly reduced in heterozygous and 
homozygous embryonic head (Figure 5.9). Heterozygous exon 2F / 3R transcript is significantly 
lower than wild-type levels, 1.00 versus 0.85 (p = 0.027, ANOVA Bonferroni post hoc) with 
homozygous levels highly reduced, 1.00 versus 0.422 (p < 0.001, ANOVA Bonferroni post hoc). 
With significant differences in Tardbp RNA transcript exon 2F / 3R levels, protein levels were 
assessed. Initially, protein was extracted from wild-type, heterozygous and homozygous MEFs, 
n = 3:3:3 per genotype (Figure 5.10). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: TDP43 F210I protein levels in MEFs. Western blot analysis was carried out by electrophoresis on 
Invitrogen 10% bis-tris gels and transferred onto low fluorescence PVDF membrane (IPFL10100 Millipore).Top 
panel: Western blot image taken on Li-Cor Odyssey system, with anti-TDP43 (ProteinTech) in green, and anti-actin 
(Invitrogen) in red, detected by anti-mouse red secondary and anti-green rabbit secondary (Li-Cor). Bottom panel: 
quantification of TDP43 levels as measured by Odyssey software, relative to actin levels. There are no significant 
differences in TDP43 soluble levels, WT versus homozygous p = 0.817 (ANOVA Bonferroni post hoc). Error bars 
represent standard deviation. 
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Figure 5.10 shows no significant difference in protein levels between wild-type, heterozygous 
and homozygous MEFs. Further protein was extracted from new wild-type, heterozygous and 
homozygous MEF samples (n = 5:5:4 per genotype) and 12 week old adult brain (Figure 5.11) 
as there was a potential trend to a reduction in homozygous levels. 
  
 
 
 
 
 
 
 
Figure 5.11: F210I protein levels in MEFs and adult brain. Western blot was run on an Invitrogen 10% bis-tris gel 
and transferred onto low fluorescence PVDF membrane. Top panel: Western blot image taken using Li-Cor Odyssey 
system. Green = anti-TDP43 (ProteinTech), Red = anti-actin (Invitrogen), using Li-Cor secondary antibodies. Band 
intensity was measured using Odyssey software, with TDP43 levels (relative to actin) shown in bar charts. In MEFs, 
WT versus homozygous TDP43 levels are significantly different: p = 0.033, with a trend in WT versus heterozygous p 
= 0.22 (ANOVA Bonferroni post hoc). There is no significant difference in WT versus heterozygous adult brain levels 
(p = 0.22). Error bars show standard deviation. 
Figure 5.11 shows that there is a significant difference in TDP43 protein levels in wild-type 
versus homozygous MEFs (p = 0.033 ANOVA Bonferroni post hoc). There is also a trend to 
reduced levels in heterozygous MEFs (p = 0.22) There are no significant differences in adult 
brain when comparing wild-type versus heterozygous adult brain (p = 0.22, Students two tailed 
T test). 
With significant differences observed in MEFs, using aliquots from the same extracted 
samples; this result was repeated. However, no significant difference in protein levels was 
observed (Figure 5.12). These samples were re-run five times, however there was no 
replicated difference between wild-type, heterozygous and homozygous TDP43 protein levels.  
Figure 5.12 shows one of multiple repeats aimed at determining whether there is significant 
difference in F210I TDP43 protein levels.  
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Figure 5.12: F210I Western repeat. Repeated Western blot from Figure 5.11 with additional adult brain samples. 
In MEFs, protein levels are not significantly different when normalized against actin (Gel 1). WT versus heterozygous 
p = 0.358, WT versus homozygous p = 1 (ANOVA Bonferroni post hoc). Adult brain protein levels were re-run with 
brains from two additional mice per genotype, however there is no significant difference in TDP43 protein levels, p 
= 0.24 (students two tailed T test, gel 2). Error bars show standard deviation. 
 
5.8. TDP43 target splicing changes 
 
TDP43 down regulation affects approximately 30% of the murine transcriptome (Polymenidou 
et al., 2011) through direct and indirect mechanisms. When knocked down in mouse adult 
brain, the splicing pattern of approximately 965 mRNAs is altered. With these changes having 
been characterized, the aim was to assess whether F210I is strongly hypomorphic and mimics 
the changes that occur when TDP43 is knocked down. 
Primer sequences from the Cleveland laboratory (Polymenidou et al., 2011) were requested 
and ordered. Genes selected were Pyruvate dehydrogenase phosphatase catalytic subunit 1 
(Pdp1), DnaJ (Hsp40) homolog, subfamily C, member 5 (Dnajc5), Polymerase (DNA-directed), 
delta interacting protein 3 (Poldip3) and Sortilin 1 (Sort1). These genes show large differences 
in splicing when TDP43 is knocked down.  RNA was extracted from wild-type, heterozygous 
and homozygous E14.5 dpc head and converted to cDNA for PCR as described in methods. The 
results showed that there are significant differences in splicing patterns of all genes assessed, 
where the ratio of the spliced band was in a reasonable range to detect differences. They are 
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all differentially spliced in E14.5 dpc head in F210I mutants, compared to wild-type controls 
(Figure 5.13, Figure 5.14, Figure 5.15 and Figure 5.16). 
Figure 5.13 shows that the ratio of Pdp1 splicing is different when comparing MEFs to adult 
brain. TDP43 promotes exon 1 inclusion and when knocked down there is more exon 1 
exclusion. In heterozygous E14.5 dpc head there is a strong trend towards more exon 1 
exclusion (p = 0.073 ANOVA Bonferroni post hoc). This is clearly visualized when assessing the 
excluded band which is more faintly present in the heterozygous lanes compared to wild-type. 
This band is almost completely absent in homozygous samples which show a significant 
increase in the proportional amount of exon 1 inclusion (p < 0.001 ANOVA Bonferroni post 
hoc). 
 
 
 
 
 
 
 
Figure 5.13: Pdp1 splicing in embryonic head. Top panel is an image taken from (Polymenidou et al., 2011), 
showing that when TDP43 is knocked down, there is more exclusion of Pdp1 exon1. In the schematic, blue boxes 
show exons, orange box is the spliced exon and purple box indicates UG repeats where TDP43 may bind. Bar chart 
shows normal splicing pattern (blue bar) and TDP43 knocked down pattern (red bar). This change was seen in the 
F210I mutants, with a significant increase in exon 1 inclusion in homozygous embryo head (p < 0.001 Bonferroni 
post hoc). Heterozygous embryos show a trend to increased exon 1 inclusion (p = 0.073 ANOVA Bonferroni post 
hoc). Middle panel shows PCR product from identical primers to Don Cleveland’s study, with exon included and 
excluded bands expected between 300 bp and 200 bp (methods contain exact amplicon lengths). Bar chart 
represents exon inclusion as a percentage of the total included versus excluded band intensity. Error bars represent 
standard deviation. N = 5:5:5. 
The splicing pattern of Dnajc5 is significantly different when comparing wild-type, 
heterozygous and homozygous embryonic head samples. Wild-type exon inclusion is 28.54%, 
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however this is significantly increased in both heterozygous (45.13%) and homozygous 
(76.19%) samples (wild-type versus heterozygous p = 0.005, wild-type versus homozygous p < 
0.001 ANOVA Bonferroni post hoc). This matches the changes observed in adult brain knock 
down (Polymenidou et al., 2011) showing that within E14.5 dpc heterozygous and homozygous 
head there is ineffective skipping compared to wild-type littermates as shown in Figure 5.14. 
 
 
 
 
 
 
 
 
 
Figure 5.14: Dnajc5 splicing in embryonic head. Top panel is an image taken from (Polymenidou et al., 2011), 
showing that when TDP43 is knocked down, there is more inclusion of the partial exon between 4 and 5. This was 
also seen in the F210I mutants, with a significant increase in exon 4.5 inclusion in heterozygous and homozygous 
embryo head (WT versus heterozygous p = 0.005, WT versus homozygous p < 0.001 ANOVA Bonferroni post hoc). 
Bar chart represents exon inclusion as a percentage of the total included versus excluded band intensity. C1 is a 
control with no RNA used in the reverse transcriptase reaction and C2 is a PCR water control. Error bars represent 
standard deviation. N = 5:5:5. 
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TDP43 promotes Poldip3 exon 3 inclusion in RNA transcripts. When knocked down, there is a 
loss in Poldip3 inclusion in adult brain (Polymenidou et al., 2011).  In E14.5 dpc head, there is 
also a significant loss in exon 3 inclusion in heterozygous and homozygous samples (wild-type 
versus heterozygous p = 0.009, wild-type versus homozygous p < 0.0001 ANOVA Bonferroni 
post hoc, Figure 5.15). Heterozygous samples show an intermediary phenotype between wild-
type and homozygous states.  
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Poldip3 splicing in embryonic head. Top panel is an image taken from (Polymenidou et al., 2011), 
showing that when TDP43 is knocked down, there is more exclusion of exon 3. This was also seen in the F210I 
mutants, with a significant increase in exon 3 exclusion in heterozygous and homozygous embryo head (WT versus 
heterozygous p = 0.009, WT versus homozygous p < 0.0001 ANOVA Bonferroni post hoc). Bar chart represents exon 
inclusion as a percentage of the total included versus excluded band intensity. Error bars represent standard 
deviation. N = 4 WT: 4 heterozygote: 5 homozygote. 
 
TDP43 promotes skipping of Sort1 exon 18 (Polymenidou et al., 2011). When assessed in F210I 
embryonic head, there is a significant decrease in exon 18 skipping in heterozygote and 
homozygote samples (p < 0.001 1 Way ANOVA Bonferroni post hoc, for both). In wild-type 
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head, exon 18 is included in 30.06% of mRNA transcripts, however in heterozygotes this 
increases to 65.28% and in homozygote samples it goes up to 92.00%. There is a striking 
difference in the splicing pattern with a dose dependent effect, matching the result from the 
Cleveland group (Figure 5.16). 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Sort1 splicing in embryonic head. Top panel is an image taken from (Polymenidou et al., 2011), 
showing that when TDP43 is knocked down, there is more inclusion of exon 18. This was also seen in the F210I 
mutants, with a significant increase in exon 18 inclusion in heterozygous and homozygous embryo head (p < 0.001 
for both ANOVA Bonferroni post hoc). Bar chart represents exon inclusion as a percentage of the total included 
versus excluded band intensity. Error bars represent standard deviation. N = 5:5:5. 
Sort1 exon skipping is reduced in F210I heterozygous and homozygous E14.5 dpc head. To 
assess whether this loss of skipping occurs in other tissues, MEFs and adult brain samples were 
harvested. RNA was extracted from MEFs and adult brain using the same protocol as 
embryonic head. Results show that Sort1 exon inclusion in MEFs and adult brain is significantly 
higher in heterozygous and homozygous F210I (Figure 5.17 and Figure 5.18). 
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Figure 5.17: Sort1 splicing in MEFs. Top panel shows reverse transcription PCR using Sort1 primers to amplify exon 
18 included / excluded transcripts. Heterozygous and homozygous F210I MEFs show significantly increased exon 18 
inclusion as shown relatively by the bar chart, representing percentage of total exon inclusion. Bands were 
measured using ImageJ software. Error bars show standard deviation. N = 3:3:3. 
Sort1 splicing assessed in MEFs (Figure 5.17) shows a similar pattern to E14.5 dpc head (Figure 
5.16). Wild-type exon inclusion (33.19%) increases to 51.58% in heterozygous and 74.54% in 
homozygous MEFs (p < 0.001 ANOVA Bonferroni post hoc). This altered splicing is also 
observed in adult F210I brain (Figure 5.18). 
 
 
 
 
 
 
Figure 5.18: Sort1 splicing in adult brain. Top panel shows reverse transcription PCR using primers to amplify exon 
18 included / excluded transcripts. C1 and C2 are controls with no RNA used in the reverse transcription reaction 
and water used in PCR reaction. Heterozygous F210I splicing in adult brain (12 weeks) is significantly increased as 
shown relatively by the bar chart. Bands were measured using ImageJ software. Error bars show standard deviation. 
N = 3 WT: 4 heterozygotes. 
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As shown in Figure 5.18, heterozygous F210I adult brain shows increased levels of Sort1 exon 
18 included transcript. Compared to wild-type littermate levels (13.06%), proportional levels in 
heterozygous brains are 26.56% (p < 0.001 students two tailed T test). In brain, the exon 
excluded transcript is dominantly present; this remains as a significant increase in 
heterozygous brains of over 10%. 
 
5.9. TDP43 target RNA level changes 
 
Alongside assessing changes in splicing patterns for TDP43 target genes, changes in mRNA 
levels were also assessed. Knock down of TDP43 in adult striatum leads to alterations in the 
levels of 601 mRNAs, as determined by RNA sequencing (Polymenidou et al., 2011). To address 
this in the context of F210I, genes were chosen with large differences or those relevant to 
amyotrophic lateral sclerosis (ALS). Fused in sarcoma (Fus), progranulin (Grn), Ca++-dependent 
secretion activator (Cadps) and cyclin dependent kinase 6 (Cdk6) were all assessed. Fus, Grn, 
and Cadps were chosen as they have been shown to be highly altered by the Cleveland lab, 
with Fus and Grn being especially relevant to TDP43 pathology. Cdk6 was chosen as knock 
down of TDP43 in HeLa cells altered Cdk6 levels ten-fold (Ayala et al., 2008a). 
Mutations in FUS are causative of ALS (Kwiatkowski et al., 2009; Vance et al., 2009). When 
TDP43 is knocked down (Polymenidou et al., 2011) levels of Fus mRNA are reduced to half of 
those in wild-type brain. As a result, Fus levels were assessed by real time PCR in E14.5 dpc 
head from wild-type, heterozygous and homozygous F210I embryos (Figure 5.19). Real time 
PCR shows no significant differences in the relative expression of Fus in any genotype. Relative 
expression remains consistent at approximately wild-type levels.  
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Figure 5.19: Fus RNA expression. Transcript levels of Fus were determined in WT, heterozygous and homozygous 
E14.5 head (n = 5:5:5 per genotype). Bar chart shows relative expression following real time PCR, through 
calculating ΔΔCT values. Control gene was S16. There is no significant difference in the relative expression of Fus 
between WT, heterozygous and homozygous E14.5 dpc head (p > 0.05 ANOVA Bonferroni post hoc). Error bars 
show standard deviation. 
Grn levels were also assessed by real time PCR. When TDP43 is knocked down in adult 
striatum, Grn mRNA levels increase six-fold. However, in F210I embryonic head, there is a 
trend to reduced levels of Grn (wild-type versus heterozygous p = 0.187, wild-type versus 
homozygous p = 0.386, ANOVA Bonferroni post hoc) (Figure 5.20). Grn levels in heterozygous 
and homozygous F210I embryonic head appear to show a trend which opposes the expected 
response to TDP43 knock down in striatum. 
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Figure 5.20: Grn RNA expression. Transcript levels of Grn were determined in WT, heterozygous and homozygous 
E14.5 head (n = 5:5:5 per genotype). Bar chart shows relative expression following real time PCR, through 
calculating ΔΔCT values. Control gene was S16. There is no significant difference in the relative expression of Grn 
between WT, heterozygous and homozygous E14.5 dpc head. Error bars show standard deviation. 
Cadps mRNA levels decrease versus wild-type, when TDP43 is knocked down (Polymenidou et 
al., 2011). Levels were assessed in F210I wild-type, heterozygous and homozygous embryonic 
head with a significant decrease in homozygous head versus wild-type (Figure 5.21). 
 
 
 
 
 
 
 
 
Figure 5.21: Cadps RNA expression. Transcript levels of Cadps were determined in WT, heterozygous and 
homozygous E14.5 head (n = 5:5:5 per genotype). Bar chart shows relative expression following real time PCR, 
through calculating ΔΔCT values. Control gene was S16. Error bars show standard deviation. 
Cadps levels are significantly reduced in homozygous versus wild-type head (p = 0.046, ANOVA 
Bonferroni post hoc). Relative expression decreases from 0.89 in wild-type, to 0.60 in 
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homozygous samples. This reduction is mild compared to the decrease observed in TDP43 
knocked down striatum (Polymenidou et al., 2011). 
Having assessed three targets identified in mouse TDP43 knock down, an alternative target 
observed in HeLa cells was assessed (Ayala et al., 2008a). Upon TDP43 depletion in HeLa cells, 
levels of Cdk6 increase tenfold. This was assessed in F210I MEFs. Figure 5.22 shows that there 
is no significant difference in Cdk6 mRNA levels between wild-type and F210I mutant 
embryonic head. However, there is a trend to increasing Cdk6 levels in homozygous versus 
wild-type embryonic head (p = 0.16, ANOVA Bonferroni post hoc) which would mimic the 
human cellular based result (Ayala et al., 2008a). 
 
 
 
 
 
 
 
 
 
 
Figure 5.22: Cdk6 RNA expression. Transcript levels of Cdk6 were determined in WT, heterozygous and 
homozygous E14.5 head (n = 5:5:5 per genotype). Bar chart shows relative expression following real time PCR, 
through calculating ΔΔCT values. Control gene was S16. There is no significant difference in the relative expression 
of Cdk6 between WT, heterozygous and homozygous E14.5 dpc head, despite a potential trend for an increase in 
homozygous E14.5 head. Error bars show standard deviation. 
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Summary tables for TDP43 target splicing and level changes are given (Table 5.5 and Table 5.6). 
Target 
Gene 
Does 
TDP43 
affect 
splicing 
Does 
TDP43 
promote 
exon 
skipping 
Pheno in 
knockout 
F210I 
Heterozygote 
Pheno 
F210I 
Homozygote 
Pheno 
Knock out 
system 
Pdp1 Yes Yes 
Less 
skipping 
Reduced 
skipping 
Highly reduced 
skipping 
ASO in 
mouse 
Dnajc5 Yes Yes 
Less 
skipping 
Reduced 
skipping 
Highly reduced 
skipping 
ASO in 
mouse 
Poldip3 Yes No 
More 
skipping 
More skipping 
Highly 
increased 
skipping 
ASO in 
mouse 
Sort1 Yes Yes 
Less 
skipping 
Reduced 
skipping 
Highly reduced 
skipping 
ASO in 
mouse 
 
Table 5.5: TDP43 RNA targets - splicing. When TDP43 is knocked down, splicing changes observed are all matched 
in heterozygote and homozygote F210I samples which are hypomorphic for splicing function. In all genes assessed, 
heterozygote samples show an intermediate loss of function and homozygote samples show a more extreme loss of 
function. 
Target 
Gene 
Does 
TDP43 
affect 
levels 
Does 
TDP43 
stabilize / 
destabilise 
RNA 
Pheno in 
knockout 
F210I 
Heterozygote 
Pheno 
F210I 
Homozygote 
Pheno 
Knock out system 
Fus Yes stabilize 
Reduce to 
0.5 
No change No Change ASO in mouse 
Grn Yes destabilize 
6 fold 
increase 
No change 
(trend to 
reduce) 
No change 
(trend to 
reduce) 
ASO in mouse 
Cadps Yes stabilize 
Reduce to 
0.32 
No change 
Reduce to 
0.67 
ASO in mouse 
Cdk6 Yes destabilize 
10 fold 
increase 
in cells 
No change 
No change 
(trend to 
increase) 
siRNA in HEK293 
cells 
 
Table 5.6: TDP43 RNA targets – mRNA levels. Shows the effects of F210I on target mRNA levels, as determined by 
quantitative real time PCR. Changes in target genes do not generally match changes in knock down systems. 
However, changes in Cadps and Cdk6 homozygotes trend towards loss of function, matching the knock down 
models. 
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5.10. Results discussion 
 
Overall, the work in this chapter confirms the F210I in vitro loss of RNA-binding function in 
vivo, showing that F210I is a strongly hypomorphic allele affecting TDP43’s roles in RNA 
metabolism. Changes in Tardbp transcripts show F210I to be an in vivo tool that will be used to 
delineate the mechanisms of auto-regulation. Significantly large alterations are observed in 
splicing and may be detected to varying degrees in other TDP43 functions. 
CFTR splicing assessment in MEFs 
In Chapter 4, the identification of F210I was described in vitro as being unable to promote 
efficient mini-gene CFTR exon 9 skipping with highly reduced UG6 RNA-binding. The aim of the 
work described in this chapter was to characterise whether this deficit translated in vivo and to 
characterise the mutation in heterozygous and homozygous forms whilst generating a colony 
for phenotypic assessment. 
In order to confirm the in vitro results from Chapter 4, wild-type, heterozygous and 
homozygous MEFs were cultured and electroporated with the CFTR mini-gene. Results showed 
a clear loss of exon skipping ability in heterozygous and homozygous MEFs with a dosage 
effect. Wild-type levels of exon inclusion (54.05%) significantly increased in heterozygous 
(67.71%) and homozygous (94.85%) MEFs (Figure 5.2). The homozygous MEFs show almost no 
exon 9 skipping with heterozygous MEFs showing an intermediary phenotype.  
The add-back assay in HeLa cells implied an approximate 50% reduction in the ability of F210I 
to promote exon 9 skipping. This was calculated based on wild-type recovery as the maximum 
baseline for exon 9 skipping and F147L / F149L skipping as complete loss of function, due to 
complete loss of RNA-binding. The observed result in vitro is much more severe in homozygous 
MEFs in vivo, where the amount of exon skipping at 94.85% is more similar to the F147L / 
F149L complete loss of function. The differences observed between the in vitro and in vivo 
results are likely to be the result of the signal to noise ratio within the two systems. The in vitro 
study is likely to be noisier considering the added complexity of siRNA and co-transfection.  
With a more extreme loss of function shown in vivo, all mutations from the allelic TDP43 ENU 
allelic array should be assessed in MEFs, to address more sensitively whether there is a 
functional deficit in any of these mutations for RNA based functions. This would be more 
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accurate than the HeLa assay. However, this experiment is practically limited by re deriving the 
mice carrying these mutations to generate the MEFs. 
 
MEFs immunofluorescence 
Having confirmed the in vitro results from Chapter 4 in vivo, MEFs were stained with anti-TDP 
(ProteinTech) and DAPI to compare protein localisation. Confocal microscopy (Figure 5.3) 
showed no overt differences in the subcellular distribution of TDP43 in wild-type, 
heterozygous and homozygous F210I MEFs. This matches the overexpression results in HeLa 
cells (Chapter 4, Figure 4.6), implying no overt effects on protein localisation caused by F210I. 
As discussed in Chapter 4, sub nuclear localisation has not been assessed. This result shows 
that alterations in RNA-binding are not due to protein mislocalisation to the cytoplasm. 
 
F210I homozygote viability 
Alongside MEF characterisation, matings were also established to assess homozygous F210I 
mouse viability. Results show that homozygous F210I mice are not viable (Table 5.1). 
Dissections at E14.5 dpc show that at this stage of development, homozygous embryos remain 
alive; however all observed showeded overt phenotypes indicating that they will not survive to 
birth. Homozygous embryos are typically a third smaller in size than littermate heterozygous 
and wild-type embryos, all displaying oedema (particularly visible as spino-oedema). Other 
phenotypes (holoprosencephaly and less developed eyes) have also been observed with low 
penetrance. All major organs assessed appear normally formed and importantly, without 
obvious developmental delay, but they are smaller. Further investigation into the cause of 
lethality is required by assessing homozygous embryos through developmental time points 
(from E10.5 dpc to E18.5 dpc) to characterise the changes that occur through time. Delineating 
a potential cause of death is potentially difficult considering the diversity of interactions and 
roles TDP43 appears to have. Arguably, affecting 30% of the murine transcriptome would 
provide multiple potential mechanisms through which F210I TDP43 could be inducing 
homozygote lethality. Although oedema is preliminarily the consistently observed phenotype 
in homozygous E14.5 dpc embryos, further assessment is required. Determining to what stage 
some survive is required alongside continued dissections to establish the frequency of 
phenotypes observed. 
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Many F210I homozygous mutants remain alive at E14.5 dpc, which is significantly later than 
TDP43 knock out mouse models and the Q101X homozygotes, which die between E3.5 to E6.5 
dpc (Kraemer et al., 2010; Sephton et al., 2010). In these models which have early lethality, 
there is a complete loss of TDP43 function. F210I is strongly hypomorphic for RNA-binding as 
described throughout Chapter 4 and this Chapter. Assuming there is no gain of function 
associated with F210I, the differences in which F210I and Q101X survive in embryonic 
development are likely to be the result of the degree of loss of function. Q101X likely results in 
100% loss of RNA-binding function as with knockouts, confirming TDP43 function is required in 
the early stages of development up to E6.5 dpc. However, F210I homozygotes, while showing a 
strong loss of function in CFTR mini-gene splicing and endogenous target splicing, are able to 
proceed in development until at least E14.5 dpc. From in vitro band shift results, a strong loss 
of RNA-binding is expected in vivo, potentially driving the described results in this chapter. 
With a strong loss of RNA-binding function, F210I homozygous embryos continue in 
development beyond knockout and Q101X lethal stages remaining alive. The presence of F210I 
protein versus its absence in the knockout may be necessary with a non RNA-binding function 
being required during early development. Alternatively, the minimal RNA-binding from F210I 
may be enough to proceed in early embryonic development. 
 
Observed F210I mutant numbers 
F210I homozygous mice are not viable. From heterozygous inter crosses; the numbers of 
heterozygous mice genotyped trends towards not being double the wild-type number. When 
assessing the ratio of heterozygous versus wild-type mice with male heterozygous F210I mice 
crossed to wild-type C57BL/6J female mice, the ratio of born mice is not significantly different 
to the expected 1:1. This result shows that in heterozygous inter crosses, homozygous mice 
are not viable and there is a trend towards heterozygous mice not being born at the expected 
ratio of 2:1 versus wild-type. This could imply some maternal driven interaction for 
heterozygous females and their litters, as when heterozygous males are crossed to wild-type 
females, the expected ratio of genotypes 1:1 is observed. In order to further determine a 
maternal genotype interaction, the ratio of mice born from female F210I heterozygotes 
crossed to male wild-type mice could be assessed. Overall, this is a preliminary result and the 
numbers need to be increased. 
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Q101X / F210I rescue attempt 
Although there is strong data for F210I being hypomorphic for RNA-binding function, there 
remains the possibility that F210I may confer elements of gain of function. In an attempt to 
rescue F210I homozygote lethality and address a potential gain of function, compound 
mutants between F210I and Q101X were generated. This cross also provides an in vivo model 
in which to assess F210I auto-regulation in the context of the Q101X allele. It was anticipated 
that in the Q101X allele context, the F210I allele may be expressed at a lower level, if it is not 
efficiently able to auto-regulate. A reduction in a potential toxic gain of function allele may 
reduce the toxicity in the developing embryo. Compound TardbpQ101X/F210I mice are not viable 
(Table 5.3). Compound embryos were observed at E11.5 dpc (Table 5.4) however they were 
either dead or in an unhealthy condition, such that they would be resorbed. These preliminary 
results indicate that compound TardbpQ101X/F210I mice die earlier than F210I homozygous 
embryos and that if the compound heterozygotes have reduced F210I levels versus F210I 
homozygotes, this may be the cause of earlier lethality. Embryos were kept for protein 
extraction. However, many of the compound heterozygotes (TardbpF210I/Q101X) were so small or 
at a resorption stage that extracting enough protein for analysis was challenging. This 
experiment could be completed by dissecting embryos at an earlier time point and pooling 
samples by genotype to extract enough protein. It is anticipated that TardbpF210I/Q101X protein 
levels would be reduced compared to TardbpF210I/F210I levels, which would confirm in vivo an 
auto-regulation deficit in F210I and also further support F210I loss of function driving 
embryonic lethality. In this case, the compound mutants dying earlier than F210I homozygotes 
would be explained by reduced TDP43 protein levels and increased loss of function. Further 
confirmation is required to support this hypothesis. 
 
Auto-regulation in vivo 
Assessment of Tardbp transcript splicing was next assessed in vivo from MEFs, embryonic head 
and adult brain. Figure 5.7 shows NMD2 primers designed to amplify full length transcript 
Tardbp-001 and nonsense mediated decay Tardbp-002, thought to be the full length encoding 
protein transcript and a nonsense mediated decay transcript respectively. According to one 
proposed model (Polymenidou et al., 2011), if TDP43 binding to the 3’ UTR CLIP identified 
sequence is required to convert transcript Tardbp-001 to Tardbp-002, then less Tardbp-002 
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should be present in F210I homozygous samples. TDP43 binds the 3’ UTR CLIP identified 
sequence promoting the inclusion of an exon in the 3’ UTR which forms transcript Tardbp-002 
which is targeted for NMD. If F210I TDP43 does not promote this efficiently, less of this 
transcript will be present and more of the unconverted Tardbp-001 is expected, which would 
also result in increased protein levels. This expected pattern was observed with more of 
transcript Tardbp-002 (Figure 5.7 and Figure 5.8) being present in heterozygous and wild-type 
samples. This needs to be further quantitatively shown by designing real time primers 
amplifying each transcript specifically. Reciprocally, more of Tardbp-001 was expected in 
homozygous samples. In MEFs, there is a faint Tardbp-001 band present, which is absent in 
heterozygous and wild-type samples. With the amplicon length between the two transcripts 
being more than 800 bp, the amplification efficiency of this large transcript explains its poor 
presence, as the PCR for this band is unable to compete with the shorter bands. As a result, 
quantification of the bands relative to each other is not possible and this is further limited by 
the poor band intensity of Tardbp-001. This data implies that the transcript ratios in the F210I 
homozygotes match that of the proposed nonsense mediated decay auto-regulation model 
(Polymenidou et al., 2011). However, the presence of the various transcripts is best quantified 
through Northern blotting or real time PCR. Assuming the Cleveland model is correct this result 
is expected to be driven by the binding of TDP43 to the 3’ UTR CLIP identified sequence, which 
is significantly reduced by F210I in vitro with this result supporting this to be the case in vivo. 
The NMD2 primers also amplified a third transcript, almost exclusively in the MEF samples. 
This transcript appears to increase in heterozygous and more so in homozygous MEFs 
compared to wild-type. The band was sequenced and identified as annotated transcript 
Tardbp-004, a short processed transcript. It contains elements of the 3’UTR and final exon 
encoding TDP43; however it has no characterised roles (as assessed at www.ensembl.org). 
RACE needs to be completed to determine whether the whole transcript in MEFs matches that 
which is annotated as well as its potential roles in MEFs. With increasing band intensity from 
wild-type through heterozygous to homozygous MEFs (although Figure 5.7 is not quantitative), 
this implies that the levels of this transcript are directly affected by the F210I mutation in a 
dose dependent manner in MEFs. Further experimentation would be required to examine the 
roles of this transcript in TDP43 auto-regulation and the relevance of tissue specific expression 
of the transcript. 
The variation between transcript Tardbp-004 levels in wild-type, heterozygous and 
homozygous MEFs shows that the regulation of this transcript is potentially dependent on 
TDP43 binding to its 3’ UTR. This binding suppresses the presence of this transcript, which 
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F210I is unable to efficiently complete resulting in increased levels in heterozygous and 
homozygous MEFs. This transcript is also absent in embryonic head and adult brain indicating 
its presence is regulated cell specifically. Tardbp-004 may have multiple roles and may be 
critical in the process of auto-regulation. Further investigation into the impacts of altered 
Tardbp-004 levels on auto-regulation, transcript and protein processes are required. 
With potential alterations in splicing characterised in F210I heterozygous and homozygous 
mutants, general transcript levels were quantified by real time PCR using primers in Tardbp 
exons 2F / 3R. These primers amplify ten annotated transcripts excluding transcripts Tardbp-
004 and Tardbp-005. As a result, they do not distinguish between transcripts destined for 
protein translation or decay, as defined by current models (Ayala et al., 2011; Polymenidou et 
al., 2011). The levels of these transcripts are significantly reduced in heterozygous and 
homozygous embryonic head, compared to wild-type littermate controls (Figure 5.9). Relative 
expression significantly deceases from 1 (wild-type) to 0.85 (heterozygous) to 0.42 
(homozygous). General transcript levels are reduced in heterozygous and homozygous 
embryonic head compared to wild-type, with potential Tardbp mediated deregulation. Further 
deconstruction of the alterations in the 3’ UTR are required in a tissue specific manner, to 
delineate the mechanism through which these changes occur. However, there is data 
supporting that this mechanism occurs through TDP43 binding to RNA. In the case of F210I 
TDP43, there is significantly restricted ability to complete this RNA binding. Therefore, this is 
likely to be the cause of these changes with F210I providing an in vivo model to assess 
alterations driven through a strongly hypomorphic allele for RNA-binding. 
TDP43 protein levels were next assessed to detect whether the changes identified at the RNA 
level affected protein levels. From the splicing results for Tardbp, there may be increasing 
levels of transcript Tardbp-001 in heterozygous and homozygous F210I MEFs with reduced 
non-protein coding Tardbp-002 levels. According to proposed models (Ayala et al., 2011; 
Polymenidou et al., 2011), this should result in increased full length TDP43 protein levels in 
heterozygous and homozygous F210I, in a dosage dependent manner. Western blots with 
protein samples from various tissues have shown inconsistent results. A reduction in TDP43 
levels in homozygous MEFs has been shown, but this has not been replicated (Figure 5.11). No 
significant difference in adult wild-type versus heterozygous brain protein has been observed 
(Figure 5.12). Overall, the lack of consistency in detecting protein level changes is a limiting 
factor but this will be repeated with an increased sample size. If levels are different, they may 
be subtle or potentially not detectable by Western blot. Despite these difficulties further 
support for lower protein levels in F210I homozygous MEFs comes from a preliminary run 
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doing stable isotope labelling by amino acids in cell culture (SILAC) experiments on F210I MEFs, 
where protein levels are reduced to 0.69 of wild-type levels (unpublished results from the 
laboratory).This experiment now needs to be replicated. Alternative anti-TDP43 antibodies 
could also be tried for re-quantification. Overall, it is not possible to say that protein levels 
between wild-type, heterozygous and homozygous samples are significantly different, 
indicating that phenotypes observed in heterozygous and homozygous samples are the result 
of the hypomorphic effects of F210I, rather than a reduction in the levels of overall protein. All 
these protein studies have analysed RIPA soluble protein.  RIPA insoluble protein will also be 
assessed as a change in solubility is thought to be critical with regards to TDP43 pathology. 
Overall, it is certainly apparent that F210I protein levels are not increased in heterozygous and 
homozygous F210I samples, as is predicted based on auto-regulation models. 
According to the Cleveland model (Polymenidou et al., 2011) when considering F210I as a 
hypomorphic allele, changes at the RNA and protein level are expected. At the RNA level, the 
NMD2 transcripts show a potential increase in Tardbp-001 and decrease in Tardbp-002 in 
homozygous F210I samples. This is matched by a general reduction in Tardbp transcripts with 
the exon 2F / 3R primers. The splicing changes match the proposed model and the general 
reduction in transcripts is indicative of F210I being unable to efficiently regulate Tardbp RNAs. 
However, the model proposes increased TDP43 protein levels in homozygous and to a lesser 
degree heterozygous samples. This result is not observed, particularly with non-replicated 
trends to reductions in TDP43 levels in both. This could potentially be the result of F210I 
affecting the protein at a level independent of RNA, such as increasing the rate of protein 
degradation. Alternatively, the mechanism of auto-regulation is likely to be more complex and 
there may be potential redundancy from other factors. Further RNA and protein 
characterisation is required, however F210I is an allele hypomorphic for RNA-binding and can 
be used in vivo as a tool to understand the mechanisms of TDP43 auto-regulation. 
 
TDP43 transcriptome targets 
Having characterised changes in Tardbp encoding transcripts, endogenous targets were 
assessed to confirm the hypomorphic effects of F210I, as characterised for TDP43 knock down 
(Polymenidou et al., 2011). In embryonic head, significant differences in splicing were 
observed in Pdp1, Dnajc5, Poldip3 and Sort1 (Figure 5.13, Figure 5.14, Figure 5.15 and Figure 
5.16), with heterozygous head showing an intermediary phenotype. Sort1 splicing was also 
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assessed in MEFs and adult brain (Figure 5.18 and Figure 5.19) confirming the altered patterns 
of splicing despite different levels of wild-type basal splicing in different tissues. These results 
mirror those when TDP43 was knocked down in adult striatum (Polymenidou et al., 2011) and 
show F210I as a hypomorphic allele affecting splicing function. Through affecting the splicing 
patterns potentially of 965 mRNAs, F210I is likely to impact on multiple pathways, with those 
relevant to ALS yet to be determined. This can be determined in cells using homozygous F210I 
cultures, as well as in adult heterozygous mice. It remains to be determined whether the 
degree of change characterised in the heterozygotes will be sufficient to affect processes at 
the level of the organism. RNA sequencing and exon microarrays from F210I samples would 
provide transcriptome-wide data as to the degree of RNA changes versus the TDP43 knock 
down model, with potential phenotypes being analysed in this context providing a powerful 
tool.  
With TDP43 affecting 30% of the murine transcriptome either directly or indirectly, the 
challenge is to determine which interactions are critical to pathology in diseases such as ALS or 
FTLD-TDP. One such potential interaction is Sort1, a multi-ligand receptor. TDP43 affects 
splicing of Sort1, a neuronally expressed protein, which acts as a receptor for Grn (Hu et al., 
2010; Zheng et al., 2011). Mutations in GRN are causative of frontotemporal Dementia (FLTD) 
(Baker et al., 2006), part of the spectrum of disease with ALS (Liscic et al., 2008). It has also 
been shown that, following neuronal injury, the levels of TDP43 and Grn are inversely related 
(Moisse et al., 2009b), and this is shown when knocking down TDP43 in the striatum, where 
levels of Grn shoot upwards six fold (Polymenidou et al., 2011). These three proteins may be 
critical to neuronal health and as such, the initial impacts of TDP43 splicing on Sort1 must be 
addressed. If the splicing changes are validated at the protein level, selected targets like Sort1 
can be assessed for altered activity. This has already been shown from an identified TDP43 
target Poldip3 / SKAR (Fiesel et al., 2011). Here, the splicing change is reflected at the level of 
the protein, with Poldip3 splicing also being altered in F210I (Figure 5.15). While the reduction 
in exon inclusion is lower in embryonic head compared to the knock down model 
(Polymenidou et al., 2011), the changes in protein should remain and a comparison of adult 
heterozygous F210I striatum splicing with wild-type controls may be a more accurate predictor 
of the degree of protein change expected as this will compare alterations from the same 
tissue. 
With endogenous targets of TDP43 showing altered splicing patterns, consistent with F210I 
being a strongly hypomorphic allele, changes in target mRNA was also characterised. Based on 
TDP43 knock down, target transcripts for Fus and Cadps were expected to be significantly 
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reduced, with Grn significantly increased. Cdk6 was also expected to increase based on cellular 
TDP43 data (Ayala et al., 2008a). These changes were generally not observed (Figure 5.19, 
Figure 5.20, Figure 5.21 and Figure 5.22). Levels of Fus and Grn in heterozygous and 
homozygous embryonic head were not significantly different from wild-type levels, with a 
potential trend for reduced Grn levels compared to wild-type (heterozygous p = 0.187, 
homozygous p = 0.386 ANOVA Bonferroni post hoc). Cadps levels were expected to decrease 
with a significant reduction in homozygous versus wild-type levels (p = 0.046 ANOVA 
Bonferroni post hoc) but with no difference between heterozygous and wild-type levels. The 
decrease in the knock down model was 0.32 versus wild-type, but the F210I homozygous 
decrease was 0.87 versus wild-type, being milder. The difference may be explained by the 
varying degrees of loss of function between F210I and knock down within mice, or tissue 
specificity. When TDP43 is knocked down in HeLa cells Cdk6 levels increase ten-fold (Ayala et 
al., 2008a). In F210I embryonic head there is a trend to increased levels but it is not significant 
(wild-type versus homozygotes p = 0.16 ANOVA Bonferroni post hoc). Overall, expected mRNA 
level changes were not observed in F210I embryonic head to the expected degree. Inevitably, 
tissue specificity and the context of the developing head versus adult injected striatum may be 
heavily contributing factors to differences observed. Alternatively the F210I allele may have 
varying impacts on some aspects of RNA regulation over others potentially affecting some 
genes more than others. This requires further characterisation. Determining changes in target 
genes shows which roles F210I results in loss of function and provides an understanding of 
what model F210I provides. 
 
Concluding remarks 
Changes in TDP43 RNA and protein as well as target genes have been characterised using 
MEFs, embryonic head and adult brain. Where complete data from embryonic head has been 
collected, there is a potential caveat in whether there are secondary consequences on gene 
changes within the head as a result of abnormal development for F210I homozygotes. 
However, there are phenotypes in target genes that are not significantly altered in these heads 
at the harvested stage and confirmation of other changes (such as Sort1 splicing) has been 
validated in MEFs and adult brain. The adult brain, MEFs and embryonic head provide 
accessible samples in which to characterise changes in TDP43 and target genes, with 
comparisons providing valuable information regarding tissue specificity differences (such as 
transcript Tardbp-004 expression exclusively in MEFs).  Further characterisation is required in 
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these and other tissues including primary cortical and embryonic motor neurons. In trying to 
address TDP43’s role in pathology and neuronal health, brain, spinal cord and specific neural 
cultures (cortical and embryonic motor neuron) will provide potentially more relevant in vivo 
models. F210I provides a powerful allele in which to assess these changes in heterozygote and 
homozygote states, where knockout and Q101X mutants are unable to due to their early 
lethality. 
Overall, F210I provides a strong in vitro and in vivo hypomorphic allele to deconstruct TDP43 
biology. Data from this chapter supports F210I being strongly hypomorphic. F210I 
heterozygotes and homozygotes provide in vivo models that will establish the consequences of 
a strongly hypomorphic allele with or without a wild-type allele. There are clear impacts on 
Tardbp transcripts and potential impacts on TDP43 protein. Further investigation into how 
F210I alters TDP43 protein properties is required. It is clear that this allele significantly impacts 
on Tardbp transcript processing and auto-regulation. Assessment of endogenous TDP43 
targets shows a clear impact on splicing. All genes assessed show a significantly altered splicing 
pattern in line with a loss of function, most severely seen in homozygotes. Further 
characterisation is required for F210I’s effects on target mRNA levels as well as the potential 
impact F210I may have on other known roles including RNA editing, stress granules, RNA 
translocation and miRNA formation. Further characterisation of F210I protein steady state 
levels, potential effects on solubility and degradation rates also need to be determined. 
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6. Discussion and Conclusions 
6.1. Main findings and contribution to field 
 
6.1.1. Introduction 
 
One nonsense and nine missense mutations were identified spanning all major domains of 
mouse TDP43. These mutations, generated by ENU mutagenesis, are expressed in endogenous 
TDP43 with a normal spatio-temporal expression pattern as expected for wild-type TDP43. 
Multiple TDP43 models have been generated across species and phyla including cell lines, 
yeast and non-human primates. In all of these systems the aims have been to model aspects of 
pathology and create tools to further understand TDP43 function and dysfunction in 
pathology. Across research groups both knock out and transgenic approaches have been 
employed, with significant data supporting both loss and gain of function elements 
contributing to neuronal health and pathology. In the mouse, homozygous knockout mice are 
not viable and in general transgenic overexpression lines there is a clear dose-dependent 
toxicity with wild-type and mutant human TDP43. The mutations identified as part of the work 
in this thesis provide an opportunity to assess the importance of different domains of mouse 
TDP43 in its normal function and potential impact on pathology. The aim was to characterise 
the functional nature of each mutation, to determine which mutations could be used as tools 
to understand TDP43 function and potential pathobiology. From the alleles that have been 
analysed to date, at the mouse behavioural level all mutations are functional. They do not 
model motor neuron disease but they have other phenotypes potentially indicative of 
neurological defects. Furthermore, in vitro and in vivo characterisation has identified F210I as a 
novel mouse hypomorphic allele for RNA-binding.   
 
6.1.2. Q101X 
 
The Q101X mutation occurs N-terminally before all major characterised domains of TDP43. 
Q101X homozygous mice are not viable and die during embryonic development, before E6.5 
dpc. This supports the Q101X mutation being a null allele, as an alternative model alongside 
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published homozygous knockout mice which die at the same stages of development. Q101X 
heterozygotes also show normal protein levels due to auto-regulation by TDP43 of its protein 
product.  As well as this, Q101X heterozygotes show behavioural phenotypes not seen in 
published knockouts. Although motor phenotypes are not observed in these mice, other 
endophenotypes including limb grasping and a softer body tone are detected which support 
potential neuronal perturbations. It is worth noting that out of three studies using TDP43 
heterozygous knockout mice, only one has identified motor phenotypes in aged mice (Kraemer 
et al., 2010). Knockout TDP43 mice may also share the phenotypes seen in the Q101X 
heterozygotes as the published mice have not been assessed for limb grasping and body tone 
phenotypes. Considering the Q101X heterozygote phenotypes, no overt TDP43 pathology is 
seen at one year at the light level or six months at the EM level with normal protein levels in 
aged heterozygote mice up to eighteen months. These assessments were made in the brain 
and spinal cord, indicating that the cause behind these phenotypes may be located elsewhere. 
Alternatively, TDP43 auto-regulation may be more subtly affected in specific cell populations 
resulting in altered TDP43 levels. This may not be reflected when assessing samples at the 
whole brain or spinal cord level.  
Within the literature there is little characterisation underlying the causes of limb grasping and 
body tone. Limb grasping is a phenotype observed in multiple mouse models and is thought to 
be the result of neurological or muscular perturbations. Under Mouse Genome Informatics 
(www.informatics.jax.org), limb grasping is classed as an abnormal reflex linked to abnormal 
motor and / or sensory capabilities. The muscular force in tests such as grip strength and 
activity of Q101X heterozygotes appears normal indicating a neurological cause. Likewise with 
body tone, there is a basal muscular tone with a reflexive elicited response. Loss of this tone 
may be due to relevant muscular alterations or a neuronal cause eliciting this response. The 
neuromuscular junctions (NMJs) have been assessed in the potentially relevant muscles with 
no overt differences. These muscles are the external oblique, internal oblique and transversus 
abdominis muscles. Causative overt pathology in the brain has not been observed and 
identifying the specific neuronal centres responsible for these phenotypes has not been shown 
in the literature previously. The physical change in body tone may also be associated with 
altered metabolism. Factors that could be assessed which may be relevant could include 
detecting allocations of fat - muscle ratio versus mass, alterations in types of fat such as lean 
fat and hormonal effects on body composition.  
These phenotypes are also specific in that using traditional tests may not identify relevant 
mechanisms. For example, if there is a sensory component to loss of body tone, assessing 
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mouse performance on a hot plate may not be appropriate to the phenotype observed for 
body tone. Locating and testing the appropriate muscles and neuronal innervations for these 
phenotypes is a significant challenge. If a sensory component is involved in either of these 
phenotypes this would match TDP43’s established role in neuronal maintenance. In flies, 
alterations in sensory neuron branching have been observed when overexpressing TBPH (Lu et 
al., 2009). This may not be expected as these mice represent a potential endogenous mild loss 
of function versus overexpression in flies. The overall data across species supports TDP43 
playing important roles in multiple aspects of neuronal function and these phenotypes while 
elusive in their cause, may be indicative of neuronal perturbations. 
 
6.1.3. K160R and compound (TardbpQ101X/K160R) mutants 
 
The K160R mutation lies in the first RNA recognition motif (RRM1). Homozygous mice are 
viable and display a number of phenotypes in common with the Q101X heterozygous mice, 
including limb grasping and a softer body tone. This supports that the K160R mutation exerts a 
similar effect as Q101X, causing a potential reduction in function of TDP43 for these 
endophenotypes. The commonality of phenotypes in limb grasping and softer body tone, with 
each line carrying different alternative ENU mutations, further supports these phenotypes 
being the result of the TDP43 mutations. These results support the Q101X mutation in 
heterozygosis and K160R mutation in homozygosis resulting in common neurological relevant 
phenotypes with an earlier onset in K160R homozygotes when comparing to Q101X 
heterozygotes. 
Compound mutants between Q101X and K160R (TardbpQ101X/K160R) also show these behavioural 
phenotypes with a higher penetrance and earlier onset. These mice also show novel 
phenotypes. The compound (TardbpQ101X/K160R) mutants reach end stage significantly earlier 
than littermate controls. In this line however, Q101X heterozygote littermates also reach end 
stage earlier, but in the original Q101X cohort they do not.  TardbpQ101X/K160R female mice are 
significantly smaller from 28 weeks of age. As with K160R homozygotes, most TardbpQ101X/K160R 
mutant mice limb grasped when suspended and slipped on the negative geotaxis test and 
mean onset of 40 weeks of age. However, they showed a softer body tone phenotype with an 
earlier onset and a higher penetrance compared to K160R homozygotes. An array of cognitive 
tests on six month old female animals also showed that only compound mutants have anxiety 
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and lower emotionality phenotypes. This was detected using the light-dark box and black-
white alley tests. K160R homozygotes and Q101X heterozygotes did not show these anxiety 
phenotypes. The numbers of mice assessed were not greater than ten per genotype and a 
second cohort has been generated to repeat these tests. At the EM level, compound 
(TardbpQ101X/K160R) mutants at six months had small TDP43 cytoplasmic structures in the 
cytoplasm neurons in the spinal cord. These structures were not seen in any of the other 
TDP43 mutants. At a molecular level there was also a trend for reduced TDP43 protein levels. 
This has been assessed in young mice through to aged mice and in all cases a trend towards 
reduced levels was observed, but not consistently shown. Where significant differences were 
seen, they were not replicated. This may support a mild reduction in protein levels that is not 
detectable at the Western blot level, using the Protein Tech TDP43 antibody.  
The compound (TardbpQ101X/K160R) mutants share phenotypes of respective Q101X heterozygote 
and K160R homozygote mice with an earlier onset. This supports an increased effect where 
being compound heterozygous enhances phenotype onset and prevalence not seen in other 
genotypes. Furthermore, an interactive or potential additive effect is also observed which is 
not present in other genotypes. With compound females being significantly smaller in 
adulthood, formation of mini aggregate like structures at the EM level and cognitive 
phenotypes in the light-dark box and black-white alley test, these mice model alterations not 
seen in Q101X heterozygotes and K160R homozygotes. This may be due to an interactive 
effect between the Q101X and K160R alleles or alternatively it may be due to having only one 
K160R allele compared to being heterozygous or homozygous for the K160R allele. At the 
protein level, western blots supporting a trend in reduced levels in the compound 
heterozygotes (TardbpQ101X/K160R) which may be the result of a single K160R allele having to 
auto-regulate protein levels to match those when having two alleles. An enhanced reduction in 
protein levels in these mice may sufficiently alter processes relevant to weight, EM alterations 
and cognitive behaviour not seen in Q101X heterozygotes and K160R homozygotes. 
Further to the existing behavioural characterisation of the compound mice the end stage 
samples for pathological assessment have yet to be completed. Therefore the final stages in 
the complete characterisation of these mice are a work in progress. Determining if there is a 
specific cause behind them reaching end stage earlier than wild-type controls remains to be 
defined.  
The reduced weight may support a subtle loss of function in compound (TardbpQ101X/K160R) 
mice. This may model a process similar to the rapid weight loss in a conditional TDP43 
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knockout mouse model (Chiang et al., 2010). This could be assessed in these mice as to 
whether a similar process is occurring more subtly or there is an alternative mechanism 
mediating weight loss. The EM phenotype of cytoplasmic deposition has not been reported in 
other transgenic TDP43 mouse models. Mini-aggregation structures in the cytoplasm may 
support a loss of endogenous TDP43 localisation and function or a gain of function in a novel 
cytoplasmic area. This may be relevant to the phenotypes that are unique to the compound 
mice including being smaller and cognitive alterations. The anxiety and emotionality 
phenotypes may also be indicative of TDP43’s role in human dementia (FTLD-TDP) by showing 
that a mild loss of function affects cognitive aspects of mouse behaviour in anxiety. This result 
will be confirmed with a second cohort of mice to conclusively support TDP43’s role in 
cognition, which may be partially modelled in these compound heterozygotes. In humans with 
anxiety disorders the forebrain and hippocampus are often highly affected areas (Simpson, 
2010) and this would be particularly relevant to TDP43’s role in FTLD-TDP where there is 
degeneration in the forebrain. A more enhanced assessment for pathology in the forebrain 
may be required. Multiple anxiety disorders also show alterations in neurotransmitters such as 
noradrenaline, serotonin and gamma-aminobutyric acid (GABA), which provide targets for 
future assessment. A cohort of TardbpQ101X/K160R mice is also being assessed by magnetic 
resonance imaging for structural abnormalities in the brain. 
 
6.1.4. Q101X / SOD1G93A 
 
TDP43 Q101X heterozygote mice were crossed to SOD1G93A low copy transgenic mice 
(Acevedo-Arozena et al., 2011) to assess for interactive effects. In human ALS pathology, 
TDP43 and SOD1 appear to show independence in inclusion formation although it has been 
shown in sporadic ALS that misfolded SOD1 is present (Bosco et al., 2010). When SOD1 causes 
ALS, mutant SOD1 is found in protein inclusions however in most ALS cases with or without 
TDP43 mutations, TDP43 is pathologically altered and is a component of inclusions.  Although 
inclusions are thought to contain exclusively SOD1 or TDP43, mutations in both genes 
converge, both resulting in selective motor neuron degeneration and ALS.  As such, it was 
decided to create double mutants to assess a possible interaction in a longitudinal study to end 
stage which is induced by the SOD1G93A transgene at 31 – 38 weeks. There were no major 
interactive effects induced by either SOD1G93A or TDP43 Q101X. There were significant motor 
performance differences in the negative geotaxis test with Q101X HET / SOD1G93A mice slipping 
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more than WT / SOD1G93A mice, but these differences did not translate quantitatively to grip 
strength measurements. There were also consistent trends for reduced startle response in 
Q101X HET / SOD1G93A mice, which has been shown to be due to motor neuron degeneration 
in SOD1G93A mice (Acevedo-Arozena et al., 2011) however this trend was not significant. This 
data supports a mild change in the SHIRPA with a trend in reduced startle but overall there 
appear to be no interactive effects between these two genes / mutations in this context. This 
does not conclusively rule out interactive effects.  
 
6.1.5. F210I 
 
The work completed in this thesis on F210I supports that it is a novel hypomorphic allele for 
TDP43 RNA-binding. This is corroborated by the general characterisation of the F210I mutation 
in Chapters 4 and 5 as well as the earlier lethality seen in TardbpQ101X/F210I compound mutants. 
F210I is not a complete null for TDP43 function, as is evident by the survival of homozygous 
embryos to a much later embryonic stage (E14.5 dpc) than knockout (up to E8.5 dpc) or Q101X 
homozygous mutants (E6.5 dpc). In inter-cross matings there is also preliminary data that 
F210I heterozygotes may not be born at the Mendelian expected ratio. Further intercross 
matings are required to increase the numbers assessed and a comparison to female F210I 
heterozygote females crossed to wild-type males is also required to compare inheritance of 
the F210I allele from maternal and paternal sources. Overall, F210I is a novel RNA-binding loss 
of function system that can be studied to assess TDP43 RNA-binding function in multiple 
processes as has been already shown to be altered in MEFs and mice for auto-regulation and 
RNA metabolism. 
The data for loss of TDP43 function in vitro is shown in F210I deficient RNA-binding to UG6 and 
CLIP identified TDP43 3’ UTR binding sequences. In vivo there is a reduction in splicing function 
with a dosage dependent effect. Crosses to generate TardbpQ101X/F210I compound mutants 
preliminarily show that these mutants die earlier. As the Q101X allele requires the F210I allele 
to auto-regulate to a greater degree than having two F210I alleles, earlier lethality supports 
increased loss of function for auto-regulation due to F210I being less able to bind the 3’ UTR 
identified CLIP sequence. If F210I were predominantly a gain of toxic function allele, it would 
be hypothesized that the compound TardbpQ101X/F210I allele may survive longer in development 
if there was an auto-regulation deficit. This would be due to a dose dependent effect where 
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the TardbpQ101X/F210I mice have one allele, which would be less toxic than two alleles. 
Assessment of protein levels in these embryos will also be used to confirm F210I’s inability to 
auto-regulate in vivo. Considering this, with TDP43’s splicing and RNA metabolic functions, 
there is no data so far for a gain of function in F210I although this cannot be ruled out.  
Within the literature, it has been shown that RRM1 is necessary and sufficient for RNA-binding. 
RRM2, which has an RNA-binding affinity two orders of magnitude lower than that of RRM1 is 
thought to have alternative roles (Buratti & Baralle, 2001; Kuo et al., 2009). The results from 
the work described in this thesis for F210I contradict deletion experiments supporting RRM2 as 
not being critical for RNA-binding. This work shows that the F210I point mutation in the 
second RRM has a significant impact on RNA-binding and function. Assessing the nature 
through which F210I has this effect is discussed in future work with regards to the experiments 
that could be completed to identify this. The mutation of a phenylalanine in losing a benzene 
ring is likely to indicate the loss of a residue which physically binds RNA. This would be 
expected as the phenylalanines 147 / 149 in the first RRM are critical for physically interacting 
with RNA. The second RRM has also been hypothesised to be important for TDP43 
dimerization for normal function and this mutation may in some way impact on this 
dimerization. Irrespective of the mechanism through which F210I confers this hypomorphic 
effect, F210I TDP43 is less able to bind RNA targets including its highest affinity UG repeats 
which are central to TDP43’s roles in RNA metabolism. As such, F210I is a novel allele re-
affirming the importance of an RRM2 point mutation on murine TDP43 RNA function.  
F210I in homozygosis is embryonic lethal. The full causes of embryonic lethality continue to be 
characterised with an oedema phenotype being consistently observed as a potential causal 
factor. With TDP43 having such diverse roles in RNA metabolism, F210I homozygous lethality 
may be the result of multiple developmental problems accumulating to cause death, rather 
than failure in development of an individual organ or system. By being lethal at a later stage of 
development (later than E14.5 dpc), F210I provides a hypomorphic allele that can be 
compared to Q101X or knockout lethality which occurs much earlier. Later survival supports 
minimal RNA-binding function being required earlier in development or a non RNA-binding 
requirement for TDP43. Later developmental stages may be more reliant on TDP43’s RNA-
binding roles. F210I is a novel model to study TDP43’s role in development at stages in the 
mouse where currently no other model exists to do this. 
F210I survival to E14.5 dpc in homozygosis also allows for culture of MEFs and primary 
neuronal cells (both cortical and embryonic motor neurons can be cultured at this stage). This 
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is not possible from knock out models due to early lethality. The unpublished transgenic RNAi 
mice (Prof Xu, SfN 2011) provide a complementary model to culture these neurons as well. By 
growing and assessing these neurons the impact of a strong loss of function on post mitotic 
neurons can be assessed using the F210I model. This provides a novel cellular model in which 
to assess TDP43 function and dysfunction. Exploiting the progress made since the discovery of 
TDP43 mutations in ALS / FTLD-TDP, this cellular model will be used to understand TDP43 basal 
function as well as function in response to stress to show the impact of loss of endogenous 
TDP43 RNA-binding function on mouse neurons. This may model aspects of human pathology 
and provide further insight into the roles of TDP43 in these neuronal cells. 
F210I heterozygous mice are viable and at a molecular level show reduced RNA-binding 
function. This reflects an underlying molecular phenotype in which a cohort of mice will be 
behaviourally phenotyped in the future as has been done for the Q101X and K160R mutations. 
F210I heterozygous mice provide an in vivo model to assess a mild loss of RNA-binding 
function in the context of a wild-type allele. This provides a novel model to assess changes in 
TDP43 and the relationship between loss of function and pathology. Both homozygous and 
heterozygous F210I cellular and animal models provide RNA-binding specific loss of function 
tools to delineate TDP43 biology in the mouse. Whether it is in development, post mitotic 
neurons or at the level of the whole animal, hypotheses relating to auto-regulation and the 
impact on RNA transcripts can be assessed using F210I. As complete knock outs do not survive 
they have not been able to assess many of the questions it is expected that F210I will, 
considering the auto-regulation in knock out heterozygotes. Likewise, transgenic mice 
overexpress human TDP43 in the context of wild-type endogenous mouse TDP43. The degree 
of endogenous mouse protein down regulation in the different models varies depending on 
exogenous protein overexpression levels. By crossing F210I to these models, these double 
mutants may delineate the importance of loss of endogenous function versus overexpressed 
human TDP43, if they rescue F210I homozygous lethality. 
6.2. Future work 
 
6.2.1. Q101X / K160R 
 
The assessment of all mutations is a work in progress. For the Q101X and K160R mutations all 
behavioural characterisation has been completed. Final assessment from end stage samples is 
220 
 
required for RNA and protein levels as well as pathology assessment. Separate compound 
heterozygote cohorts (TardbpQ101X/K160R) of mice with littermate controls have been generated 
to confirm the cognitive deficits in the light-dark box test and the black-white alley test. 
Cohorts have also been sent for sensory testing by Dr David Bennet (KCL) with results 
indicating no overt sensory deficits. Tests applied were Hargreaves reflex withdrawal to 
radiant heat, Von Frey withdrawal threshold, Randall Sellito and cold plate test. These tests 
measure various sensory mediated pain and mechanical response thresholds but are not 
specific to body tone muscles. Another cohort has also being sent to Dr Mark Lythgoe (UCL) to 
image the brains using MRI. This is being completed to assess for alterations that may link to 
any of the observed phenotypes in the compound heterozygotes. 
For the Q101X, K160R and compound mutants it is critical to further assess RNA and protein 
levels. Particularly in the compound heterozygotes, samples need to be re-extracted to 
determine if there is a significant reduction in protein levels. If this is the case it would show 
that a reduction in protein levels is causing the observed phenotypes. In all cases, only RIPA 
soluble protein has been assessed. When re-quantifying newly extracted samples, RIPA 
insoluble fractions should also be assessed as a shift in solubility is a hallmark of TDP43 
pathogenicity. Likewise, preliminary characterisation of a reduction in Sort1 splicing needs to 
be assessed with an increased number of samples and in other genes, as well as assessment of 
Tardbp transcripts. Further in depth analysis on the compound mutants is required in the 
forebrain region and hippocampus particularly, to search for pathology or structural 
alterations that may be associated with the anxiety phenotype. 
For the compound heterozygotes, further post mortem assessment is required in order to 
determine the causes of death. Post mortems are being carried out by Dr Michael Cheeseman 
(MRC Harwell) with preliminary results showing a number of causes of death across all 
genotypes. It is anticipated that there will be no mutant specific causes indicating that these 
mice are more susceptible to age related end stage associated with their genetic background. 
Overall, the aim for the Q101X and K160R mutants is to further understand the limb grasp and 
body tone phenotypes at a molecular or structural level. Pathology can be a challenging 
criterion to identify with the immediate muscles that form body tone requiring a more 
extensive analysis than the neuromuscular junction measurement that has been completed. 
Variations in these muscles or the nervous system immediately contacting / innervating them 
are potentially where the most obvious differences may be found. If body tone is a reflexive 
response assessment here as well as higher order nervous system centres is required. 
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6.2.2. F210I  
 
F210I is an exciting novel allele that has been identified and characterised as part of the work 
described in this thesis. As it is a RNA-binding hypomorphic allele, future work can be broken 
down into three further areas: continued characterisation of the degree of loss of function, 
model assessment for pathology and rescuing the homozygous lethality phenotype. 
Continued characterisation of the mutation can take place both in vitro and in vivo. The 
striking loss of RNA-binding function has already been shown. Further work is required to 
understand how F210I causes loss of RNA-binding function and ruling out any potential gain of 
function mechanisms associated with the mutation. Basic biology from protein turnover (by 
blocking the ubiquitin proteasome system using chemicals such as MG132) to more 
complicated structural alterations and dimerization (such as circular dichroism or native 
Western blotting) need to be applied.  
Beyond potential structural alterations induced by F210I, preliminary characterisation has 
shown that there are significant impacts on endogenous functional targets and auto-
regulation. Disruption of both of these processes, as discussed in the introduction, is 
hypothesised to be critical to TDP43 pathology in humans. F210I provides an ideal in vivo tool 
to assess this. Experiments already being undertaken in the group include RNA sequencing, 
exon arrays and stable isotope labelling by amino acids in cell culture (SILAC). RNA sequencing 
and exon arrays will provide fully quantitative changes in the transcriptome for mRNA levels 
and splicing, showing the degree of loss of function impact in the heterozygous and 
homozygous F210I states. SILAC will provide complementary data for changes across the 
proteome providing an excess of data for changes in vivo induced by F210I. Extensive data 
from multiple models, in particular the unpublished transgenic RNAi mice (Prof Xu, UMass, 
presented at Society for Neuroscience 2011) shows that loss of function is critical to neuronal 
health and results in pathology with progressive motor neuron degeneration. The degree to 
which characterised pathology in the mouse models the human condition is yet to be 
determined but motor phenotypes and selectively progressive neurodegeneration are relevant 
to the human condition. 
F210I provides an in vivo tool to characterise the mechanisms of auto-regulation. Although to 
date the mechanism is controversial, F210I has been shown in vitro to bind its own 3’ UTR 
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inefficiently. Transcript levels are altered as well as the splicing pattern of individual 3’ UTR 
transcripts. These RNA changes need to be characterised in a tissue specific manner, as 
differences by tissue type have been shown as part of the work described in this thesis. The 
F210I allele has a reduced ability in vivo to maintain normal auto-regulation at the RNA level, 
as shown by altered splicing and exon 2F / 3R transcript levels. This needs to be confirmed at 
the protein level, but this can also be assessed at a cellular level in homozygous cells (MEFs 
and embryonic motor neurons) and in adult tissue. With proposed models of auto-regulation, 
the individual mechanisms (such as exosome mediated decay versus nonsense mediated 
decay) can be tested in the F210I model in vivo (Ayala et al., 2011; Polymenidou et al., 2011). 
These models predict which transcripts are sent for decay and which encode full length TDP43 
protein. In particular, transcript Tardbp-001 is thought to encode full length TDP43 and this 
transcript needs to be quantified by real time PCR in wild-type and F210I mutant samples. If 
the levels inversely correlate with Tardbp-002 (based on proposed models) F210I heterozygous 
and homozygous samples should show a dose dependent increase in protein levels which is 
not anticipated based on preliminary Western blot results. Therefore, the F210I allele can 
assess the proposed models of auto-regulation in vivo in a cell specific manner, to characterise 
the mechanism of auto-regulation and assess its relevance to pathology in the mouse.  
A cohort of F210I mice has been generated for behavioural assessment. In homozygosis F210I 
is embryonic lethal. Only mice carrying the F210I mutation in heterozygosis, in the context of 
the wild-type allele, will be phenotyped. These mice will be aged and characterised to end 
stage. While aging this cohort, the preliminary characterisation from these mice at a molecular 
level has shown that Sort1 splicing as well as splicing in other target genes is significantly 
affected at 12 weeks in brain. This is likely to reflect multiple alterations in TDP43 RNA 
functions across the murine transcriptome. The question now remains as to whether the 
changes occurring at the molecular level in F210I heterozygotes will be enough to induce 
behavioural phenotypes in the relatively short lifespan of the mouse. Further assessment in 
human patients is also required to assess whether TDP43 shows functional changes in disease. 
With the production of aggregates and sequestration of TDP43 from the nucleus in ALS, a loss 
of TDP43 function is expected to cause or contribute to the disease process. If this is validated, 
it can be compared to the F210I allele in the mouse which is strongly hypomorphic for many 
roles in RNA metabolism. 
Alongside molecular and behavioural characterisation of F210I as a model, alternative data 
from in vitro models can be assessed in vivo. One such model has been to knockdown TDP43 in 
HEK293 cells, resulting in changes in cell cycle genes impacting on the morphology of cells 
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(Ayala et al., 2008a). This can be assessed in the F210I loss of function model. Taking into 
account the varying degrees of loss of function in the two models, whether F210I homozygous 
MEFs or other primary cells are affected in an identical fashion can be assessed. A model to 
consider is that TDP43 unable to bind RNA (F147L / F149L) has been shown to form large 
nuclear structures in the nucleus in cellular models (Ayala et al., 2008b; Wang et al., 2012). 
These structures may be the result of increased TDP43 self-aggregation and this can be 
assessed in the context of F210I. 
F210I is homozygous lethal. Future work will focus on establishing the cause of lethality in 
embryonic development. With knockout mice and Q101X homozygotes dying early in 
development (before E8.5 dpc) F210I already provides an allele in which to tease out degrees 
of potential loss of function at different stages of development. Establishing the cause of death 
will further delineate TDP43’s roles in development. F210I homozygotes assessed so far show 
consistent spino-oedema phenotypes indicating a critical role for TDP43 in mouse heart 
development. The lower penetrant retarded eye development and holoprosencephaly 
phenotypes also show alternative potential functions for TDP43 in development. 
Characterising these roles will further enhance understanding of TDP43 function but may also 
provide insight into pathogenesis in TDP43 proteinopathies. Mutations affecting 
developmental processes may impact on adult disease course in later life. 
As F210I is homozygous lethal, it can only be studied at a cellular level, or in embryonic 
development up to E14.5 dpc. To further utilise F210I in homozygosity, transgenic BAC TDP43 
mice (Swarup et al., 2011a) have been imported into Harwell with the aim of rescuing the 
lethality phenotype. In transgenic rodent mice published, there is inconsistency in the degree 
of nuclear clearance of endogenous TDP43 protein. If the endogenous F210I allele in 
homozygosis can be rescued in the context of a BAC transgene then F210I may represent a loss 
of function in the nucleus shown by protein clearance. It will be interesting to see if this alters 
transgene disease course, indicating a significant role for endogenous protein levels in the 
pathology seen in transgenic mice, as indicated by one study (Igaz et al., 2011).  The cross to a 
BAC transgenic TDP43 model where disease course is slow, mimicking the human condition 
more effectively provides an ideal model in which to compare F210I induced changes. This 
model may also show reduced endogenous F210I down regulation due to the nature of the 
transgene being lowly overexpressed. 
Another key element in human pathology and modelling TDP43’s role is stress. In the human 
condition, many patients are normal up until mid-life and from symptom onset there is a rapid 
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decline. One of the future directions for F210I is to characterise its functional ability to cope 
with various forms of stress. This can be achieved at multiple levels. In cells stress granule 
formation in response to oxidative, heat shock or other stresses can be measured, in particular 
assessing TDP43 localisation to stress granules as this may be an RNA-binding dependent 
event. Likewise in animals, stresses can be achieved through processes such as axotomies. 
Overall, F210I at a cellular and animal level provides an in vivo model to assess if loss of 
function can lead to pathology. The field needs to be monitored for the most relevant 
hypotheses regarding RNA functions. As such, any of these hypotheses can be tested in F210I 
post mitotic neurons in homozygosis and mice in heterozygosis to also use the F210I allele to 
deconstruct TDP43’s normal functions. These hypotheses may also be tested in potential 
rescued F210I homozygotes. 
 
6.2.3. Future work all mutations 
 
All mutations have been assessed in the CFTR mini-gene assay in vitro. Since 2006, there has 
been a large expansion in our understanding of TDP43’s roles in cell biology. This provides an 
opportunity to further develop assays to assess all remaining TDP43 point mutations for 
potential functional effects. As it is costly and time consuming to rederive mice carrying all 
mutations for assessment, if further in vitro assays are developed they could be used to assess 
the allelic array of mutations. In the case of the CFTR assay it would be ideal to rederive MEFs 
for all lines to assess each mutation, considering the increased sensitivity ex vivo. 
An alternative screen to assess the allelic series of mutations could also be to overexpress 
constructs carrying each of the mutations in various cell lines. The impacts on survival, TDP43 
localisation, protein solubility and response to stress could all be used as markers to assess the 
series of mutations. This experiment would also be relatively quick to complete. 
Experiments to delineate the functionality of an allelic series of ENU mutations in any gene are 
most effectively achieved when known functions of that gene can be assayed. In the CFTR 
context, TDP43’s role in splicing has been assayed and F210I was successfully identified. TDP43 
plays multiple roles in RNA metabolism with deficits in splicing likely to link to deficits in other 
RNA metabolism roles. Much remains unknown regarding domains such as the N terminus and 
the second RRM. Multiple roles are speculated, such as RRM2 being important for dimerization 
and chromatin organisation. The allelic series of mutations needs to be functionally validated 
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in each case and can provide future tools in which to assess these functions. Mutations in 
different domains may have large impacts on protein folding and biology or may subtly affect a 
specific function of that domain.  
Characterisation of the allelic series of mutations continues as a work in progress. F210I was 
identified through the CFTR assay which also missed that M323K shows a gain of splicing 
function (shown in vivo, data not presented). As such, while new assays need to be applied 
relating to alternative aspects of TDP43 function and dysfunction, their limitations must also 
be recognised. It is likely that many more of the missense mutations identified are functional 
considering the highly conserved nature of TDP43. Interestingly, in human screens there are no 
reports of amino acid changes in control patients or in affected patients outside the C-terminal 
region (excluding one case). As such, these mutations warrant further investigation to provide 
in vivo mouse tools to delineate TDP43 function.  
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